,PageNo,Text
0,page_0,"Official Protocol Title: NCT number: NCT03449134 Document Date: 26-APR-2019A Phase 3, Randomized, Double-blind, Placebo-controlled, 12-month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)"
1,page_1,"PRODUCT: MK-7264 1 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Title Page THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. (MSD). This protocol amendment is applicable only to theUnited Kingdom , United States of America, Ukraine, and Poland. Protocol Title: A Phase 3, Randomized, Double -blind, Placebo -controlled, 12 -month Study to Evaluate the Efficacy and Safet yof MK -7264 in Adult Participants with Chronic Cough (PN027) Protocol Number: 027-03 Compound Number: MK-7264 Sponsor Name: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or MSD) Legal Registered Address: One Merck Drive P.O. Box 100 Whitehouse Station, New Jersey , 08889 -0100, U.S.A. Regulatory Agency Identifying Number(s): IND EudraCT123007 2017- 000537- 31 Approval Date: 26 April 2019 0574PH"
2,page_2,PRODUCT: MK-7264 2 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Sponsor Signatory Typed Name: Title:Date Protocol -specific Sponsor c ontact information can be found in the Investigator Study File Binder (or equivalent). Investigator Signatory I agree to conduct this clinical study in accordance with the design outlined in this protocol and to abide b y all provisions of this protocol. Typed Name: Title:Date 0574PH
3,page_3,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35 '2&80(17+,6725< 'RFXPHQW 'DWHRI,VVXH 2YHUDOO5DWLRQDOH  $SU 7KHRYHUDOOUDWLRQDOHIRUWKHFRXQWU\VSHFLILFD PHQGPHQWLVWRDGGDPRQWK2IIWUHDWPHQW 'XUDELOLW\6WXG\3HULRGWRH[SORUHWKHLPSDFWRIZLWKGUDZLQJ0. WKHUDS\LQSDUWLFLSDQWV ZKRKDYHEHHQWUHDWHGIRU\HDU  6HS  %DVHGRQWKHUHVXOWVRIDVWXG\FRQGXFWHGLQSDUWLFLSDQWVZLWK VHYHUHUHQDOLPSDLUPHQWDQG PRGHUDWHUHQDOLPSDLUPHQWWKHH[SHFWHGLQFUHDVHLQH[SRVXUHWR 0.LQSDUWLFLSDQWVZLWK PRGHUDWHUHQDOLPSDLUPHQWLVQRWDQWLFLSDWHGWROHDGWRDQLQFU HDVHGULVNRIFOLQLFDOO\UHOHYDQW DGYHUVHHYHQWV7KHUHIRUHDQRWKHUPDMRUXSGDWHLQFOXGHGLQWKL VDPHQGPHQWLVWKDWRIWKH HVWLPDWHGJORPHUXODUILOWUDWLRQUDWH H*)5 FULWHULRQIRUSDUWL FLSDQWH[FOXVLRQIURPDFXWRIIRI P/PLQPWRFXWRIIRI P/PLQP 3DUWLFLSDQWVZLWKDQH*)5RIÂ•P/PLQPDQG P/PLQ PDW6FUHHQLQJZLWK XQVWDEOHUHQDOIXQFWLRQ GHILQHGDVDÂ•LQFUHDVHRIVHUXPFU HDWLQLQHFRPSDUHGWRDYDOXH REWDLQHGDWOHDVWPRQWKVSULRUWRWKH6FUHHQLQJ9LVLW DUHDO VRH[FOXGHG &ODULILFDWLRQVRIFHUWDLQVHFWLRQVDQGSURFHGXUHVDVGHWDLOHG EHORZZHUHDOVRPDGHLQWKH SURWRFROGXULQJWKHFUHDWLRQRIWKLVDPHQGPHQW  'HF &RUUHFWLRQWRQXPEHULQJRILQFOXVLRQFULWHULD DVZHOODVUHPRYDORIVSHFLDOFKDUDFWHUVLQ LQFOXVLRQDQGH[FOXVLRQFULWHULDWRVXSSRUWVWXG\GDWDEDVH2WK HUFODULILFDWLRQVUHTXLUHG WKURXJKRXWLQFOXGLQJWKHVFKHGXOHRIDVVHVVPHQWVVWXG\SRSXOD WLRQDQGIRUPDWWLQJ  2FW 2ULJLQDOSURWRFRO  3+CCI"
4,page_4,"PRODUCT: MK-7264 4 PROTOCOL/AMENDMENT NO.: 027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 PROTOCOL AMENDMENT S UMMARY OF CHANGES Amendment: 03 Overall Rationale for the Amendments: The overall rationale for the amendment is to add a 3 -month, Off -treatment Durability Study Period to explore the impact of withdrawing MK -7264 therapy in participants who have been treated for 1 y ear. Summary of Changes Table: Primary Reason for This Amendment: Section # and Name Description of Change Brief Rationale 10.7 Appendix 7: Country -specific RequirementsAdded information about the Off-treatment Durability Study PeriodTo explore the impact of withdrawing MK-7264 therap y after 1 y ear of treatment Additional Changes for This Amendment: Section # and Name Description of Change Brief Rationale 6 Study Intervention Removed the following text: â€œ When a replacement participant is required, the Sponsor or designee needs to be contacted prior to dosing the replacement supplies .â€Statement removed as protocol does not allow for participants to be replaced . 0574PH"
5,page_5,"PRODUCT: MK-7264 5 PROTOCOL/AMENDMENT NO.: 027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Section # and Name Description of Change Brief Rationale 6.5 Concomitant Therapy Updated text in bullet #3 (new text is in bold, italicized font): Dextromethorphan, guaifenesin, benzonatate ,and any other over the counter or prescription for the treatment of cough are not allowed from 2 weeks prior to Screening/Visit 1 through Randomiz ation/Visit 3. Furthermore , participants should not initiate therapy with dextromethorphan, guaifenesin, benzonatate, orany over the counter or prescription treatments for cough from Randomization/Visit 3 through completion of the Main and Extension study periods.To clarify that dextromethorphan, guaifenesin, andbenzonatate should not be initiated during the trial. 8.1.9 Study Intervention Administration Updated â€œVisit 13/Discontinuationâ€ to â€œVisit 13 or Discontinuationâ€To clarify that study interventi on supplies will be collected at either Visit 13 or Discontinuation 8.2.1 Objective Cough Counts Updated statement to: The cough monitor will be attached to the participant at Visit 2 and the day before for V isits 4 -6and Discontinuation during the Main study period (see Section 1.3).To provide clarit y when the cough monitor is attached by stating the exact visit numbers instead of stating â€œthe day before all other visits â€. 0574PH"
6,page_6,"PRODUCT: MK-7264 6 PROTOCOL/AMENDMENT NO.: 027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Section # and Name Description of Change Brief Rationale 8.3.7 Renal and Urological Safet y AssessmentsUpdated statement to: If during screening, a participant has crystalluria and/or unexplained hematuria (defined as, for example , participants without a history of recent menses, urinary tract infection, or recent procedure/instrumentation that would exp lain the hematuria. Note: Any other explanation for hematuria finding must be reviewed with the Sponsor ).To clarify that the protocol provides examples of explanations accepted for â€˜unexplainedâ€™ hematuria and that other explanations should be reviewed wit h the Sponsor. 10.3.1 Definition of AE -Events Meeting the AE DefinitionText below was revised to provide clarit y on which abnormal laboratory test results must be reported as an AE to the sponsor. The words â€œor areâ€ were removed. Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, or are considered clinically significant in the medical and scientific judgment of the investigator.Text has been amended to more closel y align with EDC data entry guidelines . Throughout Minor ty pographical errors corrected. Minor, therefore have not been summarized 0574PH"
7,page_7,"PRODUCT: MK-7264 7 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Table of Contents DOCUMENT HISTORY ........................................................................................................3 PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4 1 PROTOCOL SUMMARY ................................ ............................................................ 15 1.1 Synopsis ................................................................................................................. 15 1.2 Schema .................................................................................................................. 19 1.3 Schedule of Activities (SoA) ................................................................................ 21 2 INTRODUCTION .......................................................................................................... 27 2.1 Study Rationale ....................................................................................................28 2.2 Background .......................................................................................................... 29 2.2.1 Pharmaceutical and Therapeutic Background ............................................. 29 2.2.2 Phase 3 Studies in Adults ............................................................................. 29 2.3 Benefit/Risk Assessment ...................................................................................... 29 3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 30 4 STUDY DESIGN ............................................................................................................ 32 4.1 Overall Design ......................................................................................................32 4.2 Scientific Rationale for Study Design ................................................................ .33 4.2.1 Rationale for Endpoints ............................................................................... 33 4.2.1.1 Efficacy Endpoints ............................................................................. 33 4.2.1.2 Safety Endpoints ................................................................................ 35 4.2.1.3 Pharmacokinetic Endpoints ............................................................... 35 4.2.1.4 Pharmacod ynamic Endpoints ............................................................. 35 4.2.1.5 Planned Exploratory Biomarker Research ......................................... 35 4.2.1.5.1 Planned Genetic Anal ysis........................................................ 35 4.2.1.6 Future Biomedical Research .............................................................. 36 4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 36 4.3 Justification for Dose ........................................................................................... 36 4.3.1 Doses for This Study .................................................................................... 36 4.3.2 Maximum Dose/Exposure for This Study ................................................... 36 4.3.3 Rationale for Dose Interval and Study Design ............................................ 37 4.4 Beginning and End of Study Definition ............................................................. 37 4.4.1 Clinical Criteria for Early Study Termination ............................................. 37 5 STUDY POPULATION ................................................................................................ 37 5.1 Inclusion Criteria ................................................................................................ .38 5.2 Exclusion Criteria ................................................................................................ 39 5.3 Lifestyle Considerations ...................................................................................... 41 0574PH"
8,page_8,"PRODUCT: MK-7264 8 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 5.3.1 Meals and Dietary Restrictions ....................................................................41 5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 41 5.3.3 Activity Restrictions .................................................................................... 41 5.4 Screen Failures .....................................................................................................42 5.5 Participant Replacement Strategy ......................................................................42 6 STUDY INTERVENTION ............................................................................................ 42 6.1 Study Intervention(s) Administered ...................................................................43 6.1.1 Medical Devices ........................................................................................... 44 6.2 Preparation/Handling/Storage/Accountability ................................................. 44 6.2.1 Dose Preparation .......................................................................................... 44 6.2.2 Handling, Storage, and Accountability ........................................................ 44 6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 45 6.3.1 Intervention Assignment.............................................................................. 45 6.3.2 Stratification ................................................................................................ .45 6.3.3 Blinding........................................................................................................45 6.4 Study Intervention Compliance .......................................................................... 45 6.5 Concomitant Therapy .......................................................................................... 46 6.5.1 Rescue Medications and Supportive Care ................................................... 48 6.6 Dose Modification ................................................................................................ 48 6.7 Intervention After the End of the Study ............................................................ 48 6.8 Clinical Supplies Disclosure ................................................................................ 48 7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT WITHDRAWAL ............................................................................................................ 48 7.1 Discontinuation of Study Intervention ............................................................... 48 7.2 Participant Withdrawal From the Study ........................................................... 49 7.3 Lost to Follow -up................................................................................................ .50 8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 50 8.1 Administrative and General Procedures ........................................................... 51 8.1.1 Informed Consent ......................................................................................... 51 8.1.1.1 General Informed Consent ................................................................ .51 8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research ............................................................................................. 51 8.1.2 Inclusion/Exclusion Criteria ........................................................................52 8.1.3 Participant Identification Card .....................................................................52 8.1.4 Medical History ........................................................................................... 52 8.1.5 Prior and Concomitant Medications Review ............................................... 52 8.1.5.1 Prior Medications ............................................................................... 52 8.1.5.2 Concomitant Medications ..................................................................53 0574PH"
9,page_9,"PRODUCT: MK-7264 9 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.1.6 Participant Comment Card ........................................................................... 53 8.1.7 Assignment of Screening Number ............................................................... 53 8.1.8 Assignment of Treatment/Randomization Number .....................................53 8.1.9 Study Intervention Administration .............................................................. 53 8.1.9.1 Timing of Dose Administration ......................................................... 54 8.1.10 Discontinuation and Withdrawal ................................................................ .54 8.1.10.1 Withdrawal From Future Biomedical Research ................................ 54 8.1.11 Participant Blinding/Unblinding ..................................................................55 8.1.12 Calibration of Equipment ............................................................................. 56 8.2 Efficacy Assessments ........................................................................................... 56 8.2.1 Objective Cough Counts.............................................................................. 56 8.2.2 Electronic Patient -reported Outcomes ......................................................... 58 8.2.2.1 Cough Severit y Diary ........................................................................59 8.2.2.2 Cough Severity Visual Analogue Scale ............................................. 60 8.2.2.3 Leicester Cough Questionnaire .......................................................... 60 8.2.2.4 12-item Short Form Survey ............................................................... 60 8.2.2.5 Work Productivity and Activity Impairment Questionnaire .............. 61 8.2.2.6 EuroQoL 5L Dimensions Q uestionnaire ........................................... 61 8.2.2.7 Patient Global I mpression of Change Questionnaire ......................... 61 8.2.2.8 Hull Airway Reflux Questionnaire .................................................... 61 8.3 Safety Assessments ............................................................................................... 62 8.3.1 Chest Radiograph y/Computed Tomography Thorax Scan .......................... 62 8.3.2 Physical Examinations ................................................................................. 62 8.3.3 Vital Signs and Weight and Height Measurements .....................................62 8.3.4 Electrocardiograms ...................................................................................... 63 8.3.5 Spirometry ....................................................................................................63 8.3.6 Clinical Safety Laboratory Assessments ..................................................... 63 8.3.7 Renal and Urological Safety Assessments ................................................... 64 8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable Safety Events .................................................................................... 65 8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safet y Event Informa tion.......................................................... 65 8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......67 8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...67 8.4.4 Regulatory Reporting Requirements for SAE ............................................. 67 8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 68 8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as AEs or SAEs ............................................................................................ 68 0574PH"
10,page_10,"PRODUCT: MK-7264 10 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.4.7 Events of Clinical I nterest (ECI s)................................................................ 68 8.5 Treatment of Overdose ........................................................................................ 69 8.6 Pharmacokinetics................................................................................................ .69 8.6.1 Blood Collection for Plasma MK- 7264 ....................................................... 69 8.7 Pharmacodynamics .............................................................................................. 69 8.8 Biomarkers ........................................................................................................... 70 8.8.1 Planned Genetic Anal ysis Sample Collection .............................................. 70 8.9 Future Biomedical Research Sample Collection ............................................... 70 8.10 Visit Requirements ............................................................................................... 70 8.10.1 Screening......................................................................................................70 8.10.2 Baseline ........................................................................................................71 8.10.3 Main Study Period ....................................................................................... 71 8.10.4 Extension Study Period ................................................................................ 71 8.10.5 Discontinued Participants Continuing to be Monitored in the Study .......... 71 8.10.6 Poststudy ......................................................................................................72 9 STATISTICAL ANALYSIS PLAN ............................................................................. 72 9.1 Statistical Analysis Plan Summary.....................................................................73 9.2 Responsibility for Analyses/In -house Blinding ................................................. 74 9.3 Hypotheses/Estimation ........................................................................................ 75 9.4 Analysis Endpoints ............................................................................................... 75 9.4.1 Efficacy Endpoints ....................................................................................... 75 9.4.2 Safety Endpoints .......................................................................................... 76 9.4.3 Derivations of Efficacy Endpoints ............................................................... 76 9.5 Analysis Populations ............................................................................................ 78 9.5.1 Efficacy Anal ysis Populations .....................................................................78 9.5.2 Safety Anal ysis Population .......................................................................... 79 9.5.3 Pharmacokinetic Analy sis Population ......................................................... 79 9.6 Statistical Methods ............................................................................................... 79 9.6.1 Statistical Methods for Efficacy Anal yses................................................... 80 9.6.2 Statistical Methods for Safety Anal yses...................................................... 82 9.6.3 Summaries of Baseline Characteristics, Demographics, and Other Analy ses.......................................................................................................84 9.7 Interim Analyses ..................................................................................................84 9.7.1 Interim Efficacy Analy sis............................................................................ 84 9.7.2 Interim Safet y Anal yses............................................................................... 84 9.8 Multiplicity ........................................................................................................... 85 9.9 Sample Size and Power Cal culations ................................................................ .85 9.10 Subgroup Analyses ............................................................................................... 87 0574PH"
11,page_11,"PRODUCT: MK-7264 11 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 9.11 Compliance (Medication Adherence) ................................................................ .87 9.12 Extent of Exposure ............................................................................................... 88 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .....................................................................................................89 10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........89 10.1.1 Code of Conduct for Clinical Trials ............................................................. 89 10.1.2 Financial Disclosure ..................................................................................... 91 10.1.3 Data Protection ............................................................................................. 91 10.1.3.1 Confidentiality of Data ......................................................................92 10.1.3.2 Confidentiality of Participant Records ............................................... 92 10.1.3.3 Confidentiality of IRB/IEC I nformation ............................................ 92 10.1.4 Committees Structure ................................................................................... 92 10.1.4.1 Scientific Advisory Committee .......................................................... 92 10.1.4.2 Executive Oversight Committee ........................................................ 92 10.1.4.3 External Data Monitoring Committee ............................................... 93 10.1.5 Publication Policy ........................................................................................ 93 10.1.6 Compliance with Study Registration and Results Posting Requirements ...93 10.1.7 Compliance with Law, Audit, and Debarment ............................................ 94 10.1.8 Data Qualit y Assurance ............................................................................... 94 10.1.9 Source Documents ....................................................................................... 95 10.1.10 Study and Site Closure ................................................................................. 95 10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 96 10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting ............................................................... 98 10.3.1 Definition of AE .......................................................................................... 98 10.3.2 Definition of SAE ........................................................................................ 99 10.3.3 Additional Events Reported .......................................................................100 10.3.4 Recording AE and SAE ............................................................................. 100 10.3.5 Report ing of AE, SAE, and Other Reportable Safety Events to the Sponsor ......................................................................................................104 10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, F ollow -up, and Reporting ......................................... 105 10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ...................... 106 10.5.1 Definitions ..................................................................................................106 10.5.2 Contraception Requirements ......................................................................106 10.5.3 Pregnancy Testing ...................................................................................... 107 10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical Research .......................................................................................... 108 10.7 Appendix 7: Country -specific Requirements .................................................. 113 0574PH"
12,page_12,PRODUCT: MK-7264 12 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.8 Appendix 8: Abbreviations ............................................................................... 125 11 REFERENCES............................................................................................................. 127 0574PH
13,page_13,PRODUCT: MK-7264 13 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 LIST OF TABLES Table 1 Study Interventions .......................................................................................... 43 Table 2 Examples of Concomitant Treatment Permitted in the Study ........................ 47 Table 3 Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safet y Events ................................................................................. 66 Table 4 Analy sis Strategy for Primary and Key Secondary Endpoints ........................ 81 Table 5 Analy sis Strategy for Safet y Parameters .......................................................... 83 Table 6 Power for the Primary and Key Secondary Endpoints ....................................86 Table 7 Minimum Detectable Adverse Event Rate Differences in MK -7264 Compared to Placebo ....................................................................................... 86 Table 8 Protocol -required Safet y Laboratory Assessments .......................................... 96 Table 9 Contraceptive Methods .................................................................................. 107 0574PH
14,page_14,PRODUCT: MK-7264 14 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 LIST OF FIGURES Figure 1 Study Design .............................................................................................. 19 Figure 2 Cough Monitoring: Attachment Pr ocedure ............................................... 57 Figure 3 Cough Monitoring: Removal Procedure ................................................... 58 0574PH
15,page_15,"PRODUCT: MK-7264 15 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 1 PROTOCOL SUMMARY 1.1 Syno psis Protocol Title: A Phase 3, Randomized, Double -blind, Placebo -controlled, 12 -month Study to Evaluate the Efficacy and Safet y of MK -7264 in Adult Participants with Chronic Cough (PN027) Short Title: MK-7264 Phase 3 study in adult participants with chronic cough (PN027) Acronym: COUGH -1 Hypotheses, Objectives ,and Endpoints : In this stud y, the objectives/hypotheses and endpoints below will be evaluated in adult participants with chronic cough as follows: Primary Objectives Primary Endpoints -Objective: To evaluate the efficacy of MK-7264 in reducing cough frequency as measured over a 24 -hour period Hypothesis (H1): At least 1 MK -7264 dose is superior to placebo in reducing coughs per hour (over 24 hours) at Week 12-24-hour coughs per hour at Week 12 -Objective: To evaluate the safet y and tolerability of MK -7264-Number of participants experiencing an AE -Number of participants discontinuing study intervent ion due to an AE Secondary Objectives Secondary Endpoints -Objective: To evaluate the efficacy of MK-7264 in reducing cough frequency as measured while awake during a 24 -hour period Hypothesis (H2): At least 1 MK -7264 dose is superior to placebo in reducing coughs per hour (while awake during a 24 -hour period) at Week 12-Awake coughs per hour at Week 12 0574PH"
16,page_16,PRODUCT: MK-7264 16 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 -Objective: To evaluate the efficacy of MK-7264 based on the proportion of participants with a clinically significant reduction from baseline in 24- hour coughs per hour Hypothesis (H3): At least 1 MK -7264 dose is superior to placebo with respect to the proportion of participants with a â‰¥30% reduction from baseline in 24- hour coughs per hour at Week 12-Proportion of participants with a â‰¥30% reduction from baseline in 24- hour coughs per hour at Week 12 -Objective: To evaluate the efficacy of MK-7264 in improving self -rated cough severit y-Proportion of participants with a â‰¥1.3- point reduction from baseline in mean weekl y Cough Severit y Diary (CSD) total score at Week 12 -Proportion of participants with a â‰¥2.7- point reduction from baseline in mean weekl y CSD total score at Week 12 -Proportion of participants with a â‰¥30mm reduction from baseline in Cough Severit y Visual Analog Scale (VAS) s core at Week 12 -Objective: To evaluate the ability of MK-7264 to provide a clinically significant improvement in cough specific qualit y of life-Proportion of participants with a â‰¥1.3- point increase from baseline in Leicester Cough Questionnaire (LCQ) total score at Week 12 Overall Desig n: Study Phase Phase 3 Primary Purpose Treatment Indication Treatment of chronic cough Population Participants who are at least 18 y ears of age with refractory chronic cough or unexplained chronic cough Study Type Interventional 0574PH
17,page_17,"PRODUCT: MK-7264 17 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Intervention Model Parallel This is a multi- sitestudy . This study includes a 12 -week Main stud y period, followed b y a 40 -week Extension study period. Type of Control Placebo Study Blinding Double -blind Masking Participant Investigator Estimated Duration of Study The Sponsor estimates that the study will require approximately 31 months from the time the first participant signs the informed consent until the last participantâ€™s last study -related telephone call or visit. Number of Participant s: Approximately 720 participants will be enrolled. 0574PH"
18,page_18,"PRODUCT: MK-7264 18 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Intervention Groups and Du ration : Intervention Group sIntervention Group Name Dose StrengthDose FrequencyRoute of Admin .Regimen/ Treat ment Period Use MK-7264 45 mg45 mg 1 tablet BID OralMain Study Period: 12 weeks Extension Study Period: 40 weeksExp 0 mg matched to MK -7264 15mg1 tablet BID OralMain Study Period: 12 weeks Extension Study Period: 40 weeksPbo MK-7264 15 mg15 mg 1 tablet BID OralMain Study Period: 12 weeks Extension Study Period: 40 weeksExp 0 mg matched to MK -7264 45mg1 tablet BID OralMain Study Period: 12 weeks Extension Study Period: 40 weeksPbo Placebo0 mg matched to MK -7264 45mg1 tablet BID OralMain Study Period: 12 weeks Extension Study Period: 40 weeksPbo0 mg matched to MK -7264 15mg Admin=administration; BID =twice daily; Exp =experimental; Pbo =placebo . Total Number3 Duration of ParticipationEach participant will participate in the study for approximately 56 weeks from the time the participant signs the Informed Consent F orm (ICF) through the final contact. After a screening phase of up to approximately 2 weeks , each participant will be receiving assigned interventi on for approximately 52weeks. Each participant wi ll have a safet y follow -up telephone call 14 day s after completion, discontinuation ,or withdrawal of the study intervention. 0574PH"
19,page_19,"PRODUCT: MK-7264 19 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study Governance Committees: Steering Committee No Executive Oversight Committee Yes Data Monitoring Committee Yes Clinical Adjudication Committee No Scientific Advisor yCommittee Yes Study governance considerations are outlined in Appendix 1. Study Accepts Healthy Volunteers :No A list of abbreviations used in this document can be found in Ap pendix 8 . 1.2 Schema The study design is depicted in Figure 1. *Note: Visits 8, 10, 12, and follow -up Visit 14 will be conducted by telephone. BID = twice daily Figure 1 S tudy Design 0574PH"
20,page_20,"PRODUCT: MK-7264 20 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 At study entry , participants will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups: MK-7264 45 mg twice daily (BID), MK -7264 15 mg BID, or placebo. Participants will remain on their assigned intervention at Randomization throughout the study . A safet y follow -up tele phone call will be conducted at a minimum of 14 day s (with an allowed variance of up to + 7 day s) after Visit 13 or after last dose of stud y intervention (for participants who discontinue from intervention). Please refer to d etails in Section 8.10.6. 0574PH"
21,page_21,"PRODUCT: MK-7264 21 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 1.3 Schedule of Activities (SoA) Study PeriodScreen - ingBase - lineMain Study Period Extension Study PeriodFollow -upDisc Notes Visit NumberVisit 1Visit 2Visit 3Visit 4 Visit 5 Visit 6Visit 7Visit 8 (TC)Visit 9Visit 10 (TC)Visit 11Visit 12 (TC)Visit 13Visit 14 (TC)V8, V10, V12, and Follow -up to be conducted by telephone Scheduled DayDay -14 to Day -7Day 0Day 1Day 27Day 28Day 55Day 56Day 83Day 84Day 112Day 140Day 168Day 217Day 266Day 315Day 365Day 379 Scheduling Window (Recommended)NA NA NA NAÂ±4 dysNAÂ±4 dysNAÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dys+7 dys Scheduled WeekWk -2 to Wk -1Wk 0Wk 1Wk 4Wk 8Wk 12Wk 16Wk 20Wk 24Wk 31Wk 38Wk 45Wk 52Wk 54 Adm inistrative Procedures Written I nformed ConsentXSee Section 8.1.1. Participant Identification CardX Issue/I nstruct in the use of Participant Comment CardX X X X X X XSee Section 8.1.6 . Collect/Review Participant Comment CardX X X X X X XX (MS/ ES) Informed Consent for Future Biomedical ResearchX Inclusion/ Exclusion CriteriaX X Demographics, Medical, & Medication HistoryX Prior/ Concomitant MedicationsX X X X X X X X X X X X X XX (MS/ ES) 0574PH"
22,page_22,"PRODUCT: MK-7264 22 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study PeriodScreen - ingBase - lineMain Study Period Extension Study PeriodFollow -upDisc Notes Visit NumberVisit 1Visit 2Visit 3Visit 4 Visit 5 Visit 6Visit 7Visit 8 (TC)Visit 9Visit 10 (TC)Visit 11Visit 12 (TC)Visit 13Visit 14 (TC)V8, V10, V12, and Follow -up to be conducted by telephone Scheduled DayDay -14 to Day -7Day 0Day 1Day 27Day 28Day 55Day 56Day 83Day 84Day 112Day 140Day 168Day 217Day 266Day 315Day 365Day 379 Scheduling Window (Recommended)NA NA NA NAÂ±4 dysNAÂ±4 dysNAÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dys+7 dys Scheduled WeekWk -2 to Wk -1Wk 0Wk 1Wk 4Wk 8Wk 12Wk 16Wk 20Wk 24Wk 31Wk 38Wk 45Wk 52Wk 54 Study Intervention Distribution and/or AccountabilityX X X X X X X XX (MS/ ES)See Section 8.1.9 . Contact I RT SystemX X X X X X X X XX (MS/ ES) Efficacy Procedures Attach Cough MonitorX X X XX (MS)See Section 8.2.1 . Collect Cough MonitorX X X XX (MS)See Section 8.2.1 . Activate ePROs X X X X X X X X XX (MS/ ES)See Section 8.2.2 . CSD Daily X Daily Daily X XSee Section 8.2.2.1 . Cough Severity VASDaily X Daily Daily X XSee Section 8.2.2.2 . LCQ X X X X X X X X XX (MS/ ES)See Sections 8.2.2 and 8.2.2.3 . SF-12 X X XX (MS/ ES)See Section 8.2.2 . WPAI X X XX (MS/ ES) EQ5D -5L X X XX (MS/ ES) 0574PH"
23,page_23,"PRODUCT: MK-7264 23 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study PeriodScreen - ingBase - lineMain Study Period Extension Study PeriodFollow -upDisc Notes Visit NumberVisit 1Visit 2Visit 3Visit 4 Visit 5 Visit 6Visit 7Visit 8 (TC)Visit 9Visit 10 (TC)Visit 11Visit 12 (TC)Visit 13Visit 14 (TC)V8, V10, V12, and Follow -up to be conducted by telephone Scheduled DayDay -14 to Day -7Day 0Day 1Day 27Day 28Day 55Day 56Day 83Day 84Day 112Day 140Day 168Day 217Day 266Day 315Day 365Day 379 Scheduling Window (Recommended)NA NA NA NAÂ±4 dysNAÂ±4 dysNAÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dys+7 dys Scheduled WeekWk -2 to Wk -1Wk 0Wk 1Wk 4Wk 8Wk 12Wk 16Wk 20Wk 24Wk 31Wk 38Wk 45Wk 52Wk 54 PGIC X XX (MS/ ES) HARQ XSee Section 8.2.2.8 . Safety Procedures Chest Radiograph or CT ThoraxXNot required if done in past 5 years . Physical ExaminationX X XX (MS/ ES)Complete physical performed only at V1; directed physical exam at all other scheduled visits. Vital Signs X X X X X X X X X XX (MS/ ES) Height X Weight X X X X XX (MS/ ES) 12-lead ECG X Spirometry XNot required if done within past 1 year and during a clinically stable period . 0574PH"
24,page_24,"PRODUCT: MK-7264 24 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study PeriodScreen - ingBase - lineMain Study Period Extension Study PeriodFollow -upDisc Notes Visit NumberVisit 1Visit 2Visit 3Visit 4 Visit 5 Visit 6Visit 7Visit 8 (TC)Visit 9Visit 10 (TC)Visit 11Visit 12 (TC)Visit 13Visit 14 (TC)V8, V10, V12, and Follow -up to be conducted by telephone Scheduled DayDay -14 to Day -7Day 0Day 1Day 27Day 28Day 55Day 56Day 83Day 84Day 112Day 140Day 168Day 217Day 266Day 315Day 365Day 379 Scheduling Window (Recommended)NA NA NA NAÂ±4 dysNAÂ±4 dysNAÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dys+7 dys Scheduled WeekWk -2 to Wk -1Wk 0Wk 1Wk 4Wk 8Wk 12Wk 16Wk 20Wk 24Wk 31Wk 38Wk 45Wk 52Wk 54 Hematology & ChemistryX X X XX (MS/ ES) Urinalysis (w/ Microscopy)X X X XX (MS/ ES)Dipstick performed for ALL participant s. Samples are also collected and sent to central laboratory for ALL participant s. See Table 8. Specialized Urine Collection for Crystal AssayX X XX (MS/ ES)Only if central laboratory urinaly sis, after randomiza - tion,is positive for crystals and/or unexplained hematuria . See Section 8.3.7. 0574PH"
25,page_25,"PRODUCT: MK-7264 25 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study PeriodScreen - ingBase - lineMain Study Period Extension Study PeriodFollow -upDisc Notes Visit NumberVisit 1Visit 2Visit 3Visit 4 Visit 5 Visit 6Visit 7Visit 8 (TC)Visit 9Visit 10 (TC)Visit 11Visit 12 (TC)Visit 13Visit 14 (TC)V8, V10, V12, and Follow -up to be conducted by telephone Scheduled DayDay -14 to Day -7Day 0Day 1Day 27Day 28Day 55Day 56Day 83Day 84Day 112Day 140Day 168Day 217Day 266Day 315Day 365Day 379 Scheduling Window (Recommended)NA NA NA NAÂ±4 dysNAÂ±4 dysNAÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dys+7 dys Scheduled WeekWk -2 to Wk -1Wk 0Wk 1Wk 4Wk 8Wk 12Wk 16Wk 20Wk 24Wk 31Wk 38Wk 45Wk 52Wk 54 Urine Pregnan cy TestXSee Appendix 5for instructions on when pregnancy testing should be performed after Visit 1 . Serum Pregnancy TestXOnly if urine pregnancy test is positive. Adverse Event MonitoringX X X X X X X X X X X X X XX (MS/ ES)SeeTable 3 for further details. Pharmacodynamics/Biomark ers Pharmacokinetic Sample (blood)X X X X X X X XV3: pre -dose and 2 hours post-dose. V4-V9: pre-dose only. V2,V13: no dosing . Blood for Genetic AnalysisXCollected from randomized participants only; see Sections 8.8 and 8.9 . 0574PH"
26,page_26,"PRODUCT: MK-7264 26 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study PeriodScreen - ingBase - lineMain Study Period Extension Study PeriodFollow -upDisc Notes Visit NumberVisit 1Visit 2Visit 3Visit 4 Visit 5 Visit 6Visit 7Visit 8 (TC)Visit 9Visit 10 (TC)Visit 11Visit 12 (TC)Visit 13Visit 14 (TC)V8, V10, V12, and Follow -up to be conducted by telephone Scheduled DayDay -14 to Day -7Day 0Day 1Day 27Day 28Day 55Day 56Day 83Day 84Day 112Day 140Day 168Day 217Day 266Day 315Day 365Day 379 Scheduling Window (Recommended)NA NA NA NAÂ±4 dysNAÂ±4 dysNAÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dysÂ±4 dys+7 dys Scheduled WeekWk -2 to Wk -1Wk 0Wk 1Wk 4Wk 8Wk 12Wk 16Wk 20Wk 24Wk 31Wk 38Wk 45Wk 52Wk 54 AE=adverse event; CSD =Cough Severity Diary; CT =computed tomography; Disc =discontinuation; dys =days; ECG =electrocardiogram; eDiary =electronic diary; e PRO =electronic patient - reported outcome; EQ5D -5L=EuroQo L5 Version 5L dimensions questionnaire; ES = Extension study period; ET =end of treatment; FBR =future biomedical research; HARQ =Hull Airway Reflux Questionnaire; I RT=interactive response technology; LCQ =Leicester Cough Questionnaire; MS = main study period; NA =not applicable; PGIC =Patient Global I mpression of Change ; SF-12=12-item Short Form Survey; SOP =standard operating procedure; TC =telephone contact; V =visit; VAS =Visual Analog Scale; Wk =Week; WPAI =Work Productivity and Activity Impairment. 0574PH"
27,page_27,"PRODUCT: MK-7264 27 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 2 INTRODUCTION Cough is one of the most common presenting symptoms for patients seeking care from primary care specialists, allergists, otolary ngologists, or pulmonologists worldwide. The importance of cough as a clinical problem globally has led to multiple societies publishing guidelines on the dia gnosis and management of cough [Morice, A. H., et al 2004] [Chung, K. F., et al 2006] [Morice, A. H., et al 2006] [The committee for The Japanese Respiratory Society guidelines 2006] [Kardos, P., et al 2010] . In these clinical guidelines, cough is categorized based upon the duration of t he cough; within each c ategory acute, sub -acute, and chronic are likely diagnostic possibilities [Irwin, R. S., et al 2006] . Acute cough is present for less than 3 weeks and most often due to acute viral upper respiratory tract infection. A cough that has been present longer than 3 weeks is either sub -acute (3 to 8 weeks) or chronic (>8 weeks). Chronic cough may affect up to approximate ly 12% of the adult population [Chamberlain, S. A., et al 2015] . For approximately two-thirds of these patients, a potential co- morbid condition can be identified and the cough effectively managed b y optimizing therap y for the condition. A minority of patients with a potential co -morbid condition cannot be effe ctivel y managed b y optimizing therap y for the condition and are considered to have refractory chronic cough. Also, the cause of chronic cough remains unexplained in 5% to 10% of patients seeking medical attention specific to their cough [Gibson, P., et al 2016] . This protocol aims to study participants with either refractory chronic cough or unexplained chronic cough. Professional guidelines describe s ystematic approaches to the evaluation and management of chron ic cough. These guidelines are based largel y on consensus opinion and observational data from the medical literature. There are currently no treatments approved by the United States Food and Drug Administration (FDA) or European Medicines Agency (EMA) for the treatment of chronic cough. Given the prolonged nature, significant morbidity, and lack of effective treatment, unexplained or refractory chronic cough is a major unmet medical need. Mechanism of Cough Each cough occurs through the stimulation of a com plex reflex arc. Cough is initiated following activation of airway sensory nerves in the upper and lower respiratory tract. Airway sensory nerves are tailored to detect changes in the phy sical and chemical environment, and if required, elicit protective re flex events such as cough. These reflexes are normally protective; however, in disease, a irway reflexes can become h yper responsive, leading to an increase in s ymptoms and a pathologic cough. P2X3 receptors are ligand -gated ion channels that respond to adenosine triphosphate (ATP) and are almost exclusively localized on C -fiber sensory neurons, which innervate the upper and lower airway s and are the main nerve fibers responsible for cough. Adenosine triphosphate is released by damaged, stressed, and inflame d tissues. The action of ATP at sensory neurons in the periphery and spinal cord contributes to neural excitability and may cause h yper responsiveness through binding to P2X3 -containing receptors and stimulating of C-fiber neurons [North, R. A. 2004] [Khakh, B. S. 2006] . Antagonism of P2X3 -containing 0574PH"
28,page_28,"PRODUCT: MK-7264 28 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 receptors is predicted to normalize sensory neuron sensitivity , based on data from P2X3 knock- out mice and the effects of small interfering ribonucleic acid (RNA) knock -down and pharmacological antagonists [Barclay , J., et al 2002] [Cockay ne, D. A., et al 2000] [Souslova, V., et al 2000] . Adenosine triphosphate and P2X3 -containi ng receptors have been shown to be involved in airway s sensitization and their involvement provides a rationale for P2X3 antagonism in the treatment of cough. Cough Hypersensitivity Syndrome Recently , the term cough hy persensitivity syndrome has been propo sed to describe a group of patients with chronic cough and si milar clinical characteristics [Chung, K. F. 2014] . These similar clinical characteristics include irritation in the throat or uppe r chest, cough triggered by stimuli that do not normally cause cough , increased cough sensitivity to inhaled stimuli, and cough parox ysms. A potential biologic explanation for cough h ypersensitivity syndrome suggests an associated sensory neuropathy characterized by sensory nerve hyper-sensitization. Sensory nerves are susceptible to sensitization by neuroactive mediators and altered expression of ion channels which regulate sensory nerve excitability to man y chemical stimuli. As described above, the action of ATP at sensory neurons may cause h yper responsiveness through binding to P2X3 -containing receptors and contribute to the pathophy siology of patients with chronic cough. As described elsewhere in the protocol, the data from Protocol 012 support the role of P2X3 antagonism in the treatment of patients with refractory or unexplained chronic cough. MK-7264 Development Program MK-7264, a P2X3 receptor antagonist, is a clinical agent being developed for the treatment of cough. The current MK -7264 cough development plan consists of two 12 -month Phase 3 studies in participants with refractory or unexplained chronic cough: 1study (Protocol 027) with a 12-week Main study period and a 40 -week Extension study period, and a second study (Protocol 030) with a 24 -week Main stud y period and a 28- week Extension study period. 2.1 Study Rationale The purpose of this stud y is to evaluate the efficacy and safet y of MK -7264, an orall y available P2X3 antagonist, in participants, at least 18 y ears of age, who have either refractory or unexplained chronic cough. Current therapies for acute and sub -acute cough (narcotic, non -narcotic, and over -the-counter medications) have limited and/or unproven efficacy and an undesirable side effect profile. There are currently no approved therapies for chronic co ugh. Previous Phase 2 studies have demonstrated dose -related efficacy and an acceptable safet y and tolerability profile for MK -7264 in participants with refractory or unexplained chronic cough (see MK -7264 Investigatorâ€™s Brochure [IB]). This Phase 3 study will evaluate the efficacy and safet y of MK -7264 in participants with refractory or unexplained chronic cough. 0574PH"
29,page_29,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35  %DFNJURXQG 5HIHUWRWKH,% IRUGHWDLOHGQRQFOLQLFDODQGFOLQLFDOEDFNJURXQG LQIRUPDWLRQRQ0.  3KDUPDFHXWLFDODQG7KHUDSHXWLF%DFNJURXQG   0.LVDQRUDOWUHDWPHQWSURYLGHGDVDILOPFRDWHGWDEOHW 7KH0.WDEOHWV SURYLGHGIRUWKLVVWXG\FRQWDLQHLWKHU0.PJRUPJ 7KHSODFHERWDEOHWV SURYLGHGLQWKLVVWXG\DUHLQGLVWLQJXLVKDEOHIURPWKH0.W DEOHWVUHVSHFWLYHO\LQ DSSHDUDQFH7KHSODFHERWDEOHWVFRQWDLQQR0.EXWFRQWDLQ WKHVDPHLQDFWLYH H[FLSLHQWVDVWKRVHLQFOXGHGLQWKHDFWLYHWDEOHWV  3KDVH6WXGLHVLQ$GXOWV7KH6SRQVRULQWHQGVWRFRQGXFWDVHFRQG3KDVHVWXG\RI0.  3URWRFRO LQDGXOW SDUWLFLSDQWVZLWKUHIUDFWRU\RUXQH[SODLQHGFKURQLFFRXJK7KH GHVLJQRI3URWRFROZLOO LQPRVWDVSHFWVEHVLPLODUWR3URWRFRO7KHPDLQGLIIHUHQF HEHWZHHQWKH VWXGLHVZLOOEH WKHOHQJWKRIWKH0DLQVWXG\SHULRGZKLFKZLOOEHDWRWDORI ZHHNVLQ3URWRFRO FRPSDUHGWRZHHNVLQ3URWRFRO  %HQHILW5LVN$VVHVVPHQW,WFDQQRWEHJXDUDQWHHGWKDWSDUWLFLSDQWVLQFOLQLFDOVWXGLHVZ LOOGLUHFWO\EHQHILWIURP WUHDWPHQWGXULQJSDUWLFLSDWLRQDVFOLQLFDOVWXGLHVDUHGHVLJQH GWRSURYLGHLQIRUPDWLRQDERXW WKHVDIHW\DQGHIIHFWLYHQHVVRIDQLQYHVWLJDWLRQDOPHGLFLQH 0.KDVEHHQHYDOXDWHGLQDQH[WHQVLYHQRQFOLQLFDOSURJUDP 7RGDWHWKHUHLVOLWWOH HYLGHQFHIURPQRQFOLQLFDOVWXGLHVWKDW0.KDVDQ\GLUHFWF HOOXODURUGLUHFWWDUJHWRUJDQ WR[LFLW\ ,Q WKHFRPSOHWHGDQGRQJRLQJFOLQLFDOVWXGLHVQRPDMRUVDIHW\F RQFHUQVKDYHEHHQQRWHG $FURVVVWXGLHVWDVWHUHODWHG$(V ZHUHWKHPRVWIUHTXHQWUHSRUWH G$(V7KHUDWLRQDOHIRUWDVWH GLVWXUEDQFHH[LVWVZLWK3;DQWDJRQLVPEHFDXVHRIWKHSXWDWLY HSDUWLFLSDWLRQRI$73 DFWLQJYLDWKLVUHFHSWRULQWUDQVGXFLQJWDVWHVLJQDOVIURPWDV WHEXGVFHOOVWRJXVWDWRU\ VHQVRU\ QHUYHV7KHWDVWHUHODWHG$(VDUHFRQVLGHUHGPHFKDQLVPEDVHGQR QVHULRXVDGYHUVHGUXJ UHDFWLRQVDQGDUHH[SHFWHGIRU0.7RGDWHWKH\KDYH EHHQ IXOO\DQGUDSLGO\UHYHUVLEOH DIWHUGLVFRQWLQXDWLRQRIWKHGUXJ 2YHUDOOEDVHGRQJURZLQJFOLQLFDOHYLGHQFHVXSSRUWLQJWKHHIIL FDF\RI0.LQ SDUWLFLSDQWVZLWKUHIUDFWRU\RUXQH[SODLQHGFKURQLFFRXJKGHVFU LEHGLQRWKHUVHFWLRQVRIWKH SURWRFRODQGWKHODFNRIVLJQLILFDQWVDIHW\ILQGLQJVLQFRPSOHW HGDQGRQJRLQJQRQFOLQLFDODQG FOLQLFDOVWXGLHVWKHEHQHILWULVNEDODQFHRI0.LVDVVHVV HGDVSRVLWLYH  3+CCI"
30,page_30,"PRODUCT: MK-7264 30 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Additional details regarding specific benefits and risks for participants participating in thi s clinical study may be found in the accompanyi ng IB and Informed Consent Form ( ICF) documents. 3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS In this stud y, the objectives/hypotheses and endpoints below will be evaluated in adult participants with chronic cough as follows: Objectives Endpoints Primary â€¢ O bjective: To evaluate the efficacy of MK-7264 in reducing cough frequency as measured over a 24 -hour period Hypothesis ( H1): At least 1MK-7264 dose is superior to placebo in reducing coughs per hour (over 24 hours) at Week 12â€¢24-hour coughs per hour at Week 12 â€¢Objective: To evaluate the safet y and tolerability of MK -7264â€¢Number of participants experiencing an AE â€¢Number of participants discontinuing study intervention due to an AE Secondary â€¢Objective: To evaluate the efficacy of MK-7264 in reducing cough frequency as measured while awake during a 24 -hour period Hypothesis ( H2): At least 1MK-7264 dose is superior to placebo in reducing coughs per hour (while awake during a 24-hour period) at Week 12â€¢Awake coughs per hour at Week 12 â€¢Objective: To evaluate the efficacy of MK-7264 based on the proportion of participants with a clinically significant reduction from baseline in 24- hour coughs per hour Hypothesis ( H3): At least 1MK-7264 dose is superior to pla cebo with respect to the proportion of participants with a â‰¥30% reduction from baseline in 24- hour coughs per hour at Week 12â€¢Proportion of participants with a â‰¥30% reduction from baseline in 24- hour coughs per hour at Week 12 0574PH"
31,page_31,"PRODUCT: MK-7264 31 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Objectives Endpoints â€¢Objective: To evaluate the e fficacy of MK-7264 in improving self -rated cough severit yâ€¢Proportion of participants with a â‰¥1.3- point reduction from baseline in mean weekly Cough Severity Diary (CSD) total score at Week 12 â€¢Proportion of participants with a â‰¥2.7- point reduction from baseline in mean weekly CSD total score at Week 12 â€¢Proportion of participants with a â‰¥30mm reduction from baseline in Cough Severity Visual Analog Scale (VAS) score at Week 12 â€¢Objective: To evaluate the ability of MK-7264 to provide a clinically signific ant improvement in cough specific qualit y of lifeâ€¢Proportion of participants with a â‰¥1.3- point increase from baseline in Leicester Cough Questionnaire (LCQ) total score at Week 12 Exploratory â€¢Objective: To evaluate the efficacy of MK-7264 based on the p roportion of participants with a clinically significant reduction from baseline in cough frequencyâ€¢Proportion of participants with â‰¥50% and â‰¥70% reduction from baseline in 24-hour coughs per hour â€¢Proportion of participants with â‰¥30%, â‰¥50%, and â‰¥70% reducti on from baseline in awake coughs per hour â€¢Objective: To evaluate the impact of MK-7264 on generic health -related quality of life, work productivity , and global rating of changeâ€¢12-Item Short Form Survey (SF-12) â€¢Work Productivity and Activity Impairment (W PAI) questionnaire â€¢EuroQoL Five Dimension Questionnaire (EQ5D -5L) â€¢Patient Global I mpression Change (PGI C) â€¢Objective: To explore the relationship between genetic variation and response to the treatment(s) administered, and mechanisms of disease. Variation across the human genome may be anal yzed for association with clinical data collected in the studyâ€¢Germline genetic variation 0574PH"
32,page_32,"PRODUCT: MK-7264 32 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 4 S TUDY DESIGN 4.1 Overall Design Approximately 720 participants who meet entry criteria will enter the study . The duration of intervention for each participant is as follows: ï‚·Screening Period: a minimum of 7 day s and up to approximately 14days(see Section 8.10.1) ï‚·Baseline: 1 day (including 24 hours of objective measurement of cough) (see Section 8.10.2) ï‚·Main study period (12 -week treatment period after Baseline): 84 days(see Section 8.10.3) ï‚·Extension study period (40 -week treatment period after the Main study period): 281days(see Section 8.10.4) ï‚·Follow -up period: 14 days (see Section 8.10.6) During the Main study period, pa rticipants may be required to be seen b y study site personnel for 2consecutive day s (eg, Visit 2 to Visit 3, the day before Visit 4 and Visit 4, the day before Visit 5 and Visit 5, and the day before Visit 6 and Visit 6) so that the cough monitor can be a ttached and removed (see Section 1.3 ).Study site staff or mobile research nurse services may be utilized (if locally available and approved for use), so participants have the opportunity to travel to the study site on 1day instead of traveling to the stu dy site for 2consecutive day s. Individual participation is expected to be approximately 56 weeks from Screening through the Follow -up period. Specific procedures to be performed during the study , as well as their prescribed times and associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure are provided in Section 8. This study will use an adaptive design based on pre -specified criteria, using an independent, external Data Monitoring Committee (DMC) to monitor safet y and e fficacy. There will be 1planned interim efficacy anal ysis when approximately 40% of the total randomized participants have completed, or discontinued prior to completion of the Main study period. The study may be stopped for futility according to the resu lts of the interim anal ysis. Results of the interim analy sis will be reviewed by the external DMC, which will make recommendations to the Executive Oversight Committee (EOC) of the Sponsor to continue, modify or stop the stud y according to the plan described in Section 9. 0574PH"
33,page_33,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35 $QLQLWLDOGDWDEDVHORFNZLOORFFXUDIWHUDOOSDUWLFLSDQWVKDYH FRPSOHWHGRUGLVFRQWLQXHGSULRU WRFRPSOHWLRQRIWKH0DLQVWXG\SHULRGDQGDIXOODQDO\VLVZLO OEHFRQGXFWHG 7KHILQDOGDWDEDVHORFNZLOOEHFRQGXFWHGZKHQDOOSDUWLFLSDQWV KDYHFRPSOHWHGRU GLVFRQWLQXHGSULRUWRWKHFRPSOHWLRQRIWKH([WHQVLRQVWXG\SH ULRG'HWDLOVRIWKHEOLQGLQJ DUHLQ6HFWLRQ   6FLHQWLILF5DWLRQDOHIRU6WXG\'HVLJQ 5DWLRQDOHIRU(QGSRLQWV (IILFDF\(QGSRLQWV7KHSULPDU\HIILFDF\HQGSRLQWLVWKHKRXUFRXJKVSHUKRXU L HDYHUDJHKRXUO\FRXJK IUHTXHQF\EDVHGRQKRXUVRXQGUHFRUGLQJV DW:HHN&RXJK FRXQWVZLOOEHPHDVXUHG XVLQJDGLJLWDOUHFRUGLQJGHYLFH 9LWDOR-$.ÂŒ9LWDORJUDSK%XFN LQJKDP8QLWHG.LQJGRP  KHUHDIWHUUHIHUUHGWRDVFRXJKPRQLWRU :RUQVLPLODUWRD+ROW HUPRQLWRUZLWKPLFURSKRQHV DIIL[HGWRWKHSDUWLFLSDQWÂ¶VFKHVWZDOODQGDWWDFKHGWRWKHSDU WLFLSDQWÂ¶VFORWKLQJWKHFRXJK PRQLWRUSURYLGHVKLJKILGHOLW\UHFRUGLQJVDQGIDFLOLWDWHVVLJQDO SURFHVVLQJWRDFFXUDWHO\ LGHQWLI\DQGTXDQWLI\FRXJK'LJLWDOUHFRUGLQJVZLOOEHSURFHVV HGLQ9LWDORJUDSKÂ¶VFHQWUDOL]HG UHDGLQJFHQWHUZKHUHUHFRUGLQJVDUHFRQGHQVHGXVLQJDFRPSXWHU DOJRULWKPEHIRUHKXPDQ DQDO\VWVLGHQWLI\DQGWDJLQGLYLGXDOFRXJKV7KHRXWSXWRIWKLV SURFHVVLVDFRXQWRIFRXJKV IRUHDFKKRXUUHFRUGLQJSHULRGDVZHOODVFRXJKFRXQWVIRU SRUWLRQVRIWKHGD\ZKHQWKH SDUWLFLSDQWLVDZDNHDQGDVOHHS 7KHJRDORIWKLVVWXG\LVWRGHPRQVWUDWHWKDW0.LVHIIHFW LYHLQWKHWUHDWPHQWRI UHIUDFWRU\RUXQH[SODLQHGFKURQLFFRXJKDVHYLGHQFHGE\DFKDQ JH UHGXFWLRQ IURPEDVHOLQH DW:HHNLQKRXUFRXJKVSHUKRXULQ0.UHODWLYHWRSO DFHER8WLOL]LQJKRXU FRXJKVSHUKRXUDVWKHSULPDU\HQGSRLQWLVIXUWKHUVXSSRUWHGZL WKVXFFHVVIXOGDWDIURP 0.3URWRFRO VHH0.,% 5HVXOWVIURP0.3UR WRFRO  GHPRQVWUDWHGVWDWLVWLFDOO\VLJQLILFDQWUHGXFWLRQLQFKDQJHIUR PEDVHOLQHLQKRXUFRXJKV SHUKRXUZLWKPJ0.%,'FRPSDUHGWRSODFHERDW:HHN  7KHILUVWVHFRQGDU\HQGSRLQWRIWKLVVWXG\LV DZDNHFRXJKVSHUK RXUDW:HHN$V GHVFULEHGDERYHWKHKRXUSHULRGFDQEHGLYLGHGLQWRSHULRGV RIDZDNHDQGDVOHHS,Q 0.3URWRFRODZDNHEDVHOLQHFRXJKUDWHVZHUHQXPHULFDO O\KLJKHUWKDQKRXU EDVHOLQHFRXJKUDWHVDQGVLJQLILFDQWO\KLJKHUWKDQVOHHSFRXJK UDWHV%DVHGRQWKHVHGDWD DZDNHWLPHPD\EHDPHDQLQJIXOWLPHSHULRGIRUSDUWLFLSDQWVZLW KUHIUDFWRU\RUXQH[SODLQHG FKURQLFFRXJK7KHUHIRUHDZDNHFRXJKVSHUKRXUZLOOEHHYDOXDW HGDVDVHFRQGDU\HQGSRLQW LQWKLVVWXG\        3+CCI"
34,page_34,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35 $QDVVHVVPHQWRIFRXJKIURPWKHSDUWLFLSDQWÂ¶VSHUVSHFWLYHLVDO VRLPSRUWDQWIRUHYDOXDWLQJ WKHUHVSRQVHWRWKHUDS\3DWLHQWUHSRUWHGRXWFRPHV 352 DVVRFL DWHGZLWKFRXJKFDQEH PHDVXUHGLQWHUPVRIFRXJKV SHFLILFTXDOLW\RIOLIHFRXJKIUHT XHQF\LQWHQVLW\GLVUXSWLRQ GXHWRFRXJKDQGFRXJKVHYHULW\7RVXSSOHPHQWLQIRUPDWLRQREWD LQHGIURPWKHSULPDU\ HQGSRLQWREWDLQHGGXULQJWKH0DLQVWXG\SHULRGWKHIROORZLQJV HFRQGDU\PHDVXUHVZLOOEH LQFOXGHGWKURXJKRXWWKLVVWXG\  &RXJK6HYHULW\'LDU\ &6'  &RXJK6HYHULW\9LVXDO$QDORJ6FDOH 9$6  /HLFHVWHU&RXJK4XHVWLRQQDLUH /&4  $VYDOLGDWHG352PHDVXUHVRIFRXJKVSHFLILFKHDOWKUHODWHGTXDO LW\RIOLIH +54R/ DQG FRXJKVHYHULW\GDWDREWDLQHGIURPWKH&6'&RXJK6HYHULW\9$6 DQG/&4ZLOOSURYLGH LPSRUWDQWLQIRUPDWLRQUHOHYDQWWRWKHHIILFDF\RI0.LQSD UWLFLSDQWVZLWKUHIUDFWRU\ FKURQLFFRXJKRUXQH[SODLQHGFKURQLFFRXJK 7KH&6'LVDLWHPGLVHDVHVSHFLILF352PHDVXUHZLWKDUHFDOO SHULRGRIÂ³WRGD\Â´7KH PHDVXUHHYDOXDWHVIUHTXHQF\RIFRXJK LWHPV LQWHQVLW\RIFR XJK  LWHPV DQGGLVUXSWLRQ LWHPV HDFKLWHPLVUDWHGRQDQSRLQWVFDOHUDQJLQJIURP WRZLWKKLJKHUVFRUHV LQGLFDWLQJJUHDWHUVHYHULW\$&6'WRWDOVFRUHDQGGRPDLQVFR UHV IUHTXHQF\LQWHQVLW\ GLVUXSWLRQ FDQEHFDOFXODWHG     7KH&RXJK6HYHULW\9$6LVDVLQJOHLWHPTXHVWLRQDVNLQJWKHSDU WLFLSDQWWRUDWHWKHVHYHULW\ RIWKHLUFRXJKÂ³WRGD\Â´XVLQJDPP9$6DQFKRUHGZLWKÂ³1R&RX JKÂ´DWDQGÂ³([WUHPHO\ 6HYHUH&RXJKÂ´DW6LPLODUWRWKHZHOOHVWDEOLVKHGXVHRI9$ 6VFRUHVLQFKURQLFSDLQWKH &RXJK6HYHULW\9$6PHDVXUHSURYLGHVDTXLFNYDOLGDQGHDVLO\L QWHUSUHWHGVXEMHFWLYH DVVHVVPHQWXVHIXOIRUFOLQLFLDQVWRPRQLWRULPSURYHPHQWRIWKHL UFKURQLFFRXJKSDWLHQWV IROORZLQJWUHDWPHQW   FRQVLVWHQWZLWKWKHSURYLVLRQDOEHQFKPDUNVRXWOLQHGE\WKH,QLW LDWLYHRQ0HWKRGV  3+CCI CCI CCI"
35,page_35,"PRODUCT: MK-7264 35 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Measurement, and Pain Assessment in Clinical Trials which recommends that an improvement of approximately 30% on a 0 to 10 numeric rating scale can be co nsidered clinically meaningful [Dworkin, R. H., et al 2009] . The impact of chronic cough on HRQoL as assessed by the L CQ is included as the third secondary endpoint. The goal is to demonstrate that a greater pro portion of participants treated with MK -7264 relative to placebo achieve a clinically meaningful improvement from baseline in HRQoL defined as a â‰¥1.3- point increase in the L CQ total score at Week 12. 4.2.1.2 Safety Endpoints The safet y data for MK -7264 to date has been described in detail in the MK -7264 IB. In support of the safet y objective to evaluate the safet y and tolerability profile of MK -7264, the safet y and tolerability endpoints will be assessed by clinical evaluation of AEs and inspection of other stud y parameters including vital signs, physical examination, and standard laboratory safety tests at timepoints specified in the SoA. Adverse events are graded and r ecorded according to Section 8.4 andAppendix 3 . 4.2.1.3 Pharmacokinetic Endpoints The relationship betw een MK -7264 plasma concentrations and cough frequencies/side effects will be explored. Population pharmacokinetic (PK) analyses will be conducted to understand the exposure -response relationships between MK- 7264 and efficacy and safety data. 4.2.1.4 Pharmacodynamic Endpoints No pharmacod ynamic biomarkers that will require modeling are planned for this study. 4.2.1.5 Planned Exploratory Biomarker Research 4.2.1.5.1 Planned Genetic Analysis Genetic variation may impact a participantâ€™s response to therap y, susceptibility to, severit y, and progression of disease. Variable response to therap y ma y be due to genetic determinants that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of the drug; disease etiology; and/or molecular subtype of t he disease being treated. Therefore, where local regulations and I RB/IEC allow, a sample will be collected for DNA anal ysis from consenting participants. DNA samples will be used for research related to the study intervention(s), the disease under study , and related diseases. They may also be used to develop tests/assay s including diagnostic tests related to the disease under study, related diseases, and study intervention(s). Genetic research may consist of the analy sis of 1 or more candidate genes or the analysis of genetic markers throughout the genome [or anal ysis of the entire genome] (as appropriate). 0574PH"
36,page_36,"PRODUCT: MK-7264 36 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 DNA samples will be analy zed for variation across the entire genome. Analy ses may be conducted if it is hy pothesized that this may help furthe r understand the clinical data. The samples may be analy zed as part of a multi -study assessment of genetic factors involved in the response to understand study disease or related conditions. 4.2.1.6 Future Biomedical Research The Sponsor will conduct future biomedical resear ch on DNA spe cimens for which consent was pr ovided during this clinical study . Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main study ) and will only be conducted on specimens from appropriatel y consented participants. The objective of collecting/retaining specimens for future biomedical research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The ov erarching goal is to use such information to develop safer, more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of the correct drug/vaccine at the correct time. The details of this future biomedical research substudy are presented in Appendix 6. 4.2.2 Rationale for t he Use of Comparator/Placebo A placebo is included in this study to maintain the study blinding, allowing for an unbiased assessment of efficacy and safet y. Participants may discontinue the stud y intervention at an y time. Given that there is no approved treatment for chronic cough, use of a placebo is justified. 4.3 Justification for Dose 4.3.1 Dose sfor This Study The dose for this stud y will be either MK -7264 15 mg BID or MK -7264 45 mg BID as determined b y the individual allocation per the assigned treatment g roup (see Section 6). The known mechanism of action of MK -7264 and related clinical study results support that the efficacy of MK -7264 in decreasing cough, and the prevalence of the most common AE, dysgeusia, are both dose related. In order to allow patients and prescribers appropriate flexibility based upon individual clinical needs, the MK -7264 development program has targeted 2 different doses to study in the Phase 3 program. 4.3.2 Maximum Dose/Exposure for This Study Themaximum dose/exposure for this study will be at 45 mg BID. Participants who a re administered MK-7264 (either 15 mg BID or 45 mg BID)will be exposed to MK -7264 for approximately 365 days (see Section 6 ). 0574PH"
37,page_37,"PRODUCT: MK-7264 37 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 4.3.3 Rationale for Dose Interval and Study Design In this study , MK -7264 will be orally administered as MK -7264 45 mg BID and 15 mg BID based on the safet y and PK efficacy results observed to date. Based on PK studies, MK- 7264 is rapidly absorbed with a median time to reach maximum plasma concentration of 1. 0 to 2.0 hours. I n addition, the half -life of MK -7264 is approximately 7 to 10 hours and consistent with a BID dosing schedule. For this study , 12 weeks duration of intervention for the Main study period was selected based on regulatory guidance regarding duration of therapy for s ymptomatic treatment in chronic diseases. The study includes an extension for a total duration of intervention of up to 1 y ear, in order to provide a more robust assessment of the longer -term safet y, tolerability and efficacy of MK-7264 in the treatment of refractory or unexplained chronic cough. 4.4 Beginning and End ofStudy Definition The overall study begins when the first participant signs the ICF. The overall study ends when the last participant completes the last study -related telephone -call or visit, withdraws from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the investigator). 4.4.1 Clinical Criteria f orEarly Study Termination Early study termination will be the result of the following specif ied criteri on: a.During the interim anal ysis, based on the interim data, if the futility criteria are met, then the study may be stopped for futility . 5 STUDY POPULATION This study will enroll male and f emale participants with chronic cough â‰¥1 year and a diagnosis of refractory chronic cough or unexplained chronic cough according to the American College of Che st Phy sician (ACCP) guidelines [Irwin, R. S., et al 2006] . For the purposes of this study , refractory chronic cough is defined as participants who have had a clinical evaluation that suggested a co -morbid condition that may be associated with chronic cough (eg, gastroesophageal reflux disease [GERD], asthma, or upper airway cough syndrome [UACS] ), the partic ipant has received appropriate diagnostic work -up and at least 2 months of therap y,prior to Screening ,according to ACCP guidelines, and the participant continues to cough despite being on therap y. Also for the purposes of this study , unexplained chronic cough is defined as participants who have had a clinical evaluation of their cough per ACCP guidelines and this evaluation has not suggested a co -morbid condition that may be associated with chronic cough. Participants with refractory chronic cough or unex plained chronic cough and who are at least 18 years of age will be enrolled in this study . 0574PH"
38,page_38,"PRODUCT: MK-7264 38 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted. 5.1 Inclusion Criteri a Participants are eligible to be included in the study onl y if all o f the following criteria apply: 1.Chest radiograph or computed tomograph y scan of the thorax (within 5 y ears of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator (note: sub- investigator must be a physician). 2.Have chronic c ough for â‰¥1 year and a diagnosis of refractory chronic cough or unexplained chronic cough ,as specified in Section 5. 3.Have a score of â‰¥40 mm on the Cough Severity VAS at both the Screening and Baseline visits, as specified in Section 8 .2.2. Demographics 4.Participant is Male or Female at least 18 years of age at the time of signing the informed consent . Female Participants 5.A female participant is eligible to participate if she is not pregnant (Appendix 5 ), not breastfeeding, and at least 1 of th e following conditions applies: a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 . OR b.A WOCBP who agrees to follow the contraceptive guidance i n Appendix 5 from the time of signing the informed consent through at least 14 days after the last dose of study intervention. Informed Consent 6.The participant (or legally acceptable representative if applicable) provides written informed consent for the study . The participant may also provide consent for f uture biomedical r esearch. However, the participant may participate in the main study without participating in future biomedical r esearch. 0574PH"
39,page_39,"PRODUCT: MK-7264 39 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study Participation 7.The participant is willing and able to comply with all aspects of the protocol, including demonstrating an ability to follow study procedures (including use of the digital cough recording device and completion of the Cough Severit y VAS, CSD, L CQ, and other protocol questionnaires) to the satisfaction of the investigator/qualified designee prior to randomization. 5.2 Exclusion Criteria Participants a re excluded from the study if any of the following criteria apply : Medical Conditions 1.Current smoker. 2.Individuals who have given up smoking within 12 months of Screening/Visit 1. 3.Former smokers with a pack/ year history greater than 20 pack- years. 4.Forced e xpiratory volume in 1 second (FEV 1)/ forced vital capacit y (FVC) ratio <60% (spirometry performed within the past y ear is acceptable if the investigator confirms that spirometry was done during a period where the participant was clinicall y stable, eg, not during an upper respiratory infection). 5.History of upper or lower respiratory tract infection or recent clinicall y significant change in pulmonary status within 4 weeks of Screening/Visit 1. 6.History of chronic bronchitis, defined as a cough that produces a clinicall y significant amount of sputum (greater than approximately 1 tablespoon of phlegm) that occurs every day for at least 3 months in a row, with those periods occurring at least 2 y ears in a row. 7.Individuals who are currently taking an angiotensin c onverting enzy me inhibitor or have taken an angiotensin converting enzyme inhibitor within 3 months of Screening/Visit 1. 8.Estimated glomerular filtration rate (eGFR) < 30mL/min/1.73 m2at Screening OReGFR â‰¥30mL/min/1.73 m2 and <50 mL /min/1.73 m2at Scree ning with unstable renal function (defined as a â‰¥50% increase of serum creatinine compared to a value obtained at least 6months prior to Screening /Visit 1). 9.Has a history of malignancy â‰¤5 years prior to signing informed consent except for adequatel y treated basal cell or squamous cell skin cancer or in situ cervical cancer. 10.Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last y ear) of drug or alcohol abuse or dependence. 11.Screening s ystolic blood pressure >160 mm Hg or a diastolic blood pressure >90 mm Hg. 0574PH"
40,page_40,"PRODUCT: MK-7264 40 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 12.History of anaph ylaxis or cutaneous adverse drug reaction (with or without sy stemic symptoms) to sulfonamide antibiotics or other sulfonamide -containing drugs. 13.Has a known al lergy /sensitivity or contraindication to MK -7264 or its excipients (note: refer to the IB for details regarding excipients for MK -7264). 14.Has donated or lost â‰¥1 unit of blood (approximately 300 mL) within 8 weeks prior to the first dose of MK -7264. 15.A WOCBP who has a positive urine pregnancy test at Visit 1. I f the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Prior/Concomitant Therapy 16.Requiring treatment with a therap y that does not adhere to the guidanc e parameters specified in S ection 6.5. Prior/Concurrent Clinical Study Experience 17.Has previousl y received MK -7264. 18.Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 30 d ays of participating in this current stud y. Diagnostic Assessments 19.Significantl y abnormal laboratory tests at Screening (see Sections 8.3.6 and 8.3.7), including: a.alkaline phosphatase, alanine aminotransferase (ALT, SGPT), aspartate aminotransferase (AST , SGOT) >200% of the upper limit of normal, or bilirubin >150% of the upper limit of normal. b.hemoglobin <10 gm/dL, white blood cell count (WBC) <2500 mm3(<2.5 Ã—103/uL), neutrophil count <1500 mm3(<1.5 Ã—103/uL), platelet count <100 Ã— 103/mm3 (<100 Ã—103/uL). For an y of the above listed laboratory assessments, 1 repeat measure ment will be allowed at the investigatorâ€™s discretion, before being considered a screen fail ure. 0574PH"
41,page_41,"PRODUCT: MK-7264 41 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Other Exclusions 20.Has a history or current evidence of any condition, therap y, lab abnormality, or other circumstance that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study result s, and in the judgment of the investigator or Sponsor, would make the participant inapprop riate for entry into this study . 21.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponso r staff directly involved with this study . 5.3 Lifestyle Considerations 5.3.1 Meals and Dietary Restrictions No restrictions are required. 5.3.2 Caffeine, Alcohol ,and Tobacco Restrictions Participants who currently smoke, who have given up smoking within the past 12 months, as well as participants who are former smokers with a pack/ year history greater than 20pack -years will not be permitted in the study . For the purposes of the study , smoking is intended to include cigars, e -cigarettes, cigarettes, vapes, etc. Smoking of any kind is not permitted during the course of the stud y. Based on known metabolism of MK- 7264, there are no effects of alcohol and caffeine associated with the stud y intervention. However, participants will refrain from consumption of alcohol 24 hou rs prior to and after all study visits (including the PK sampling visits). On intermediate day s, and at all other times, alcohol consumption per day is limited to no more than approximately 3 servings of alcoholic beverages or equivalent (1 serving is approximately equivalent to: beer [354 mL /12 ounces], wine [118 mL /4 ounces], or distilled spirits [29.5 mL /1 ounce]). 5.3.3 Activity Restrictions Participants should abstain from strenuous exercise and avoid nois y environments (eg, hair dryer, lawn equipment, open windows while driving, cinemas, listening to music, etc.) while the cough monitor is attached over a 24- hour period. However , participants may participate in light recreational activities (eg, watching television at a low volume, reading). Participants should also avoid allowing the c ough monitor , microphone, or chest sensor to get wet. Thus, they must avoid bathing or showe ring for the duration of the 24 -hour recording. The chest sensor will be applied to the participantâ€™s chest with an adhesive (sticky pad). If the participant has a known allergic sensitivity/reaction to adhesives, and in the opinion of 0574PH"
42,page_42,"PRODUCT: MK-7264 42 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 the investigator the sensitivity /reaction is severe enough to impact the ability of the participant to complete the study , the participant should not be enrolled in this study . See the VitaloJAKâ„¢ site manual for further details. 5.4 Screen Failures Screen failures are defined as participants who consent to participate in the c linical study , but are not subsequently randomized in the study . Participants identified as screen failures can be rescreened once for possible participation, and only with Sponsor consultation. Any participant who is re -screened will retain the original screening number assigned at the initial screening visit. If the Cough Severity VAS inclusion criterion i s not met at screening at Visit 1, the participant will not be allowed to be re -screened. If the Cough Severit y VAS criterion is not met at Visit 2 (Bas eline), the participant may be re -screened only with Sponsor consultation. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSOR T) publishing requirements and to respond to queries from regulatory authorities . Minimal information includes demograph y, screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting requirements as outlined in the data entry guidel ines. 5.5 Participant Replacement Strategy Participant s who discontinue from stud y intervention or withdraw from the study will not be replaced. 6 STUDY INTERVENTION Study intervention is defined as an y investigational intervention(s), marketed product(s), placebo, or me dical device(s) intended to be administered to a study participant according to the study protocol. Clinical supplies of MK -7264 or placebo will be packaged to support enrollment and replacement participants as required. Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements. 0574PH"
43,page_43,PRODUCT: MK-7264 43 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 6.1 Study Intervention(s) Administered The study interventions to be used in this study areoutlined inTable 1. Table 1 S tudy Interventi ons Arm Nam eArm TypeIntervention Nam eTypeDose Form ulationUnit Dose Strength(s)Dosage Level(s)Route of Admin.Regim en/ Trea tment PeriodUseIMP/ NIMPSourcing MK- 7264Experi mentalMK-7264 Drug Tablet 45 mg 1 tablet BIDOral Main Study Period: 12weeks Extension Study Period: 40 w eeksExperi mentalIMP Central Placebo Placebo Com par atorPlacebo matched to MK-7264 45mgOther Tablet 0 mg 1 tablet BIDOral Main Study Period: 12weeks Extension Study Period: 40 w eeksPlacebo IMP Central MK- 7264Experi mentalMK-7264 Drug Tablet 15 mg 1 tablet BIDOral Main Study Period: 12weeks Extension Study Period: 40 w eeksExperi mentalIMP Central Placebo Placebo Com par atorPlacebo matched to MK-7264 15mgOther Tablet 0 mg 1 tablet BIDOral Main Study Period: 12weeks Extension Study Period: 40 w eeksPlacebo IMP Central Admin. = administration; BID =twice daily; IMP =investigational medicinal product ; NIMP =non-investigational medicinal product . 0574PH
44,page_44,"PRODUCT: MK-7264 44 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 All supplies indicated in Table 1will be provided per the ""Sourcing"" column depending upon local country operational requirements. Every attempt should be made to source these supplies from a single lot/batch number. The stu dy site is responsible for recording the lot number, manufacturer, and expiry date for an y locally purchased product (if applicable) as per local guidelines unless otherwise instructed b y the Sponsor. Refer to Section 8.1.9 for details regarding administra tion of the study intervention. All placebos were created by the Sponsor to match the active product. 6.1.1 Medical Devices Not applicable. 6.2 Preparation/Handling/Storage/Accountability 6.2.1 Dose Preparation There are no specific calculations or evaluations required to be performed in order to administer the proper dose to each participant. T he rationale for selection of doses to be used in this study is provided in Section 4.3. 6.2.2 Handling, Storage ,and Accountability The investigator or designee must confirm appropria te temperature conditions have been maintained during transit for all study intervention received, and an y discrepancies are reported and resolved before use of the stud y intervention . Only participants enrolled in the study may receive study intervention ,and only authorized site staff may supply or administer study intervention . All study intervention s must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with acc ess limited to the investigator and authorized site staff. The investigator, institution, or the head of the medical institution (where applicable) is responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, receipt, r econciliation, and final disposition records). For all stud y sites, the local country Sponsor personnel or designee will provide appropriate documentation that must be completed for drug accountability and return, or local discard and destruction if appropriate. Where local discard and destruction is appropriate, the investigator is responsible for ensuring that a local discard/destruction procedure is documented. The study site is responsible for recording the lot number, manufacturer, and expiry date for any locall y purchased product (if applicable) as per local guidelines unless otherwise instructed by the Sponsor. 0574PH"
45,page_45,"PRODUCT: MK-7264 45 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage , handling, distribution, and usage of stud y interventions in accordance with the protocol and any applicable laws and regulations. 6.3 Measures to Minimize Bias: Randomization and Blinding 6.3.1 Intervention Assignment Allocation or randomization to study interven tionwill occur centrall y using an interactive response technology (IRT) sy stem. There are 3study intervention arms. Participants will be assigned randoml y in a 1:1:1 ratio to MK -7264 45 mg BID, MK- 7264 15 mg BID, or placebo. Study sites should contact the IRT s ystem for the purposes of enrollment tracking and study intervention dispensation as outlined in Section 1.3 .Participants will be assigned to treatments based on a randomization scheme. The details of the randomization scheme and identification for each participant will be included in the clinical study report (CSR). Randomization data will be kept strictly confidential, filed securely b y an appropriate group in Merck or contract research organization, and accessible onl y to authorized persons per standard operating procedures until the time of unblinding . 6.3.2 Stratification Treatment allocation/randomization will be stratified according to the following factors: 1.Gender (Male, Female) 2.Geographical Region (North America, Europe, Asia -Pacific, Others) 6.3.3 Blinding Adouble -blinding technique with in- house blinding will be used. MK -7264 and placebo w ill be packaged identicall y, respectivel y, during the study . The participant, the investigator, and Sponsor personnel or delegate(s ) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the group assignments. Details on the anal ysis and in -house blinding are provided in Section 9.2. See Section 8.1.11 for a description of the method of unblinding a participant during the study , should such action be warranted. 6.4 Study Intervention Compliance Records of intervention compliance for each participant will be kept during the study . The clinical research associates will review intervention compliance during investigational site visits and at the completion of the study . Compliance should be based on participant reporting and confirmed by tablet count where possible. I ssues with compliance shou ld be discussed with the participant and addressed as deemed appropriate b y the investigator. 0574PH"
46,page_46,"PRODUCT: MK-7264 46 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Interruptions from the protocol specified intervention plan of <80% compliance between visits, based on the review with the participant require consultation betw een the investigator and the Sponsor and written documentation of the collaborative decision on participant management. 6.5 Concomitant Therapy Medications specifically prohibited in the exclusion criteria are not allowed during the ongoing stud y unless otherw ise stated in this section. If there is a clinical indication for an y medication or vaccination specificall y prohibited, di scontinuation from study intervention may be required. The investigator should discuss any questions regarding this with the Sponsor Clinical Director . The final decision on any supportive therap yrests with the investigator and/or the participant â€™s primary physician. However, the decision to continue the participant on study intervention requires the mutual agreement of the investigato r, the Sponsor, and the participant. For participants who receive study intervention , any medication (including over -the-counter medications) or therap y administered to the participant during the course of the study will be recorded on the Prior and Concom itant Therap y case report form ( CRF ). Treatments for chronic cough received by the participant will also be recorded. The investigator(s) will record an y AE on the AEs CRF for which a concomitant medication/therapy was administered. Listed below are specific restrictions for prior/concomitant therap y during the course of the study : 1.Opioids (including codeine) for the treatment of cough are not allowed from 1 week prior to Screening/Visit 1 through Randomization/Visit 3. Participants should not initiat e therap y with opioids (including codeine) for the treatment of cough from Randomization/Visit 3 through completion of the Main and Extension study periods. Opioids (including codeine) for indications other than chronic cough are permitted provided the participant is receiving a stable treatment regimen for at least 1 week prior to Screening/Visit 1 and in the opinion of the investigator, is likely to remain on the stable treatment regimen through completion of the Main and Extension study periods. 2.Pregaba lin, gabapentin, amitripty line, or nortripty linefor the treatment of cough is not allowed from 2 weeks prior to Screening/Visit 1 through Randomization/Visit 3. Participants should not initiate therap y with pregabalin, gabapentin, amitriptyline , or nortri ptylinefor the treatment of cough from Randomization/Visit 3 through completion of the Main and Extension study periods. 0574PH"
47,page_47,"PRODUCT: MK-7264 47 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Pregabalin, gabapentin, amitripty line, or nortripty linefor indications other than chronic cough are permitted provided the participant is receivi ng a stable treatment regimen for at least 2 weeks prior to Screening/Visit 1 and in the opinion of the investigator, is likely to remain on the stable treatment regimen through completion of the Main and Extension study periods. 3.Dextromethor phan, guaifenesin, benzonatate and any other over the counter or prescription for the treatment of cough are not allowed from 2 weeks prior to Screening/Visit 1 through Randomization/Visit 3. Furthermore , participants should not initiate therap y with dextr omethorphan, guaifenesin, benzonatate ,orany over the counter or prescription treatments for cough from Randomization/Visit 3 through completion of the Main and Extension study periods. Lozenges/drops, teas/drinks, natural/herbal remedies, a nd other simil ar treatments which do not contain an active ant itussive or expectorant are allowed , provided they have been used on a regular basis for at least 2 weeks prior to Screening/Visit 1. Lo zenges/drops, teas/drinks, and natural/herbal remedies should not be initiated during the stud y. The Sponsor needs to be consulted for further information. 4. Treatments for conditions associated with chronic cough, such as GERD, asthm a, UACS (formerl y called post -nasal drip), or non -asthmatic eosinophilic bronchitis, are perm itted provided that participants have been treated for at least 2 months for these co -morbid conditions associated with chronic cough and are receiving a stable treatment regimen for at least 2 weeks prior to Screening/Visit 1 and in the opinion of the inv estigator, are likely to remain on the stable treatment regimen through completion of the Main and Extension study periods. Possible treatments are provided in Table 2.Note, this list is not meant to be comprehensive. Sponsor to be consulted for further information. Table 2 Examples of Concomitant Treatment Permitted in the Study Condition Treatment GERD Anti-reflux therapy (proton pump or H2 blockers), and/or pro-kinetic agents Asthma Bronchodilators, inhaled cor ticosteroids, and/or other anti-inflammatory agents UACS (formerl y postnasal drip)Antihistamine/decongestant therap y with a first -generation antihistamine Non- asthmatic eosinophilic bronchitisInhaled/oral corticosteroids GERD = gastroesophageal reflux disease ; UACS = upper airway cough syndrome . 5.Non- pharmacologic treatments (eg, ph ysiotherap y, speech and language therap y) for cough are not allowed from 3 months prior to Screening/Visit 1 through completion of the Main and Extension study periods. 0574PH"
48,page_48,"PRODUCT: MK-7264 48 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 6.Angiotensin converting enzy me inhibi tors are not al lowed from 3 months prior to Screening/Visit 1 through completion of the Main and Extension study periods. 6.5.1 Rescue Medications and Supportive Care No rescue or supportive medications are specified to be used in this study. 6.6 Dose Modification No dose modification is allowed in this study . 6.7 Intervention After the End of the Study There is no stud y-specified intervention following the end of the stud y. 6.8 Clinical Supplies Disclosure The emergency unblinding call center will use the intervention/randomization schedule for the study to unblind participants and to unmask study intervention identity . The emergency unblinding call center should only be used in cases of emergency (see Section 8.1.1 1). In the event that the emergency unblinding call ce nter is not available for a given site in this study , the central electronic intervention allocation/randomization sy stem (IRT) should be used to unblind participants and to unmask study intervention identity . The Sponsor will not provide random code/discl osure envelopes or lists with the clinical supplies. See Section 8.1.11 fora description of the method of unblinding a participant during the study , should such action be warranted. 7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT WITHDRAWAL 7.1 Discontinuation of Study Intervention Discontinuation of study intervention does not represent withdrawal from the study . As certain data on clinical events bey ond study intervention discontinuation may be important to the study , they must be collected thr ough the participantâ€™s last scheduled follow - up, even if the participant has discontinued study intervention. Therefore, all participants who discontinue study intervention prior to completion of the protocol -specified trea tment period will still continue to participate in the study as specified in Sections 1.3 and 8.10.5. Participants may discontinue study intervention at any time for any reason or be d iscontinued from the study intervention at the discretion of the investigator should an y untoward effect occur. In addition, a participant may be discontinued from study intervention by the investigator or the Sponsor if study intervention is inappropriate, the stud y plan is violated, or for administrative and/or other safet y reasons. Specific details regardin g procedures to be performed at study intervention discontinuation are provided in Section 8.1 0.5. 0574PH"
49,page_49,"PRODUCT: MK-7264 49 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 A participant must be discontinued from study intervention but continue to be monitored in the study for an y of the following reasons: â€¢The participant or par ticipantâ€™s legall y acceptable representative requests to discontinue study intervention. â€¢The participantâ€™s treatment assignment has been unblinded by the investigator, Merck Sharp & Dohme Inc. subsidiary , or through the emergency unblinding call center. â€¢The participant has a medical condition or personal circumstance which, in the opinion of the investigator and/or Sponsor, placed the participant at unnecessary risk from continued administration of study intervention (including recommendation to discontinue participant from stud y intervention as part of monitoring for cry stalluria/urolithiasis , see Section 8.3.7). â€¢The participant has a confirmed positive serum pregnancy test. â€¢In case of clinicall y significant and potentiall y drug related rash or signs and/or symptoms consistent with allergic drug reaction or anaph ylaxis to study intervention . â€¢Chronic failure to comply with the dosing, evaluations, or other requirements of the study , despite documentation at the site of repeated efforts to reinforce compliance. For participants who are discontinued from study intervention but continue to be monitored in the study , all visits and procedures, as outlined in the SoA, should be completed. Also see Section 8.10.5. Discontinuation from study intervention is â€œpermanent.â€ Once a participant is discontinued, he/she shall not be allowed to restart stud y intervention . 7.2 Participant Withdrawal From the Study A participant must be withdrawn from the study if the participant or participantâ€™s legall y acceptable repr esentative withdraws consent from the study . If a participant withdraws from the study, they will no longer receive stud y intervention or be followed at scheduled protocol visits. Specific details regarding procedures to be performed at the time of withdra wal from the study ,as well as specific det ails regarding withdrawal from future biomedical r esearch, are outlined in Section 8.1.10. The procedures to be performed should a participant repeatedl y fail to return for scheduled visits and/or if the study sit e is unable to contact the participant are outlined in Section 7.3. 0574PH"
50,page_50,"PRODUCT: MK-7264 50 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 7.3 Lost t o Follow -up If a participant fails to return to the clinic for a required study visit and/or if the site is unable to contact the participant, the following procedures are to be performed: â€¢The site must attempt to contact the participant and reschedule the missed visit. I f the participant is contacted, the participant should be counseled on the importance of maintaining the protocol -specified visit schedule. â€¢The investigator or de signee must make every effort to regain contact with the participant at each missed visit (eg, telephone calls and/or a certified letter to the participantâ€™s last known mailing address or locally equivalent methods). These contact attempts should be docume nted in the participantâ€™s medical record. â€¢Note: A participant is not considered lost to follow -up until the last scheduled visit for the individual participant. The missing data for the participant will be managed via the prespecified statistical data handling and anal ysis guidelines. 8 STUDY ASSESSMENTS AND PROCEDURES â€¢Study procedures and their timing are summarized in the SoA. â€¢Adherence to the stud y design requirements, including those specified in the SoA, is essential and required for study conduct. â€¢The investigator is responsible for ensuring that procedures are conducted by appropriatel y qualified or trained staff. Delegation of study site personnel responsibilities will be documented in the Investigator Trial File Binder (or equivalent). â€¢All study -related medica l decisions must be made by an investigator who is a qualified physician . â€¢All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening lo g to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable. â€¢Procedures conducted as part of the participantâ€™s routine clinical management (eg, blood count) and obtained before signing of ICF may be utilized for screening or baseline purposes provided the procedure met the protocol -specified criteria and were performed within the time frame defined in the SoA. â€¢Additional evaluations/testing may be deemed necessary by the investigator and or the Sponsor for reasons related to participant safet y. In some cases, such evaluation/testing may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations may require that additional informed consent be obtained from the pa rticipant. I n these cases, such evaluations/testing will be performed in accordance with those regulations. 0574PH"
51,page_51,"PRODUCT: MK-7264 51 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 The maximum amount of blood collected from each participant over the duration of the study including an y extra assessments that may be required, wil l be approximately 70 mL. Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the samples. 8.1 Administrative and General Procedures 8.1.1 Informed Consent The investigator or medically qualified designee (consistent with local requirements) must obtain documented consent from each potential participant or each participantâ€™s legall y acceptable representative prior to participating in a clinical study or future biomedical research .If there are changes to the participantâ€™s status during the stud y (eg, health or age of majority requirements), the investigator or medically qualified designee must ensure the appropriate consent is in place. 8.1.1.1 General Informed Consent Consent must be documented by the participantâ€™s dated signature or b ythe participantâ€™s legally acceptable representativeâ€™s dated signature on a consent form along with the dated signature of the person conducting the consent discussion. A cop y of the signed and dated consent form should be given to the participant before participation in the study . The initial I CF, any subsequent revised written ICF, and an y written information provided to the participant must receive the Institutional Review Board/Independent Ethics Committeeâ€™s (IRB/IECâ€™s )approval/favorable opinion in advance of use. The participant or his/her legall y acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the participantâ€™s willingness to continue participation in the study . The communica tion of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the participantâ€™s dated signature or b y the participantâ€™s legally acceptable representativeâ€™s dated signature. Specifics about a stud y and the study population will be added to the consent form template at the protocol level. The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and Sponsor requirements . 8.1.1.2 Consent and Collection o f Specimens for Future Biomedical Research The investigator or medically qualified designee will explain the future biomedical r esearch consent to the participant, answer all of his/her questions, and obtain written informed consent before performin g any procedure related to the future biomedical research sub study . A cop y of the informed consent will be given to the participant. 0574PH"
52,page_52,"PRODUCT: MK-7264 52 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.1.2 Inclusion/Exclusion Criteria All inclusion and exclusion criteria will be reviewed by the investigator who is a qualified physician to ensure that the participant qualifies for the study .Inclusion and exclusion criteria for this study are defined in Sections 5 .1 and 5 .2, respectivel y. For inclusion criterion 2, which statesthat eligible participants are to have chronic cough for â‰¥1year and a diagnosis of refractory chronic cough of unexplained cough (Section 5.1) , a combination of medical records and/or verbal history from participant /parent/legal guardian may be elicited at Screening/ Visit 1and can be used to fulfill this criterion if documented in the participant study file by the investigator . Source documentation for all eligibility criteria need sto be maintained at the site. For participants with eGFR â‰¥30 mL /min/1.73 m2and <50 mL /min/1.73 m2at Screening with stable renal function (unstable renal function is defined as a â‰¥50% increase of serum creatinine compared to a value obtained at least 6 months prior to the Screening Visit) , documentation of stable serum creatinine must be retained as source documentation at the study site. 8.1.3 Participant Identification Ca rd All participants will be given a participant identification card identify ing them as participants in a research stud y. The card will contain study site contact information (including direct telephone numbers) to be us ed in the event of an emergency . The investigator or qualified designee will provide the participant with a participant identification card immediately after the participant provides written informed consent. At the time of intervention allocation/randomiz ation, site personnel will add the intervention/randomization number to the participant identification card. The participant identification card also contains contact information for the emergency unblinding call center so that a healthcare provider can obtain information about study intervention in emergency situations where the investigator is not available. 8.1.4 Medical History A medical history will be obtained by the investigator or qualified designee (refer to eCRF entry guidelines) . 8.1.5 Prior and Concomitant Medications Revi ew 8.1.5.1 Prior Medications The investigator or qualified designee will review prior medication u se prior to Screening (see Section 6.5 and refer to electronic case report form (eCRF )entry guidelines). 0574PH"
53,page_53,"PRODUCT: MK-7264 53 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.1.5.2 Concomitant Medications The investigator or qualified designee will reco rd in the eCRF concomitant medication, if any, taken by the participant during the stud y. 8.1.6 Participant Comment Card Participants randomized into the study will be provided a separate participant comment card to capture an y AEs th at occur and an y concomitant medications used between scheduled study site visits. The investigator or study site staff personnel will train the participant on the use of the participant comment card prior to dispensing stud y intervention to the participant at Visit 3. The participant comment card should be dispensed and collected/reviewed as outlined in Section 1.3. Any AE data from the participant comment card will be entered into the eCRF with appropriate assessments made b y the investigator. Any concom itant therapy data from the participant comment card will be entered as appropriate into the eCRF. 8.1.7 Assignment of Screening Numb er All consented participants will be given a unique screening number that will be used to identify the participant for all procedures that occur prior to randomization .Each participant will be assigned onl y 1 screening number. Screening numbers must not be re-used for different participants. Any participant who is screened multiple times will retain the original screening number assigned at the initial screening visit. Specific details on the screening/rescreening visit requirements are provided in Section 8.10.1. 8.1.8 Assignment of Treatment/Randomization Numb er All eligible participants will be randomly allocated and will receive a treatment /randomization number. The treatment/randomization number identifies the participant for all procedures occurring after tre atment allocation/randomization. Once a treatment /randomization number is assigned to a participant, it can never be re -assigned to another participant. A single participant cannot be assigned more than 1 treatment /randomization number. 8.1.9 Study Intervention Administrati on The distribution of study intervention will be witnessed b y the investigator and/or study staff at the study site visits. Since MK -7264 45 mg and 15 mg will differ in appearance and have corresponding matching placebos, participants will rec eive 2 study intervention bottles (ie, either MK -7264 45 mg and placebo matched to MK -7264 15 mg OR MK-7264 15 mg and placebo matched to MK -7264 45 mg OR placebos matched to MK -7264 45 mg and 15 mg). Participants should be instructed to take 1tablet from each bottle BID. 0574PH"
54,page_54,"PRODUCT: MK-7264 54 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study intervention should begin on the day of intervention allocation/randomization and will be administered at the study site at Visit 3. This first dose of study intervention at Visit 3 should be administered after the cough monitor is removed, after the pre -dose PK sample collection, and before approximately 11 AM. As dosing is BID, the next dose should be taken orall y in the evening, approximately 12 hours later. Subsequent dosing will be performed b y the participant (ie, unsupervised at his/her home) BID, approximately 12hours apart at approximately the same time each day . However, on the day of a study site visit, the morning dose should not be taken at home and instead will be given as a witnessed dose at the study site, after the cough monitor is removed, after the pre -dose PK sample collection, and before approximately 11 AM (see Section 8.2.1 for further details) . On the day before Visits 4, 5, and 6, the morning dose should notbe taken at home and instead will be given as a wi tnessed dose at the study site. If the attachment of the cough monitor is to be managed by study site staff or a mobile nurse (where locally available and approved per regulations), the morning dose will be a witnessed dose with the study site staff or mobile nurse, at the participantâ€™s home. The cough monitor should be attached prior to dosing and TURNED ON immediately AFTER dosing, before approximately 11AM(see Section 8.2.1 for further details) . Following the last Main study period visit (ie, Visit 6) , participants will continue their assigned intervention in the Extension study period. The last dose of stud y intervention will be on the evening prior to V isit 13. Study intervention supplies will be collected at V isit13 or Discontinuation . 8.1.9.1 Timing of Dose Administration Study intervention will be administered orally , BID, approximately 12 hours apart for approximately 84 day s (12 weeks) during the Main study period and then administered orally , BID, approximately 12 hours apart for approximately anothe r 40 weeks during the Extension study period. 8.1.10 Discontinuation and Withdrawal Participants who discontinue study intervention prior to completion of the study should be encouraged to continue to be followed for all remaining stud y visits. When a participant withdraws from participation in the study , all applicable activities scheduled for the discontinuation/early withdrawal study visit as described in Section 1.3 should be performed (at the time of withdrawal). Any AEs that are present at the time of withdr awal should be followed in accordance with the safet y requirements outlined in Section 8.4. 8.1.10.1 Withdrawal From Future Biomedical Research Participants may withdraw their consent for future biomedical research. Participants may withdraw consent at an y time by contacting the principal investigator for the main study . If medical records for the main study are still available, the investigator will contact the 0574PH"
55,page_55,"PRODUCT: MK-7264 55 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Sponsor using the designated mailbox (clinical.specimen.management@merck.com). Subsequently ,the particip ant's consent for future biomedical r esearch will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the investigator to inform the participant of completion of withdrawal. An y analyses in progress at the time of request for withdrawal or alread y performed prior to the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analys es would be generated after the r equest is received. In the event that the medical records for the main study are no longer available (eg, if the investigator is no longer required b y regulatory authorities to retain the main study records) or the specimens have been completel y anon ymized, there will no longer be a link between the participantâ€™s personal information and their specimens. In this situation, the request for specimen withdrawal cannot be processed. 8.1.11 Participant Blinding/Unblindi ng STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY EFFORT SHOULD BE MADE NOT TO UNBLIND THE PARTI CIPANT UNLESS NECESSARY. For emergency situations where the investigator or medically qualified designee (consistent with local requirements) needs to identify the study intervention used b y a participant and /or the dosage administered , he/she will contact the emergency unblinding call center b y telephone and make a request for em ergency unblinding. As requested b y the investigator or medically qualified designee, the emergency unblinding call center will provide the information to him/her promptly and report unblinding to the Sponsor. Prior to contacting the emergency unblinding call center to request unblinding of a participantâ€™s intervention assignment, the investigator who is a qualified physician should make reasonable attempts to enter the intensit yof the AEs observed, the relation to study intervention, the reason thereof , etc., in the medical chart. If it is not possible to record this assessment in the chart prior to the unblinding, the unblinding should not be delayed. In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and person performing the unblinding) must be documented promptly , and the Sponsor Clinical Director notified as soon as possible. Once an emergency unblinding has taken place, the principal investigator, site personnel, and Sponsor personnel may be unblinded so that the appropriate follow -up medical care can be provided to the participant . Participants whose trea tment assignment has been unblinded by the investigator or medicall y qualified designee and/or nonstudy treating ph ysician must be discontinued from study intervention, but should continue to be monitored in the study. Additionally , the investigator or medically qualified designee must go into the I RT sy stem and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 0574PH"
56,page_56,"PRODUCT: MK-7264 56 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 emergency unblinding call center is not available for a given site in this study , the IRT system should be used for emergency unblinding in the event that this is required for participant safety . In the instance of identify ing MK-7264 crystalsin the urine , the participant will be discontinue d from the study intervention (see Section 8.3.7 for further details) . If a participant has confirmed MK -7264 cry stals, it will be known that the participant was receiving MK- 7264, but not which dose . In this circumstance, formal non- emergency unblinding should not be performed . 8.1.12 Calibration of Equipme nt The investigator or qualified designee has the responsibility to ensure that any device or instrument used for a clinical evaluation/test during a clini cal study that provides information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. Documentation of equipment calibrat ion must be retained as source documentation at the study site. 8.2 Efficacy Assessmen ts Compliance with the efficacy and safety assessments (along with study intervention use) is essential, and an y non -compliance noted b y the investigator or designee should r esult in consultation with the participant on corrective measures needed to ensure compliance. 8.2.1 Objective Cough Counts The assessment of 24 -hour coughs per hour (ie, average hou rly cough frequency based on 24-hour sound recordings) will be evaluated using t he VitaloJAKâ„¢ cough monitor , a 510k approved device (Premarket Notification per the US Food, Drug and Cosmetic Act) that has been implemented successfully in clinical studies of potential cough therapies, including 2Phase 2 studies of MK- 7264. The VitaloJ AKâ„¢ cough monitor is a digital recording device that uses 2 input channels: biometric sensor and air microphone. The first records sounds from the lungs and trachea through a chest contact biometric sensor, which is attached to the skin at the top of the sternum. The second channel captures ambient sounds through a lapel air microphone. The device will be carried in a cloth belt bag worn around the participantsâ€™ waist, and all sounds the participant makes during cough monitoring will be recorded o n the compact flash (CF) card. T he CF card contains the full, raw, sound recording data that is the output from the validated cough monitor and is the source for the recording data. The sound recordings on the CF cards are uploaded to the Vitalograph Web Portal for storage and anal ysis to generate cough data per Vitalograph standard operating procedures , and the Web Portal is the so urce for the cough counts data. Sites will be uploading the CF card recordings to the Vitalograph Web Portal; however, if after troubleshooting the sites are unsuccessful, the site will securel y ship the CF card to 0574PH"
57,page_57,"PRODUCT: MK-7264 57 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Vitalograph for uploading. Long -term storage of the CF cards may be done by Vitalograph for those sites unable to provide long -term storage of the cards. When the digital recording arrives at the central reading center, a human analyst uses standardized criteria to identify transitions between awake and a sleep states. To reduce review time, the 24- hour recordings are processed through a computerized algorithm that removes periods of silence and a high proportion of non -cough sounds. A cough anal yst then evaluates the abbreviated recording b y listening to b oth audio channels and inspecting the visual wave form of potential cough sounds. The anal yst tags the explosive portion of each cough using software built for anal ysis and annotation of sound recordings (Vitalograph Web Portal). Cough counts are then tall ied automatically for the 24- hour period from the annotated audio file. Awake cough counts are tallied only during the time the participant is determined to be awake for the awake coughs per hour assessment. The cough monitor will be attached to the parti cipant at Visit 2 and the day before for Visits 4-6and Discontinuation during the Main study period (see Section 1.3). Attachment should occur before approximately 11 AM and the cough monitor should be worn for 24 hours (see VitaloJAKâ„¢ site manual for further details). The participant should not remove the cough monitor during the 24 -hour period; the monitor will be removed during the actual visit, at the clinic, by site staff the next day . The f irst dose of study intervention administered is at V isit 3 after the cough monitor is removed, after the pre -dose PK sample collection, and before approximately 11AM. Attachment of the cough monitor may be managed by study site staff or mobile nurses if available and approve d.On the day of a study site visit after Visit 3 (or mobile nurse visit where applicable) when the cough monitor will be attached, study intervention dosing should occur prior to the cough monitor being turned on. Therefore, the cough monitor should first be attached, the participant should then be dosed, and then the cough monitor should immediately be turned on (see Figure 2). V =Visit Figure 2 C ough Monitoring: Attachment Procedure 0574PH"
58,page_58,"PRODUCT: MK-7264 58 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Removal of the cough monitor will occur at the study site and be managed by study site staff. On the day of a study site visit when the cough monitor will be removed, the morning dose should not be taken at home and instead will be given as a wi tnessed dose at the study site. Therefore, dosing will occur after the cough monitor is removed (once 24- hour reco rding has completed) , after the pre -dose PK sample collection, and before approximately 11 AM (see Figure 3). PK=Pharmacokinetic; V =Visit . Figure 3 C ough Monitoring: Removal Procedure It is recommended that the monitor first be removed (once the 24 -hour recording has completed) to avoid an y interference. Pre -dose PK should then be collected, prior to study intervention dosing . All visits, where the cough monitor will be attached/removed, should be scheduled prior to 11 AM to meet the attachment/removal timeframes, as well as the PK sample collection(s), and study site dosing requirements. If cough data is not usable and patient is required to return to the clinic to repeat , it should only be repeated upon Sponsor approval . Participants who discontinue study interven tionearly will continue to be monitored in the study and should be encouraged to continue to complete the assessment of 24 -hour coughs per hour for the remaining visits (as outlined in the SoA) through the end of the study. 8.2.2 Electronic Patient -reported Out comes At Screening (Visit 1), each participant will be properly trained and instructed on the use of an electronic diary (eDiary ) for completing the ePRO measures. Participants should bring their eDiary device for all study visits, and should be contacted and reminded to do so (eg, b y telephone or text) before each stud y site visit. 0574PH"
59,page_59,"PRODUCT: MK-7264 59 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Compliance with daily completion of the eDiaries must be monitored by the investigator or designee. Each investigator site will contact individual participants who are non -compl iant in order to retrain and/or remind them to complete their assessments as per Section 1.3 (SoA). Participants will be instructed to complete dail y ePRO measures (CSD and Cough Severit y VAS) at approximately the same time in the evening as outlined in the SoA .If a participant fails to complete the CSD and/ or Cough Severit y VAS ePRO measure (s), the eDiary will allow the participant, based on recall, to complete measures at an y time in the next 24 hours (also see vendorâ€™s site manual for further details). Participants will also be asked to complete visit e PRO measures ( Hull Airway Reflux Questionnaire [ HARQ ], LCQ, SF- 12, EQ5D 5L, WPAI and/or PGIC) on the day of the visits as outlined in the SoA (also see vendorâ€™s site manual for further details). If a parti cipant fails to complete the HARQ, LCQ, SF -12, EQ5D 5L, WPAI and/or PGIC ePRO measure(s), the eDiary will allow the participant, based on recall, to complete these measures at an y time in the next 48 hours. I f these visit PROs are not completed, based on r ecall, within the 48 hours, participants may be asked to complete them at a later date . All Visit 2 e PRO measures MUST be activated and completed prior to thefirst dose of study intervention /Randomization (see vendorâ€™s site manual for further details). Electronic PRO measures must be activated as outlined in the SoA. Visit8, Visit 11, V isit 13, and the Discontinuation Visit ePROs are â€œactivatedâ€ b y entering actual visit/event dates in the vendor portal ( Engage ). All other visit ePROs are activated at the clinic visit using the site menu on the device or remotel y using a PIN if the participant forgets to bring the device to the clinic visit. Participants who discontinue study intervention early will continue to be monitored in the study and should be enco uraged to continue to complete the e PRO measures (along with the assessment of 24 -hour coughs per hour) for the remaining visits (as outlined in the SoA) through the end of the study . Data collection for all ePRO measures will be dependent on ePRO device and software availability. 8.2.2.1 Cough Severity Diary Participants will be asked to record their cough frequency, intensit y, and disruption due to cough using the 7 item CSD. Participants will rate each item using an 11 -point sc ale ranging from 0 to 10 with higher scores indicating greater severit y. Participants will complete the CSD at approximately the same time daily,beginning at Visit 1until Visit 9 (with a minimum requirement of 7 days of completion prior to first dose of study intervention/R andomization ). During the Extension study period, completion of the CSD will be required daily , at approximately the same time for a 1 week period, beginning 1 week prior to Visit 11 and beginning 1 week prior to Visit 13. Participants should be contacted (eg, by telephone or 0574PH"
60,page_60,"PRODUCT: MK-7264 60 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 text) during the Extension study period to remind them to complete the CSD during these weeks. 8.2.2.2 Cough Severity Visual Analogue Scale Participants will be asked to rate the severity of their cough over the past 24 hou rs using a 100 mm Cough Severit y VAS single -item questionnaire with the response ranging from 0(â€œNo Coughâ€) to 100 (â€œExtremely Severe Coughâ€). Participants will complete the Cough Severit y VAS at approximately the same time daily , beginning at Visit 1 unt il Visit 9 (with a minimum requirement of 7 day s of completion prior to first dose of stud yintervention/R andomization ). In order to confirm participant eligibility, stud y site staff will be required to review/confirm the: ï‚·Participant met the Screening Cou gh Severit y VAS criteria from the measurement done on the day of Visit 1 (or from the next day ,if the evening measure was missed). ï‚·Participant met the Baseline Cough Severity VAS criteria from the measurement done on the day prior to Visit 2 ,prior to con ducting an y other Visit 2 procedures (or from the morning of Visit 2 ,prior to conducting any Visit 2 procedures , if the evening measure was missed). A score of â‰¥40 mm on the Cough Severity VAS, at both the Screening and Baseline visits is required for randomization into the study . During the Extension study period, completion of the Cough Severity VAS will be required daily , at approximately the same time for a 1 week period, beginning 1 week prior to Visit 11 and beginning 1 week prior to Visit 13. Participants should be contacted (eg, by telephone or text) during the Extension study period to remind them to complete the Cough Severity VAS during these weeks. 8.2.2.3 Leicester Cough Questionnaire Participants will be asked to complete the 19- item L CQ to assess the impact of their cough severit y on ph ysical, social and ps ychological functioning. 8.2.2.4 12-item Short Form Survey The SF -12 is a validated, 1 2-item questionnaire designed to assess general health- related quality of life. It is a widely used instrument that has been shown to be responsive to changes in disease severity following intervention. The SF -12 is scored such that a total score and 8domain scores can be calculated with higher scores indicating better func tioning: Phy sical Functioning, Role Ph ysical, Role -Emotional, Bodily Pain, General Health, Social Functioning, Mental Health, and Vitality . Data obtained from the SF -12 will be used in health economic anal yses. 0574PH"
61,page_61,"PRODUCT: MK-7264 61 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.2.2.5 Work Productivity and Activity Impairment Que stionnaire The WPAI questionnaire y ields 4types of scores as follows: (1) absenteeism (work time missed); (2) presenteeism (impairment at work / reduced on -the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presen teeism); and (4) activity impairment. The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, ie, worse outcomes. Participants will be asked to indicate if they are currentl y empl oyed and to respond to the following questions referring to â€œthe past 7 daysâ€: work hours missed due to health problems, work hours missed for other reasons, hours actually worked, the degree to which their health has affected productivity while working, a nd the degree to which their health affected productivity in regular unpaid activities. 8.2.2.6 EuroQo L5L Dimensions Questionnaire The EQ5D -5L is a standardized instrument for measuring generic health status used for estimating preference weights for that health status. By combining the weight with time, quality adjusted life years can be computed. The EQ5D -5L descriptive s ystem comprises the following 5 dimensions: mobility , self -care, usual activities, pain/discomfort and anxiety /depression. Each dimension has 5 levels and the participant will be asked to indicate their health state using a 5- level rating scale. The EQ VAS records the participantâ€™s self -rated health on a vertical VAS where the endpoints are labeled â€˜best imaginable health stateâ€™ and â€œworst imaginable health stateâ€. This information can be used as a quantitative measure of health outcome as judged by the individual participant. 8.2.2.7 Patient Global Impression of Change Questionnaire Participants will be asked to rate the change in their chronic cough compared to the start of the study using the PGIC with response options ranging from â€œvery much improvedâ€ to â€œ very much worseâ€. 8.2.2.8 Hull Airway Reflux Questionnaire Unlike the other cough questionnaires used in this study (ie, LCQ, CSD, and Cough Severit y VAS), HARQ was designed as an aid to diagnosis rather than assess quality of life impacts or cough severit y. The HARQ has demonstrated good psychometric properties and no redundant items. The HARQ consists of 14 questions with responses on a numeric scale from 0to 5. A score of â€˜â€˜0â€™â€™ means that no problems are caused b y the cough s ymptom and â€˜â€˜5â€™â€™ means severe/frequent problems. The HARQ will be used to more completely characterize the patient population. 0574PH"
62,page_62,"PRODUCT: MK-7264 62 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.3 Safety Assessments Details regarding specific safet y procedures/assessments to be performed in this study are provided below . The total amount of blood/tissue to be drawn/collected over the course of the study (from prestud y to poststudy visits), including approximate blood/tissue volumes drawn/collected b y visit and by sample ty pe per particip ant, can be found in Section 8. Planned timepoints for all safet y assessments are provided in the SoA. 8.3.1 Chest Radiography/Computed Tomography Thorax Scan A chest radiograph or computer tomograph y scan of the thorax should be performed locall y for participants, at Screening, if this has not been done within the last 5 years and after the onset of chronic cough. The chest radiograph or computer tomograph y scan of the thorax should not demonstrate any abnormality considered to be significantly contributing to the chronic cough or an y other clinicall y significant lung disease in the opinion of the principal investigator (or sub investigator, see inclusion criterion 1, Section 5.1 ). 8.3.2 Physical Examinations A complete ph ysical examination will include assessments of the following: general appearance; skin and ly mphatic; ey es, ears, nose, throat; cardiovascular s ystem; respiratory system; abdomen/gastrointestinal sy stem; urological sy stem; musculoskeletal and neurological s ystems. Other body systems may be examined. Any clinically significant abnormalities in phy sical examinations noted after Visit 1 will be recorded as AEs in the eCRF . A brief directed ph ysical exam may be performed at any study site visit th at does not alread y include a ph ysical exam if deemed necessary by the investigator due to signs/sy mptoms. A physical exam (complete or directed) can be performed at an y unscheduled visit if deemed necessary by the investigator. Investigators should pay special attention to clinical signs related to previous serious illnesses. 8.3.3 Vital Signs and Weight and Height Measur ements Vital sign measurements, including s ystolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), heart rate (beats per minute), r espiratory rate (breaths per minute), and body temperature (in centigrade) will be collected as outlined in the SoA. All blood pressure measurements should be performed on the same arm, preferabl y by the same person. Height (cm) and weight (kg) will also b e collected as per the SoA . Any clinically significant abnormalities in vital signs noted after Visit 1 will be recorded as AEs in the eCRF. 0574PH"
63,page_63,"PRODUCT: MK-7264 63 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.3.4 Electrocardiograms A 12 -lead ECG will be performed at Screening using local standard procedures. Clinically signif icant abnormal findings should be recorded in the AE eCRF. 8.3.5 Spirometry A spirometry assessment will be performed locally at Screening using a calibrated spirometer. Assessments will include FEV 1, FVC ,and FEV 1/FVC ratio. Spirometry should be performed in ac cordance with guidelines established by the ATS/ERS (Available from: http://www.thoracic.org/statements/). For safet y reasons, spirometry should be performed with the participant sitting, using a chair with arms and without wheels; however, if necessary toundertake the testing with the participant standing or in another position, this should be noted in the participantâ€™s study file. Spirometry performed within the past y ear of Screening is acceptable if the investigator confirms that spirometry was done du ring a period where the participant was clinically stable (eg, not during an upper respiratory infection). 8.3.6 Clinical Safety Laboratory Assessments â€¢Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for the timing an d frequency . â€¢The investigator or medically qualified designee (consistent with local requirements) must review the laboratory report, document this review, and record an y clinically relevant changes occurring during the stud y in the AE section of the case report form (CRF). The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are those which are not associated with the underly ing disease, unless judged b y the investigator to be more severe than expected for the participant's condition. â€¢All protocol -required laboratory assessments, as defined in Appendix 2, must be conducted in accordance with the laboratory manual and the SoA . â€¢If laboratory values from nonprotocol specified laboratory assessments performed at the institutionâ€™s local laboratory require a change in study participant management or are considered clinically significant by the investigator (eg, SAE or AE or dose modification), then the results must be recorded in the appropriate CRF (e g, SL AB). â€¢For an y laboratory tests with values considered clinically significantl y abnormal during participation in the study or within 7days after the last dose of study intervention , every attempt should be made to perform repeat assessments until the values return to normal or baseline or if a new baseline is established as determined by the investigator . 0574PH"
64,page_64,"PRODUCT: MK-7264 64 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.3.7 Renal and Urological Safety Assessments Safety assessments will be performed in all participants in order to monitor renal and urological safet y duri ng the course of the stud y. Participants will be monitored for hematuria using urinary dipstick (performed at the stud y site) and urinary crystals and hematuria through urinaly sis (performed at the central laboratory ).Dipstick and urinaly ses (including microscop y) will be collected as outlined in the SoA. Ifduring screening ,a participant has cry stalluria and/or unexplained hematuria (defined as , for example ,participants without a history of recent menses, urinary tract infection, or recent procedure/ins trumentation that would explain the hematuria ; Note: any other explanation for hematuria finding must be reviewed with the Sponsor. ), the investigator should : ï‚·Review and confirm if the finding is a new finding or a previousl y documented finding . ï‚·Evaluate the participantâ€™s medical history to identify conditions (ie,prior renal disease, prior history of kidney stones, medications, gastrointestinal conditions) and make a clinical determination if the participant is at high or low risk of potential complications/worsening due to an associated renal/urinary condition or its treatment, or requires a change in therap y for that condition that may interfere with interpretation of safet y data collected during the study . ï‚·If high risk, the participant should notbe enrolled and should be considered for further evaluation. ï‚·If low risk, the participant may continue with screening. If after randomization , the participant has confirmed, unexplained hematuria and/or urinary crystals per the central laboratory , an additional urine sample will need to be collected. One half of the sample will be sent to the central lab oratory for reconfirmation of unexplained hematuria and/or urin ary crystals. The other half of the sample will be collected via a specialized filter and shipped to Sponsor or designee and assessed for the presence of MK-7264 urinary crystals via Raman spectroscopy . Raman spectroscopy is sensitive to the chemical struc ture of the molecule and MK -7264 has a unique chemical structure compared to common urinary crystals. See vendorâ€™s site manual for further procedural details. If a participant ha sconfirmed MK -7264 urinary crystals, the Sponsor will inform the investigator and require discontinuation of the participant from study intervention with the recommendation to follow -up at approximately 2-week intervals with additional specialized urine anal yses performed until resolution of the MK -7264 urinary crystals. Once a par ticipant has confirmed MK -7264 cry stals, it will be known that the participant was receiving MK-7264 (formal unblinding should not be performed [see Section 8.1.11]). 0574PH"
65,page_65,"PRODUCT: MK-7264 65 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable Safety Events The definitions of an AE or SAE, as well as the method of recording, evaluating, and assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, SAE, and other reportable safety event reports can be found in Appendix 3. Adverse events, SAEs, and other reportable safety events will be reported by the participant (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized representative). The investigator and an y designees are responsible for detectin g, documenting, and reporting events that meet the definition of an AE or SAE as well as other reportable safet y events. Investigators remain responsible for following up AE, SAEs, and other reportable safety events for outcome according to Section 8.4.3 . The investigator, who is a qualified ph ysician, will assess events that meet the definition of an AE or SAE as well as other reportable safet y events with respect to seriousness, intensity /toxicity and causality . 8.4.1 Time Period and Frequency for Collecting AE , SAE ,and Other Reportable Safety Event Information All AEs, SAEs, and other reportable safety events that occur after the consent form is signed but before treatment allocation/randomization must be reported b y the investigator if the participant is rece iving placebo run -in or other run -in treatment, if the event cause the participant to be excluded from the study , or is the result of a protocol -specified intervention, including but not limited to washout or discontinuation of usual therap y, diet, or a pr ocedure. From the time of treatment allocation/randomization through last stud y-related intervention safet y follow -up telephone call, all AEs, SAEs and other reportable safet y events must be reported b y the investigator; however, for those participants who discontinue from the stud y intervention but continue to be monitored, only the AEs and other reportable safet y events that are shown in Table 3need to be reported. This specific approach for reporting starts from completion of the safet y follow -up telephone call/visit following cessation of intervention until the last study -related off -intervention telephone call/visit. Additionally , any SAE brought to the attention of an investigator at an y time outside of the time period specified in the previous paragraph must be reported immediately to the Sponsor if the event is considered drug -related. Investigators are not obligated to actively seek AE or SAE or other reportable sa fety events in former stud y participants. However, if the investigator learns of an y SAE, including a death, at an y time after a participant has been discharged from the study, and he/she considers the event to be reasonabl y related to the study interventi onor study participation, the investigator must promptly notify the Sponsor. 0574PH"
66,page_66,"PRODUCT: MK-7264 66 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and reported to the Sponsor or designee within the time frames as indicated in Table 3 . Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other Reportable Safet y Events Type of Event Reporting Time Period: Consent to Randomization/ AllocationReporting Time Period: Randomizati on/ Allocation through Protocol -specified Follow -up PeriodReporting Time Period: After the Protocol -specified Follow -up PeriodTimeframe to Report Event and Follow -up Information to Sponsor : Non-serious Adverse Event (NSAE)Report if: -due to protocol - specified intervention -causes exclusion -participant is receiving placebo run-in or other run-in treatmentReport all Not required Per data entry guidelines Serious Adverse Event (SAE)Report if: -due to protocol - specified intervention -causes exclusion -participant is receiving placebo run-in or other run-in treatmentReport all Report if: -drug/vaccine related (Follow ongoing to outcome)Within 24hours of learning of event Pregnancy/Lactati on ExposureReport if: -due to intervention -causes exclusionReport allaPreviously reported â€“ Follow to completion/terminatio n; report outcomeWithin 24hours of learning of event Event of Clinical Interest (require regulatory reporting)Report if: -due to intervention -causes exclusionReporta -Potential DILI -Require regulatory reportingNot required Within 24hours of learning of event Event of Clinical Interest (Do not require regulatory reporting)Report if: -due to intervention -causes ex clusionReporta -non-DILI ECIs and those not requiring regulatory reportingNot required Within 5 calendar days of learning of event 0574PH"
67,page_67,"PRODUCT: MK-7264 67 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Type of Event Reporting Time Period: Consent to Randomization/ AllocationReporting Time Period: Randomizati on/ Allocation through Protocol -specified Follow -up PeriodReporting Time Period: After the Protocol -specified Follow -up PeriodTimeframe to Report Event and Follow -up Information to Sponsor : Cancer Report if: -due to intervention -causes exclusionReport all Not required Within 5 calendar days of learning of event Overdose Report if: -receiving placebo run- in or other run- in medication Report allaNot required Within 5 calendar days of learning of event DILI = d rug-induced liver injury; ECI = event of clinical interest . aParticipants who discontinue study intervention and are continuing to be monitored in the study do not require the reporting of ECIs, pregnancy/ lactation exposure, and overdose. Previously reported pregnancies/lactations exposure need to be followed for completion/termination; report outcome. 8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable safet y events. Open -ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrence. 8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information After the initial AE/SAE report, the investigator is required to proactivel y follow each participant at subsequent visits/contacts. All AE, SAE, and other reportable safety events including pregnancy and exposure during breastfeeding, events of clinical interest (ECI), cancer, and overdose will be followed until resolution, stabilization, until the event is otherwise explained, or the partici pant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will make every attempt to follow all nonserious AEs that occur in randomized participants for outcome. Further information on follow -up procedures is given in Appendix 3. 8.4.4 Regulatory Reporting Requirements for SAE Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential so that legal obligations and ethical responsibilities towards the safet y of participants and the safety of a stud y intervention under clinical investigation are met. The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safet y of a stud y intervention under clinical investigation. All AEs will be reported to regulatory authorities, IRB/IECs, and investigators in accordance 0574PH"
68,page_68,"PRODUCT: MK-7264 68 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for Good Clinical Practice [GCP] ). Investigato r safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR s) according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary . An investigator who receives an investigator safety report describing an SAE or other specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it along with the I Band will notify the IRB/IEC, if appropriate according to local requirements . 8.4.5 Pregnancy and Exposure During Breastfeed ing Although pregnancy and infant exposure during breastfeeding are not considered AEs, an y pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to the investigator or their designee) that occurs during the stud y are r eportable to the Sponsor. All reported pregnancies must be followed to the completion/termination of the pregnancy . Pregnancy outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, blighted ovum, fetal death, intrauterine death, misca rriage, and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported. 8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as AEs or SAEs There are no disease -related events and/or disease -related outcomes not qualify ing as AEs or SAEs. 8.4.7 Events of Clinical Interest (ECI s) Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor. Events of clinical interest for this study include: a.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X the upper limit of normal, as determined by way of protocol -specified laboratory testing or unscheduled laboratory testing.* *Note: These criteria are based upon available regulatory guidance documents. T he purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underl ying etiology. The study site guidance for assessment and follow -up of these criteria can be found in the Investigator Stu dy File Binder (or equivalent). 0574PH"
69,page_69,"PRODUCT: MK-7264 69 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.5 Treatment of Overdose In this stud y, an overdose is any dose higher than the amount of study intervention taken outside the intervention assignment (Section 4.3.2). Study intervention should be taken once in the morning and once in the evening. If more than the protocol -specified intervention is taken within a 1- dayperiod (ie , >2tablets/day from either bottle )this is regarded as an overdose. No specific information is available on the treatment of overdose . Oral doses of u p to 1800 mg BID for 14 days were explored in earlier clinical studies without any untoward clinical effects (see MK -7264 IB). Overdose should be treated according to the participantâ€™s clinical signs and s ymptoms . Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the Sponsor Clinical Director based on the clinical evaluation of the participant. 8.6 Pharmacokinetics The date and time for the last dose of study intervention taken prior to the study visit on which the PK sample was collected should be recorded in the eCRF. In addition, the date and time of the PK sample collection should also be recorded in the eCRF. 8.6.1 Blood Collection for Plasma MK -7264 Blood s ample swill be collected at several visits during th e stud y for determination of MK-7264 as outlined in the SoA. Samples will be collected pre -dose at the specified study site visits (ie, the morning dose of study intervention will be taken after the PK sample is collected). Onl y at Visit 3, there will be 2 PK sample collections: 1at pre -dose and the other at 2hours (Â±30minutes) post-dose. Scheduled PK sample collections for all other visits, as outlined in the SoA, will be predose onl y. There will not be any dosing at Visit 13, but PK sample collection will be done. MK-7264 plasma concentrations will be determined using a validated LC -MS/MS assay . Sample collection, storage and shipment instructions for plasma samples will be provided in the operations/laboratory manual for the stud y . 8.7 Pharmacodynamics Pharmacod ynamic parameters will not be evaluated in this study . 0574PH"
70,page_70,"PRODUCT: MK-7264 70 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 8.8 Biomarkers Collection of samples for other biomarker research is also part of this study. The following samples for biomarker research are required and will be collected from all randomized participants as specified in the SoA: â€¢Blood for genetic analy sis 8.8.1 Planned Genetic Analysis Sample Collection The p lanned genetic a nalysis sample should be drawn for planned analy sis of the association between genetic variants in DNA and drug response. This sample will not be collected at the site if there is either a local law or regulation prohibiting collection, or if the I RB/IEC does not approve the collection of the sample for these purposes. If the sample is collected, leftover extracted DNA will be stored for future biomedical researc h if the participant signs the future biomedical r esearch consent. If the planned genetic analysis is not approved, but future biomedical r esearch is approved and consent is given, this sample will b e collect ed for the purpose of future biomedical r esearch. Sample collection, storage, and shipment ins tructions for planned genetic a nalysis samples will be provided in the operations/laboratory manual. 8.9 Future Biomedical Research Sample Collection If the particip ant signs the future biomedical r esearch consent, the following specime ns will be obtained as part of future biomedical r esearch: â€¢Leftover DNA for future research 8.10 Visit Requirements Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided in Section 8. 8.10.1 Screening Potential participants will be evaluated at Screening to determine if they fulfill the entry requir ements as set forth in Section s5.1and 5.2 . If an y participant fails to meet the study entry criteria, screen ing procedures may be repeated once based on investigator judgment after initial screening, and after consultation with the Sponsor. However, participants will not be permitted to rescreen if inclusion criteria for the Cough Se verity VAS was not met at Visit1. Participants who are consented and then are considered for washout of prohibited therap y (see Section 6.5) , should complete the washout prior to completing other screening procedures. For these individuals, t he screening period would begin after the completion of washout and when the participant returns to the clinic. Participants who washout of 0574PH"
71,page_71,"PRODUCT: MK-7264 71 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 prohibited therap y should return to the clinic after washout to complete the remaining Visit 1 procedures. Participant s who are consented may ,at the i nvestigatorâ€™s discretion, consider beginning the completion of daily ePROs (CSD and VAS) on the day of Visit 1prior to completing other screening procedures (in order to first determine if the participant meets the Visit 1 VAS entry criterion). For participants who meet the Visit 1 VAS criterion, t he screening period is noted as starting when the participant has provided consent. Participants who meet the Visit 1 VAS inclusion criterion should return to the clinic as soon as possible (within the recommended scheduling windows) after availability of the Visit 1 VAS score to complete the remaining Visit 1 procedures. 8.10.2 Baseline The Baseline visit must be scheduled between 7 day s and approximately 14 day s after Screening. Blood for PK assessments will be collected during Visit 2, and should be collected before attachment of the cough monitor (to avoid interference) as cough assessments will begin at Visit 2. The cou gh monitor should be attached before approximately 11AM and worn for 24hours. 8.10.3 Main Study Period Participants will be required to be seen in the clinic at Visit 3 to have the cough monitor removed that was attached at Visit 2. Additionally , 1day prior to Visits 4, 5, 6, and Discontinuation (from the Main study period) participants should return to the clinic to have the cough monitor attached. Attachment of the cough monitor at these visits, may be managed b y stud y site staff or mobile nurses (if locally available and approved for use), who will attach the cough monitor at the home of the participant. Cough monitors will be removed at study site Visits 4, 5, 6, and Discontinuation (from the Main study period). Refer to the vendorâ€™s site manual for additional details. For all stud y site visits, participants are to be reminded to bring their eDiary device with them to the visit. 8.10.4 Extension Study Period Participants will continue their assigned treatments during the 40 -week Extension study period. Cough counts will not be collected during this period. Electronic PRO measures will continue to be completed as outlined in the SoA . 8.10.5 Discontinued Participants Continuing to be Monitored in the Study If a participant is discontinued from the stud y intervent ionearly, the Discontinuation Visit assessments are to be performed at the final study site visit. 0574PH"
72,page_72,"PRODUCT: MK-7264 72 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 It is intended that all participants should be followed through completion of the study, regardless of premature discontinuation of intervention , unless the participant withdraws consent. Thus, participants who discontinue from study intervention prior to completion of the study should continue to be monitored to obtain relevant information through the end of the study . Study site visits/ telephone calls shou ld be made at timepoints that correspond to each remaining study visit. Such contacts will allow collection of follow -up information, limited to AEs, concomitant medication use, objective cough counting and eDiary assessments as outlined in the SoA (Sectio n 1.3). Concomitant therapies specifically prohibited (see Section 6.5) while the patient was on study intervention are no longer prohibited after discontinuation of study intervention. For these participants who have discontinued study intervention early, sites will be instructed to exert diligent efforts to continue to contact them. To enable sites to reach participants, the participants should provide primary and secondary contact information (eg, home telephone, work telephone, mobile tele phone). Sites must document the outcome of the telephone contact(s), to demonstrate diligent efforts have been made. If a participant does not agree to be contacted for follow -up for each of the remaining visits (as described in Section 7.1), the participant should be encouraged to accept a telephone contact at least at the final visit date (at the end of Main study period if they discontinue intervention during the Main study or at the end of the Extension study period if they discontinue intervention during the Extens ion). Additionally , the ICF will explain the importance of continued data collection from participants, including the use of continued contact by tele phone. 8.10.6 Posts tudy All participants will be required to complete the safety follow -up telephone call approx imately 14 day s (+ 7 day s) after the last dose of study intervention to determine if an y AEs have occurred since discontinuing study intervention . If the safet yfollow -up telephone contact occurs less than 14 days after the last dose of study intervention, a subsequent follow- up tele phone call should be made at approximately 14days (+ 7 day s) post the last dose of study intervention . 9 STATISTICAL ANALYSIS PLAN This section outlines the statistical analysis strategy and procedures for the study. If, after t he study has begun, but prior to any unblinding, there are changes made to the primary and/or key secondary hypotheses, or the statistical methods related to those h ypotheses, then the protocol will be amended (consistent with I CH Guidance for Industry E9). Chan ges to exploratory or other non -confirmatory anal yses made after the protocol has been finalized, but prior to unblinding, will be documented in a supplemental Statistical Analysis Plan (sSAP) and referenced in the CSR for the study . Post -hoc explora tory anal yses will be clearl y identified in the CSR. Separate anal ysis plans (ie, separate documents from the sSAP) will be developed to detail other planned anal yses including those specific to the analy sis of PK data and e PROs. 0574PH"
73,page_73,"PRODUCT: MK-7264 73 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 9.1 Statistical Analysis Plan Summary Key elements of the statistical anal ysis plan are summarized below. The comprehensive plan is provided in Sections 9.2 t hrough 9.12. Study Design OverviewA Phase 3, Randomized, Doubl e-blind, Placebo-c ontrolled, 12-m onth Study to Evaluate the Efficacy and Safety of MK -7264 in Adult Participants with Chronic Cough (PN027) Treatment AssignmentParticipants will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups: MK -7264 45 mg BID, MK -7264 15 mg BID, or placebo. Analysis PopulationsEffic acy: Full Anal ysis Set (FAS) population which consists of all randomized participants who have taken at least 1dose of study intervention and have at least 1 Baseline and at least 1post-Baseline endpoint observation during the treatment period; and Per -protocol (PP) population which excludes participants due to important deviations from the protocol from the FAS population. Safety : All Participants as Treated (APaT) population ,which consists of all randomized participants who received at least 1dose of study intervention . Primary Endpoint 24-hour coughs per hour at Week 12 Statistical Methods for Key Efficacy AnalysesThe primary anal ysis will be based on the FAS population. The primary anal ysis approach will be conducted utilizing the longitudinal analysis of covariance (ANCOVA) model. I n this model, the response vector consists of the change from baseline in log-transformed 24 -hour coughs per hour at each post -Baseline visit. The model will include factors for treatment group , visit, the interaction of treatment group by visit, gender, and region; and the log-transformed baseline v alue and the interaction of log-transformed baseline value by visit as covariates. The model will use all available 24 -hour coughs per hour data at baseline and on Week 4, 8 and 12. Contrasts will be constructed to compare each of the 2 MK-7264 treatment groups to the placebo group at each post-Baseline visit. The least squares mean change from baseline (in log scale) with the associated standard errors will be displayed for each treatment group. Estimated treatment differences (MK -7264 âˆ’ placebo) along with corresponding 95% confidence intervals (CIs) will also be presented for each MK -7264 treatment group. In addition, the geometric mean of the 24 -hour coughs per hour will be presented b y treatment group and by visit. The percent difference in the change from baseline between MK -7264 and placebo will be estimated by 100*(ediff-1), where diff is the difference provided b y the anal ysis of the log transformed variable. 0574PH"
74,page_74,"PRODUCT: MK-7264 74 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Statis tical Methods for Key Safety AnalysesThe anal ysis of safet y endpoints will follow a tiered approach. The tiers differ with respect to the anal yses that will be performed. Tier 1 safet y endpoints will be subject to inferential testing for statistical signi ficance with p- values and 95% CIs provided for between -group comparisons. Tier 2 safety endpoints will be evaluated via point estimates and 95% CIs for between -group comparisons. Tier 3 safet y endpoints will be evaluated via point estimates only. Interim Analyses One planned interim efficacy anal ysis will be performed in this study . Results will be reviewed b y an external DMC. The interim analysis is summarized below. Details are provided in Section 9.7. ï‚·Timing: To be performed when approximately 40% of participants have either completed, or discontinued prior to completion of the Main study period. ï‚·Testing: Futility anal ysis based on the primary endpoint of 24-hour coughs per hour at Week 12 will be provided. Additional interim safety reviews will also b e conducted at regular intervals. Multiplicity The T ype-I error rate over the multiple treatment group comparisons and multiple endpoints will be controlled by a step down testing procedure in a pre -specified order (det ails are described in Section 9.8). Sample Size and Power CalculationsThe planned sample size is 720 participants. For the primary endpoint of 24 -hour coughs per hour at Week 12, the study has at least 90% power to detect 20% and 30% relative reductions (versus placebo) for the MK -7264 15 mg BID or MK -7264 45 mg BID, respectivel y, at an overall 2 -sided 0.0499 alpha level. The det ails are described in Section 9.9. 9.2 Responsibility for Analyses/In -house Blinding The statistical anal ysis of the data obtained from this study will be the respons ibility of the Sponsor. This study (both the Main study period and the Extension study period) will be conducted as a double -blind study under in -house blinding procedures. At the end of the Main study period, a cop y of the database will be locked after me dical/scientific review has been completed, and data have been declared final and complete .The stud y team will be unblinded in order to perform and review the full anal ysis of data from the Main study period, as well as author a CSR for regulatory submiss ion. A separate, blinded Sponsor team (ie, blinded to participant -level intervention assignment) will then be assigned to continue the conduct of the Extension study period. All personnel who are unblinded for the Main study period will be excluded from an y future data review at the individual participant level. 0574PH"
75,page_75,"PRODUCT: MK-7264 75 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 At the end of the Extension study period, the CSR from the Main study period will be updated to include analy ses of the additional data acquired from the completion of the Extension study period. The investigator site personnel and the participants will be blinded to intervention assignment until the entire study completion. The Clinical Biostatistics department will generate the randomized allocation schedule(s) for study intervention assignment. Unblinding for Interim Efficacy and Safety Analyses Planned interim anal yses are described in Section 9.7. Study enrollment is likely to be ongoing at the time of any interim analy ses. Blinding to intervention assignment will be maintained at all investigational sites. The results of interim anal yses will not be shared with the investigators prior to the completion of the study. Results of the interim efficacy and safet y analyses will be provided by the external unblinded statistician to the DMC. Limited additional Sponsor personnel may be unblinded to the treatment -level results of the interim anal yses, if required, in order to act on the recommendations of the DMC. The extent to which individuals are unblinded with respect to results of interim anal yses will be documented b y the unblinded statistician. The DMC will serve as the primary reviewer of the results of the interim efficacy and safety analyses and will make recommendations for discontinuation of the study or modification to an EOC of the Sponsor. If the DMC recommends modifications to the design of the protocol or discontinuation of the study , the EOC may be unblinded to the results at the treatment -level in order to act on these recommendations. Additional logistical details will be provided in t he DMC Charter. Key aspects of the interim an alyses are described in Section 9.7. The external unblinded statistician will not be involved in any discussions regarding modifications to the protocol, statistical methods, identification of protocol deviation s, or data validation efforts after the interim anal yses. 9.3 Hypotheses/Estimation The primary and secondary hypotheses for this stud y are stated in Section 3. 9.4 Analysis Endpoints Efficacy and safety endpoints for evaluation are listed below, followed b y the descriptions of the derivations of selected endpoints. 9.4.1 Efficacy Endpoints Primary Efficacy Endpoint ï‚·24-hour coughs per hour at Week 12 0574PH"
76,page_76,"PRODUCT: MK-7264 76 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Secondary Efficacy Endpoints ï‚·Awake coughs per hour at Week 12 ï‚·Proportion of participants with a â‰¥30% reduction from baseli ne in 24 -hour coughs per hour at Week 12 ï‚·Proportion of participants with a â‰¥1.3 point reduction from baseline in mean weekl y CSD total score at Week 12 ï‚·Proportion of participants with a â‰¥2.7 point reduction from baseline in mean weekl y CSD total score at W eek 12 ï‚·Proportion of participants with a â‰¥30 mm reduction from baseline in Cough Severity VAS score at Week 12 ï‚·Proportion of participants with a â‰¥1.3- point increase from baseline in LCQ total score at Week 12 Exploratory Efficacy Endpoints Exploratory efficacy endpoints are stated in Section 3. 9.4.2 Safety Endpoints Safety endpoint s are stated in Section 3. 9.4.3 Derivations of Efficacy Endpoints Baseline for efficacy variables is defined as the last non -missing value prior to the first study intervention. Data Handling Rules for Cough Data In general, each 24- hour session starts with awake status and is composed of an awake monitoring period and a sleep monitoring period. If a participant did not have a sleep time available before the end of the recording sessio n, it will be considered that the participant was awake during the entire session. The last monitoring period of a session will be censored after the end time of the session. The cough data will contain all cough events occurring during that 24- hour monito ring period as well as the information about â€œsleep timeâ€ and â€œawake timeâ€. Any session with a duration of recording <20 hours will be considered as missing. If a session has a duration less than 24 hours but no less than 20 hours, the 24- hour coughs per h our will be based on the actual duration of the session. 0574PH"
77,page_77,"PRODUCT: MK-7264 77 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 On each collection day , the cough counts, the actual cough monitoring duration (in hours), and the coughs per hour will be derived for the total 24- hour period, the awake period, and the sleep period, respectively . 24-hour Coughs per Hour The 24- hour coughs per hour at Baseline and each post -Baseline visit are calculated as follows: 24-hour coughs per hour =Total number of cough events during the monitoring period (24-hour interval)/24 hours (where the denominator may be different, as noted above, if the recording period is actually <24 hours but â‰¥20 hours) As the change from baseline in 24- hour coughs per hour may have a skewed and wide distribution, the data will be (natural) log -transformed prior to analysis for the primary approach. The variable of change from baseline in log -transformed 24 -hour coughs per hour will be used in the anal ysis of the p rimary endpoint. For each post -Baseline visit, the primary efficacy variable of anal ysis is defined as f ollows: Change from baseline in log -transformed 24 -hour coughs per hour = Log (24 -hour coughs per hour at post -Baseline visit) â€“Log (24 -hour coughs per hour at Baseline ) The primary anal ysis of the primary endpoint will be on the natural log scale of the cough rate data. Awake Coughs per Hour Awake is time between waking up and sleep during the 24 -hour monitoring period. The awake coughs per hour are defined as follows: Awake coughs per hour =Total number of cough events during the monitoring period (24-hour interval) the participant is awake/Total duration (in hours) for the monitoring period the participant is awake. Similar to the primary efficacy variable, change from baseline in log -transformed awake coughs per hour will be used in the anal ysis and defi ned as below: Change from baseline in log -transformed awake coughs per hour = Log (Awake coughs per hour at post -Baseline visit) â€“Log (Awake coughs per hour at baseline). 0574PH"
78,page_78,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35 5HVSRQGHUVLQKRXU&RXJKVSHU+RXU  $QDO\VLV3RSXODWLRQV  (IILFDF\$QDO\VLV3RSXODWLRQV7KH)$6SRSXODWLRQZLOOVHUYHDVWKHSULPDU\SRSXODWLRQIRUWKH DQDO\VLVRIHIILFDF\GDWDLQ WKLVVWXG\7KH)$6SRSXODWLRQFRQVLVWVRIDOOUDQGRPL]HGSDUWL FLSDQWVZKRKDYHWDNHQDW OHDVW GRVHRIVWXG\LQWHUYHQWLRQDQGSURYLGHGDWOHDVW EDVHOLQ HDQGDWOHDVW SRVWEDVHOLQH HQGSRLQWREVHUYDWLRQGXULQJWKHWUHDWPHQWSHULRG  3+CCI"
79,page_79,"PRODUCT: MK-7264 79 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 The PP population excludes participants due to important deviations from the protocol that may substantiall y affect the results o f the primary efficacy endpoint. Potential deviations that may result in the exclusion of a participant from the PP population will be specified in the sSAP. The final determination on important protocol deviations, and thereby the composition of the PP population, will be made prior to the first unblinding of the database and will be documented in a separate memo. A supportive analy sis using the PP population may be performed for the primary efficacy endpoint if the proportion of the participants with impo rtant protocol deviations is >10%. Participants will be included in the treatment group to which they are randomized for the analysis of efficacy data using both the FAS and PP populations. Details on the approach to handling missing data are provided in Section 9.6. 9.5.2 Safety Analysis Population The APaT population will be used for the anal ysis of safet y data in this study. The APaT population consists of all randomized participants who received at least 1dose of study intervention. Participants will be inc luded in the treatment group corresponding to the study intervention they actuall y received for the anal ysis of safet y data using the APaT population. For most participants this will be the treatment group to which they are randomized. Participants who take incorrect stud y intervention for the entire treatment period will be included in the treatment group corresponding to the study intervention actually received. At least 1 laboratory or vital sign measurement obtained subsequent to at least 1 dose of study intervention is required for inclusion in the analy sis of each specific parameter. To assess change from baseline, a baseline measurement is also required. 9.5.3 Pharmacokinetic Analysis Population The evaluable PK population for PK data anal ysis is defined as all participants with 1measurable PK sample. 9.6 Statistical Methods This section describes the statistical methods that address the primary and secondary objectives. Methods related to exploratory objectives and supportive analyses will be described in the sSAP. Statistical testing and inference for efficacy and safet y analy ses are described in Sections 9.6.1 and 9.6.2, respectivel y. Controlling of family -wise T ype I error rate is described in Section 9 .8. Unless otherwise stated, all statistical tests w ill be conducted at Î±=0.0499 (2 -sided) level. 0574PH"
80,page_80,"PRODUCT: MK-7264 80 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 9.6.1 Statistical Methods for Efficacy Analyses The anal ysis of efficacy endpoints will be based on the FAS population. Unless otherwise specified, all efficacy data, regardless of participant exposure to study intervention , will be included in efficacy analy ses. Primary Efficacy Analysis Cough monitoring is conducted for baseline and 24 hours after administration of the study intervention on Weeks 4, 8, and 12. The primary efficacy endpoint of this study is 24 -hour coughs per hour at Week 12. As the change from baseline in 24 -hour coughs per hour may have a skewed and wide distribution, the data will be log -transformed prior to analy sis for the primary approach. The primary anal ysis of the primary endpoint will b e on the natural log scale of the cough rate data. The variable of change from baseline in log -transformed 24- hour coughs per hour will be used in the anal ysis of the primary endpoint. A negative result indicates a decrease in cough rate, while a positive result indicates an increase in cough rate. The primary anal ysis approach will be conducted utilizing the longitudinal ANCOVA model. In this model, the response vector consists of the change from baseline in log -transformed 24-hour coughs per hour at each post-Baseline visit. The model will include factors for treatment group , visit, the interaction of treatment group by visit, gender, and region; and the log-transformed baseline value and the interaction of log -transformed baseline value by visit as covari ates. The model will use all available 24 -hour coughs per hour data at Baseline and on Weeks 4, 8 and 12. Contrasts will be constructe d to compare each of the 2MK-7264 treatment groups to the placebo group at each post -Baseline visit. The least squares me an change from baseline (in log scale) with the associated standard errors will be displayed for each treatment group. Estimated treatment differences (MK -7264 âˆ’ placebo) along with corresponding 95% CIs wil l also be presented for each MK -7264 treatment gr oup. In addition, the geometric mean of the 24- hour coughs per hour will be presented by treatment group and b y visit. The percent difference in the change from baseline between MK -7264 and placebo will be estimated b y 100*(ediffâˆ’ 1), where diff is the di fference provided by the analysis of the log transformed variable. An observation of zero coughs per hour will be replaced b y a cough rate of 0.1/hour for the calculation of geometric means. If this rule is used, the table will have a footnote detailing the participant(s) and treatment group(s) that had observations of zero coughs per hour. Further details of the model specification, assumptions, and SAS implementation codes will be provided in the sSAP. 0574PH"
81,page_81,"PRODUCT: MK-7264 81 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Secondary Efficacy Analysis The continuous secondary efficacy endpoints will be anal yzed using a similar longitudinal ANCOVA model as used for the primary efficacy anal ysis. As the change in awake coughs per hour may have a skewed and wide distribution, the data will be log -transformed (natural log) prior t o analy sis. The variable of change from baseline in log transformed awake coughs per hour will be used in the anal ysis. Responder endpoints will be anal yzed by the logistic regression model. The logistic regression model will include terms for treatment group, visit, the interaction of treatment group by visit, gender, region, baseline, and the interaction of baseline b y visit for the underlying continuous response. L og odds ratio will be back transformed into odds ratio for final reporting. Table 4 summarizes the analy sis strategy of the primary and key secondary efficacy endpoints. Table 4 Analy sis Strategy for Primary and Key Secondary Endpoin ts Endpoint/Variable (At Week 12)Statistical Method Missing Data Approach Primary 24-hour coughs per hour Longitudinal ANCOVA Model -baseda Secondary Awake coughs per hour Longitudinal ANCOVA Model -baseda Proportion of participants with a â‰¥30% reduction from baseline in 24- hour coughs per hourLogistic Regression Model -baseda Proportion of participants with a â‰¥1.3 point reduction from baseline in mean weekly CSD total scoreLogistic Regression Model -baseda Proportion of participants with a â‰¥2.7 point reduction from baseline in mean weekly CSD total scoreLogistic Regression Model -baseda Proportion of participants with a â‰¥30 mm reduction from baseline in Cough Severity VAS scoreLogistic Regression Model -baseda Proportion of participants wi th a â‰¥1.3 point increase from baseline in LCQ total scoreLogistic Regression Model -baseda a Includes data collected after intervention discontinuation. ANCOVA = analysis of covariance ;CSD =Cough Severity Diary; LCQ =Leicester Cough Questionnaire ; VAS = visual analogue scales . 0574PH"
82,page_82,"PRODUCT: MK-7264 82 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 The strategy to address multiplicity issues with regard to multiple treatment comparisons, multiple efficacy endpoints, multiple timepoints, and interim anal yses is described in Sections 9.7 and 9.8. Handling of Missing Data The missing data approach is specified in the above mentioned primary and secondary efficacy endpoints analy sis sections. All other analy ses will be conducted based on the observed data only . Additional sensitivity analy ses with respect to the handling of mi ssing data will be specified in the sSAP. 9.6.2 Statistical Methods for Safety Analyses The safet y endpoints will be anal yzed based on the data collected in the Main study period, as well as based on the cumulative data collected across both the Main and Extension study periods. Safety and tolerability will be assessed b y clinical review of all relevant parameters including AEs, laboratory tests, and vital signs. The anal ysis of safet y results will follow a tiered approach ( Table 5). The tiers differ with respect to the anal yses that will be performed. Tier 1 safet y endpoints will be subject to inferential testing for statistical significance with p -values and 95% CI s provided for between -group comparisons. Tier 2 safety endpoints will be evaluated via point estimates and 95% CIs for between -group comparisons. Tier 3 safet y endpoints will be evaluated via point estimates only . Taste -related AEs (including d ysgeusia, ageu sia, and hy pogeusia, as well as other related terms) will be classified as belonging to â€œTier 1â€. The unadjusted p -values and point estimates with 95% CI s from the pairwise comparison between each of MK -7264 dose versus placebo will be provided. The defini tion of taste -related AEs will be finalized and documented before the database lock of the Main study period. The frequency of taste -related AEs across pre -defined time intervals will be provided, where the time intervals will be defined as: >0 to â‰¤1 week , >1 to â‰¤4 weeks, >4 to â‰¤8 weeks, and >8to â‰¤12 weeks in Main study period; and >12 to â‰¤24 weeks, >24 to â‰¤38 weeks, and >38toâ‰¤52 weeks in Extension study period. In each time interval, the denominator for calculation of percentage will be the number of participants exposed at the beginning of the time interval and the numerator will be the number of participants with at least 1taste-related AE occurring in this time interval. Only the first event will be counted and all recurrent events will not be inclu ded. The broad clinical and laboratory AE categories consisting of the percentage of participants with any AE, a drug related AE, a serious AE, an AE which is both drug- related and serious, an oral paresthesia AE, an oral hypoesthesia AE, and who discontin ued due to an AE will be classified as belonging to â€œTier 2â€. 0574PH"
83,page_83,"PRODUCT: MK-7264 83 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Adverse experiences (specific terms as well as s ystem organ class terms) and predefined limits of change in laboratory and vital signs will be classified as belonging to â€œTier 2â€ or â€œTier 3â€, ba sed on the number of events observed. Membership in Tier 2 requires that at least 4 participants in an y treatment group exhibit the event; all other adverse experiences and predefined limits of change will belong to Tier 3. The threshold of at least 4 events was chosen because the 95% CI for the between -group difference in percent incidence will alway s include zero when treatment groups of equal size each have less than 4 events and thus would add little to the interpretation of potentially meaningful diffe rences. Because man y 95% CIs may be provided without adjustment for multiplicity , the CIs should be regarded as a helpful descriptive measure to be used in review, not a formal method for assessing the statistical significance of the between -group differen ces in adverse experiences and predefined limits of change. The Tier 1 and Tier 2 safety endpoints will be analy zed using t he Miettinen & Nurminen method [Miettinen, O. and Nurminen, M. 1985] . Continuous measur es such as changes from baseline in laboratory , and vital signs will be considered Tier 3 safet y parameters. Summary statistics for baseline, on treatment, and change from baseline values will be provided b y treatment group in table format. Table 5 Analy sis Strategy for Safety Parameters Safety Tier Safety Endpointsap-value95% CI for Treatment ComparisonDescriptive Statistics Tier 1 Any taste -related AE X X X Tier 2 Any oral paresthesia AE X X Any oral hy poesthesia AE X X Any AE X X Any Serious AE X X Any Drug -related AE X X Any Serious and Drug -related AE X X Discontinuation due to AE X X Specific AEs, SOCs, or PDL Csb (incidence â‰¥4 participants in one of the treatment groups) X X Tier 3 Specific AEs, SOCs, or PDL Csb (incidence <4 participants in all the treatment groups) X Change from baseline results (L abs, Vital Signs) X a Adverse experience references refer to both clinical and laboratory AEs. b Includes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier -2 endpoints. AE=adverse event; CI =confidence interval; PDLC =Pre-defined Limit of Change; SOC = System Organ Class; X=results will be provided. 0574PH"
84,page_84,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35  6XPPDULHVRI%DVHOLQH&KDUDFWHULVWLFV'HPRJUDSKLFVDQG2 WKHU$QDO\VHV 'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV 7KHQXPEHUDQGSHUFHQWDJHRISDUWLFLSDQWVVFUHHQHGUDQGRPL]HG WKHSULPDU\UHDVRQVIRU VFUHHQLQJIDLOXUHDQGWKHSULPDU\UHDVRQIRUGLVFRQWLQXDWLRQZ LOOEHGLVSOD\HG 'HPRJUDSKLFYDULDEOHV LQFOXGLQJDJHJHQGHUUDFHZHLJKWDQG KHLJKW EDVHOLQH FKDUDFWHULVWLFVSULPDU\DQGFRPRUELGFRQGLWLRQVDQGSULRUDQ GFRQFRPLWDQWWKHUDSLHVZLOO EHVXPPDUL]HGE\WUHDWPHQW JURXS HLWKHUE\GHVFULSWLYHVWDWLVWLFV RUFDWHJRULFDOWDEOHV7KH FRPSDUDELOLW\RIWKHWUHDWPHQWJURXSVIRUHDFKUHOHYDQWFKDUDFW HULVWLFZLOOEHD VVHVVHGE\WKH VXPPDU\WDEOHV1RVWDWLVWLFDOK\SRWKHVLVWHVWVZLOOEHSHUIRUP HGRQWKHVHFKDUDFWHULVWLFV  ,QWHULP6DIHW\$QDO\VHV ,QWHULPVDIHW\DQDO\VHVZLOOEHSHUIRUPHGSHULRGLFDOO\ GHWHUPL QHGHLWKHUE\FDOHQGDUGDWHRU HQUROOPHQWPLOHVWRQHVWREHVSHFLILHGVHSDUDWHO\LQWKH'0&FK DUWHU )RUWKHVHLQWHULP DQDO\VHVDJHQHUDOUHYLHZRIVDIHW\UHVXOWVZLOOEHSHUIRUPHG EDVHGRQUHYLHZRI$(V ODERUDWRU\VDIHW\SDUDPHWHUVDQGRWKHUVDIHW \HQGSRLQWV  3+CCI"
85,page_85,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35  0XOWLSOLFLW\ 3ULPDU\DQG.H\6HFRQGDU\(QGSRLQWV'XHWRWKHLQWHULPDQDO\VLVIRUIXWLOLW\DQÄ®VSHQGLQJRI ZLOOEHDSSOLHGWRWKHVLGHG 7\SH,HUURUUDWHRIIRUWKHSULPDU\DQGVHFRQGDU\K\SRWKH VHVEDVHGRQWKH +D\ELWWOH3HWRPHWKRG >+D\ELWWOH-/  @>3HWR5HWDO  @0XOWLSOLFLW\DGMXVWPHQW ZLOOEHPDGHIRUWHVWLQJGRVHVRQWKHSULPDU\ DQGWKHNH\VHFR QGDU\HQGSRLQWVIRUWKH DQDO\VLVLHIRUWHVWLQJDIDPLO\RIWKHIROORZLQJK\SRWKHVHV â€¢+ 0.PJ%,'LVVXSHULRUWRSODFHERLQUHGXFLQJKR XUFRXJKVSHU KRXUDW:HHN â€¢+ 0.PJ%,'LVVXSHULRUWRSODFHERLQUHGXFLQJKR XUFRXJKVSHU KRXUDW:HHN â€¢+ 0.PJ%,'LVVXSHULRUWRSODFHERLQUHGXFLQJDZDNH FRXJKVSHUKRXU DW:HHN â€¢+ 0.PJ%,'LVVXSHULRUWRSODFHERRQWKHSURSRUWLRQ RISDUWLFLSDQWV ZLWKDÂ•UHGXFWLRQIURPEDVHOLQHLQKRXUFRXJKVSHUKRXU DW:HHN â€¢+ 0.PJ%,'LVVXSHULRUWRSODFHERLQUHGXFLQJDZDNH FRXJKVSHUKRXU DW:HHN â€¢+ 0.PJ%,'LVVXSHULRUWRSODFHERZLWKUHVSHFWWRW KHSURSRUWLRQRI SDUWLFLSDQWVZLWKDÂ•UHGXFWLRQIURPEDVHOLQHLQKRXUFRX JKVSHUKRXUDW :HHN 7RVWURQJO\FRQWUROWKH7\SH ,HUURUUDWHIRUWKLVIDPLO\DVW HSGRZQWHVWLQJSURFHGXUHZLOO EHDSSOLHGLQWKHRUGHUVSHFLILHG DERYH(DFKK\SRWKHVLVZLOOE HIRUPDOO\WHVWHGRQO\LIWKH SUHFHGLQJRQHLVVLJQLILFDQWDWÄ®  OHYHO  3+CCI"
86,page_86,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35 7DEOHSURYLGHVSRZHUIRUWKHSULPDU\DQGNH\ VHFRQGDU\ HIILFDF\HQGSRLQWVZLWKDWRWDORISDUWLFLSDQWV SDUWLF LSDQWVSHUWUHDWPHQWJURXS $OO FDOFXODWLRQVDUHEDVHGRQVLGHGÄ®  VLJQLILFDQFHOHYHO 7KHGURSRXWUDWHLVH[SHFWHGWR EHDW:HHN 7DEOH 3RZHUIRUWKH3ULPDU\DQG.H\6HFRQGDU\(QGSRLQWV (QGSRLQWV $W:HHN 3RZHULQ 0.PJ %,'*URXS3RZHULQ 0.PJ %,'*URXS KRXUFRXJKVSHUKRXU !   $ZDNHFRXJKVSHUKRXU   3URSRUWLRQRISDUWLFLSDQWVZLWKDÂ•UHGXFWLRQIURPEDVHOLQHLQKRXUFRXJKVSHUKRXU   %,' WZLFHGDLO\  3+CCI CCI CCI"
87,page_87,"352'8&7 0.  35272&2/$0(1'0(1712  0.),1$/35272&2/ $35 1RWH GHWDLOVRIWKHFRQFRPLWDQWPHGLFDWLRQVZLOOEHSURYLGHGL QDVHSDUDWHV6$3 $VLPLODUORQJLWXGLQDO$1&29$PRGHODVWKHSU LPDU\HIILFDF\HQG SRLQWZLOOEHSHUIRUPHG )RUHDFKVXEJURXSVXPPDU\VWDWLVWLFVLQFOXGLQJPHDQ6'DQG &,VZLOOEHSURYLGHGIRU HDFKWUHDWPHQWJURXS  &RPSOLDQFH 0HGLFDWLRQ$GKHUHQFH )RUHDFKSDUWLFLSDQWSHUFHQWFRPSOLDQFHZLOOEHFDOFXODWHGXVL QJWKHIROORZLQJIRUPXOD 7KHUDS\RQ%H6KRXOG'D\VRI 1XPEHU7KHUDS\RQ'D\VRI 1XPEHU&RPSOLDQFH3HUFHQW Ã— = $GD\ZLWKLQWKHVWXG\ZLOOEHFRQVLGHUHGDQÂ³2QWKHUDS\Â´GD\L IWKHSDUWLFLSDQWWDNHVDOO UHTXLUHGLQWHUYHQWLRQDVLQVWUXFWHGLQ6HFWLRQ:KHQDSDUWLF LSDQWWDNHVOHVVWKDQRUPRUH WKDQWKHUHTXLUHGLQWHUYHQ WLRQRQDGD\WKDWGD\LVQRWFRQVLG HUHGDQ2QWKHUDS \GD\ )RUSDUWLFLSDQWVZKRDUHIROORZHGIRUWKHHQWLUHVWXG\SHULRG WKHÂ³1XPEHURI'D\V6KRXOG EHRQ7KHUDS\Â´LVWKHWRWDOQXPEHURIGD\VIURPWKHILUVWVFKHG XOHGLQWHUYHQWLRQGD\WRWKH ODVWVFKHGXOHGLQWHUYHQWLRQGD\)RUSDUWLFLSDQWVZKRGLVFRQWLQ XHIURPWKHVWXG\ SHUPDQHQWO\WKHÂ³1XPEHURI'D\V6KRXOG%HRQ7KHUDS\Â´LVWKHW RWDOQXPEHURIGD\VIURP WKHILUVWVFKHGXOHGLQWHUYHQWLRQGD\ WRWKHODVWGRVHGD\  3+CCI"
88,page_88,"PRODUCT: MK-7264 88 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Summary statistics will be provided on pe rcent compliance by treatment group for the APaT population. 9.12 Extent of Exposure The duration of intervention for each participant will be evaluated b y calculating the number of day s on therapy . Exposure to study intervention will be summarized using descri ptive statistics (mean, SD, median, minimum, and maximum) for the APaT population. 0574PH"
89,page_89,"PRODUCT: MK-7264 89 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 10.1.1 Code of Conduct for Clinical Trials Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD) Code of Conduct for Interventional Clinical Trials I. Introduction A.Purpose MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH - GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. B.Scope Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or which are retrospective. Further, this Code does not apply to investigator- initiated trials , which are not under the full control of M SD. II.Scientific Issues A.Trial Conduct 1.Trial Design Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine patient preferences, etc. The design (ie, participant population, duration, statistical power) must be adequate to address the specific purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 2.Site Selection MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by M SD personnel to assess the ability to success fully conduct the trial. 3.Site Monitoring/Scientific Integrity Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completene ss, and consistency. Data are verified versus source documentation according to standard operating procedures. Per M SD policies and procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues 0574PH"
90,page_90,"PRODUCT: MK-7264 90 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 areinvestigated . When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified . B. Publication and Authorship Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the extent scientifically appropriate, MSDseeks to publish the results of other analyses it conducts that are important to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues such as multiplicity. MSDâ€™s policy on authorship is consistent with the re commendations published by the International Committee of Medica l Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in publications. III.Participant Protection A. Ethics Committee Review (Institutiona lReview Board [IRB ]/Independent Ethics Committee [ IEC]) All clinical trials will be reviewed an d approved by an IRB/IEC before being initiated at each site. Significant changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except changes required urgently to protect participant safety that may be enac ted in anticipation of ethics committee approval. For each site, the ethics committee and M SDwill approve the participant informed consent form. B. Safety The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local stand ard of care. All participation in M SD clinical tria ls is voluntary. Participants enter the trial only after informed consent is obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or receipt of, medical care that may otherwise be available to them. C. Confidentiality MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by law, only the investigator, Sponsor (or representative), ethics committee, and/or regulatory authorities will have access t o confidential medical records t hat might identify the participant by name. D. Genomic Research Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an ethics c ommittee. IV. Financial Considerations A. Payments to Investigators Clinical trials are time -and labor -intensive. It is M SDâ€™s policy to compensate investigators (or the sponsoring institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra recruiting efforts. MSD does not pay for participant referrals. However, M SDmay compensate referrin g physicians for time spent on chart review to identify potentially eligible participants. 0574PH"
91,page_91,"PRODUCT: MK-7264 91 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 B.Clinical Research Funding Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring institution is being pai d or provided a grant for performing the trial. However, the local ethics committee may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, all publications resulting from M SDtrials will indicate M SD as a source of funding. C. Funding for Travel and Other Requests Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be consistent with local guidelines and practices . V. Investigator Commit ment Investigators will be expected to review M SDâ€™s Code of Conduct as an appendix to the trial protocol, and in signing the protocol, agree to support these ethical and scientific standards. 10.1.2 Financial Disclosure Financial Disclosur e requirements are outlined in the US Food and Drug Administration Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the Sponsor's responsibility to determine, based on these regulations, whether a request for Financial Di sclosure information is required. It is the investigator's/subinvestigator's responsibility to comply with any such request. The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 CFR Part 54, to provide his/her financ ial interests in and/or arrangements with the Sponsor to allow for the submission of complete and accurate certification and disclosure statements. The investigator/subinvestigator(s) further agree to provide this information on a Certification/Disclosure Form, commonly known as a financial disclosure form, provided by the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this information to the Sponsor in the United States for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data. 10.1.3 Data Protection Participants will be assigned a unique identifier by the Sponsor. An y participant records or datasets that are transferred to the Sponsor will contain the identifier only ; participant names or an y information that would make the participant identifiable will not be transferred. The participant must be informed that his/her personal study -related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant. The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authori zed personnel appointed by the S ponsor, by appropriate IRB/IEC members, and b y inspectors from regulatory authorities. 0574PH"
92,page_92,"PRODUCT: MK-7264 92 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.1.3.1 Confidentiality of Data By signing this protocol, the investigator affirms to the Sponsor that information furnished to the investigator b y the Sponsor will be maintained in confidence, and such information will be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and employ ees, only under an appropriate understanding of confidentialit y with such board or committee, affiliated institution and emp loyees. Data generated b y this study will be considered confidential by the investigator, except to the extent that it is included in a publication as provided in the Publications section of this protocol. 10.1.3.2 Confidentiality of Participant Records By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), IRB/IEC, or regulatory authority representatives may consult and/or cop y study documents to verify worksheet/ CRF report form data. By signing the consent form, the partici pant agrees to this process. If stud y documents will be photocopied during the process of verifying worksheet/ CRF information, the participant will be identified b y unique code only; full names/initials will be masked prior to transmission to the Sponsor. By signing this protocol, the investigator agrees to treat all participant data used and disclosed in connection with this study in accordance with all applicable privacy laws, rules and regulations. 10.1.3.3 Confidentiality of IRB/IEC Information The Sponsor is re quired to record the name and address of each IRB/IEC that reviews and approves this study . The Sponsor is also required to document that each IRB/IEC meets regulatory and ICH GCP requirements b y requesting and maintaining records of the names and qualific ations of the IRB/IEC members and to make these records available for regulatory agency review upon request b y those agencies. 10.1.4 Committees Structure 10.1.4.1 Scientific Advisory Committee This study was developed in collaboration with a Scientific Advisory Committee (SAC). The SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input with respect to study design, interpretation of study results, and subsequent peer -reviewed scientific publications. 10.1.4.2 Executive Oversight Committee The Executi ve Oversight Committee (EOC) is comprise d of members of Sponsor Senior Management. The EOC will receive and decide upon any recommendations made by the DMC regarding the study. 0574PH"
93,page_93,"PRODUCT: MK-7264 93 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.1.4.3 External Data Monitoring Committee To supplement the routine study monitoring outlined in this protocol, an external DMC will monitor the interim data from this study . The voting members of the committee are external to the Sponsor. The members of the DMC must not be involved with the study in an y other way (eg, they cannot be study investigators) and must have no competing interests that could affect their roles with respect to the study . The DMC will make recommendations to the EOC regarding steps to ensure both participant safet y and the continued ethical integrity of the study. A lso, the DMC will review interim study results, consider the overall risk and benefit to study participants (Section 9.7) and recommend to the EOC whether the stud y should continue in accordance with the protocol. Specific details regarding composition, re sponsibilities, and governance, including the roles and responsibilities of the various members and the Sponsor protocol team ; meeting facilitation; the study governance structure; and requirements for and proper documentation of DMC reports, minutes, and recommendations will be described in the DMC charter that is reviewed and approved by all the DMC members. 10.1.5 Publication Policy The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. I n accordance with standard editorial and ethical practice, the Sponsor will generall y support publication of multicenter studies only in their entiret y and not as individual site data. I n this case, a coordinating investigator will be designated b y mutual agreement. If publication activity is not directed b y the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information an d to provide comments. Authorship will be determined by mutual agreement and in line with I nternational Committee of Medical Journal Editors authorship requirements. 10.1.6 Compliance with Study Registration and Results Posting Requirements Under the terms of t he Food and Drug Administration Amendments Act (FDAAA) of 2007 and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor of the study is solel y responsible for determining whether the stud yand its results are subject to the requirements for submission to http://www.clinicaltrials.gov, www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will review this protocol and submit the information necessary to fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. Information posted will allow participants to identify potentiall y appropriate studies for their disease conditions and pursue participation by calling a central contact number f or further information on appropriate study locations and study site contact information. 0574PH"
94,page_94,"PRODUCT: MK-7264 94 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 By signing this protocol, the investigator acknowledges that the statutory obligations under FDAAA, the EMA clinical trials directive or other locally mandated regist ries are that of the Sponsor and agrees not to submit any information about this study or its results to those registries. 10.1.7 Compliance with Law, Audit, and Debarmen t By signing this protocol, the investigator agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; generall y accepted standards of G CP (eg, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other gen erally accepted standards of good clinical practice); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix under the Code of Conduct for Clinical Studies. The investigator agrees not to seek reimbursement from participants, their insurance providers, or from gove rnment programs for procedures included as part of the study reimbursed to the investigator b y the Sponsor. The investigator will promptly inform the Sponsor of an y regulatory authority inspection conducted for this study . The investigator agrees to provide the Sponsor with relevant information from inspection observations/findings to allow the Sponsor to assist in responding to an y citations resulting from regulatory authority inspection and will provide the Sponsor with a copy of the proposed response for consultation before submission to the regulatory authority . Persons debarred from conducting or working on clinical studies by any court or regulatory authority will not be allowed to conduct or work on this Sponsorâ€™s studies. The investigator will immed iately disclose in writing to the Sponsor if any person who is involved in conducting the study is debarred or if any proceeding for debarment is pending or, to the best of the investigatorâ€™s knowledge, threatened. 10.1.8 Data Quality Assurance All participant data relating to the stud y will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator or qualified designee is responsible for verify ing that data entries are accurate an d correct by physicall y or electronically signing the CRF. Detailed information regarding Data Management procedures for this protocol will be provided separatel y. The investigator must maintain accurate documentation (source data) that supports the inform ation entered in the CRF. 0574PH"
95,page_95,"PRODUCT: MK-7264 95 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents. Study documentation will be promptly and fully disclosed to the Sponsor by the investigator upon request and also shall be made available at the study site upon request for inspection, copy ing, review, and audit at reasonable times b y representatives of th e Sponsor or an y regulatory authorities. The investigator agrees to promptly take an y reasonable steps that are requested b y the Sponsor or any regulatory authorit ies as a result of an audit or inspection to cure deficiencies in the stud y documentation and worksheets/CRFs . The Sponsor or designee is responsible for the data management of this study including quality checking of the data. Study monitors will perform ongoing source data review and verification to confirm that data entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from source documents; that the safet y and rights of participants are being protected; and that the study is being conducted in accordance with the currentl y approved protocol and an y other study agreements, ICH GCP, and all applicable regulatory requirements. Records and documents, including signed ICF, pertaining to the conduct of this study must be retained b y the investigator for 15 ye ars after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or part y without written notification to the Sponso r. 10.1.9 Source Documents Source documents provide evidence for the existence of the participant and substantiate the integrit y of the data collected. Source documents are filed at the investigatorâ€™s site. Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study . Also, current medical records must be available. 10.1.10 Study and Site Closure The Sponsor or its designee may stop the study or study site participation in the study for medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, regulations, and GCP. In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will promptly notify that study siteâ€™s IRB/IEC. 0574PH"
96,page_96,"PRODUCT: MK-7264 96 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.2 Appendix 2: Clinical Laboratory Tests â€¢The tests detailed in Table 8will be performed at the study site or by the central labor atory . â€¢Protocol -specific requirements for inclusion or exclusion of partic ipants are detailed in Section 5 of the protocol. â€¢Additional tests may be performed at an y time during the stud y as determined necessary by the investigator or required by local regulations. Table 8 Protocol -required Safet y Laboratory Assessments Laboratory AssessmentsParameters Hem atology Platelet Count RBC Indices: MCV MCH %ReticulocytesWBC count with Differential: Neutrophils Lymphocytes Monocytes Eosinophils BasophilsRBC Count Hem oglobin Hem atocrit Chemistry Electrolytes Sodium Potassium Chloride Bicarbonate Calcium Phosphorous Liver function tests AST/ SGOT ALT/ SGPT Alkaline phosphatase Total bilirubin (and direct bilirubin, if total bilirubin is elevated above the upper limit of normal) Renal function tests Blood Urea Nitrogen Creatinine eGFR calculation eGFR will be calculated with each serum creatinine measurement (using the Chronic Kidney Disease Epidemiology Collaboration [ CKD EPI ]formula [http://mdrd.com/]) Other Glucose (nonfasting) Albumin Total Protein Urine Dipstick/ Routine Urinalysisï‚·Specific gravity , pH, glu cose, protein, blood, ketones, bilirubin, urobilinog en, nitrite, leukocyte esterase by dipstick ï‚·Microscopic examination ( crystals will be characterized ) Note: Dipstick performed at site for ALL participants. Urine s amples are also collected and sent to central laboratory for ALL participants. 0574PH"
97,page_97,PRODUCT: MK-7264 97 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Laboratory AssessmentsParameters Other Screening Testsï‚·Serum or urine Î² human chorionic gonadotropin (Î² hCG) pregnancy test (as needed for w omen of childbearing potential) a.Urine pregnancy test will be performed at site in women of child bearing potential. Refer to Section 1.3. ALT/SGPT = alanine aminotransferase (SGPT); AST/SGOT = aspartate aminotransferase (SGOT); eGFR = estimated glomerular filtration rate; MCH = mean corpuscular hemoglobin ; MCV = mean corpuscular volume ; RBC = red blood cell; SGOT = serum glutamic -oxaloacetic transaminase ;SGPT = serum glutamic -pyruvic transaminase ;WBC = white blood cell. The investigator (or medically qualified designee) must document their review of each laboratory safet y report. 0574PH
98,page_98,"PRODUCT: MK-7264 98 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting 10.3.1 Definition of AE AE definition â€¢An AE is an y untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. â€¢NOTE: An AE can therefore be an y unfavorable and unintended sign (including an abnormal laboratory finding), s ymptom, or disease (new or exacerbated) temporally associated with the us e of a study intervention. â€¢NOTE: For purposes of AE definition, study intervention (also referred to as Sponsorâ€™s product) includes an y pharmaceutical product, biological product, vaccine, device, diagnostic agent, or protocol specified procedure whether investigational (including placebo or active comparator product) or marketed, manufactured b y, licensed by, provided b y, or distributed by the Sponsor for human use in this study. Events meeting the AE definition â€¢Any abnormal laboratory test results (hemat ology , clinical chemistry, or urinaly sis) or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinicall y significant in the medical and scientific judgment of the invest igator. â€¢Exacerbation of a chronic or intermittent pre -existing condition including either an increase in frequency and/or intensity of the condition. â€¢New conditions detected or diagnosed after stud y intervention administration even though it may have been present before the start of the study . â€¢Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction. â€¢Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. â€¢For all reports of overdose (whether accidental or intentional) with an associated AE, the AE term should reflect the clinical s ymptoms or abnormal test result. An overdose without any associated clinical sy mptoms or abnormal laboratory results is reported using the terminology â€œaccidental or intentional overdose without adverse effect.â€ â€¢Any new cancer or progression of existing cancer. 0574PH"
99,page_99,"PRODUCT: MK-7264 99 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Events NOT meeting the AE d efinition â€¢Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to the procedure is the AE. â€¢Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). â€¢Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the start of the study that do not worsen. â€¢Surgery planned prior to informed consent to treat a pre- existing condition that has not worsened. â€¢Refe r to Section 8.4.6 for protocol -specific exceptions. 10.3.2 Definition of SAE If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met. An SAE is defined as any untoward medical occurrence that, at any dose: 1.Results in death 2.Is life -threatening â€¢ The term â€œ life-threatening â€in the definition of â€œseriousâ€ refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which h ypothetically might have caused death, if it were more severe. 3.Requires inpatient hospitalization or prolongation of existing hospitalization â€¢Hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a pre -existing c ondition that has not worsened is not an SAE. A pre -existing condition is a clinical condition that is diagnosed prior to the use of an MSD product and is documented in the participantâ€™s medical history . 4.Results in persistent or significant disability/inca pacity â€¢The term disability means a substantial disruption of a personâ€™s ability to conduct normal life functions. 0574PH"
100,page_100,"PRODUCT: MK-7264 100 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 â€¢This definition is not intended to include experiences of relativel y minor medical significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, and accidental trauma (eg, sprained ankle) that may interfere with or prevent every day life functions but do not constitute a substantial disruption. 5.Is a congenital anomaly/birth defect â€¢In offspring of participant taking the produ ct regardless of time to diagnosis. 6.Other important medical events â€¢Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually be considered serious. Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dy scrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug a buse. 10.3.3 Additional Events Reported Additional events that require r eporting In addition to the above criteria, AEs meeting either of the below criteria, although not serious per ICH definition, are reportable to the Sponsor. â€¢Is a cancer â€¢Is associated with an overdose 10.3.4 Recording AE and SAE AE and SAE r ecording â€¢When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory , and diagnostics reports) related to the event. â€¢The investigator will record all relevant AE/SAE information on the AE CRFs /worksheets at each examination. â€¢It is not acceptable for the investigator to send photocopies of the participantâ€™s medical records to the Sponsor in lieu of completion of the AE CRF page. 0574PH"
101,page_101,"PRODUCT: MK-7264 101 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 â€¢There may be instances when copies of medical records for certain cases are requested b y the Sponsor. I n this case, all participant identifiers, with the exception of the participant number, will be blinded on the copies of the medical records before submission to the Sponsor. â€¢The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. I n such cases, the diagnosis (not the individual signs/sy mptoms) will be documented as the AE/SAE. Assessment of intensity â€¢An event is defined as â€œseriousâ€ when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, not when it is rated as severe. â€¢The investigator will make an assessment of intensity for each AE and SAE (and othe r reportable safet y event) reported during the stud y and assign it to 1 of the following categories: -Mild: An event that is easily tolerated b y the participant, causing minimal discomfort, and not interfering with every day activities (for pediatric studies , awareness of symptoms, but easily tolerated). -Moderate: An event that causes sufficient discomfort to interfere with normal every day activities (for pediatric studies, definitely acting like something is wrong). -Severe: An event that prevents normal ever yday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category used for rating the intensity of an event; and both AE and SAE can be assessed as severe (for pediatric studies, extremely distressed or unable to do usual activities). Assessment of c ausality â€¢Did the Sponsor â€™s product cause the AE? â€¢The determination of the likelihood that the Sponsor â€™s product caused the AE will be provided b y an investigator who is a qualified ph ysician. The investigatorâ€™s signed/dated initials on the source document or worksheet that supports the causalit y noted on the AE form, ensures that a medically qualified assessment of causalit y was done. This initialed document must be retained for the required regulatory time frame . The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test product and the AE based upon the available information. â€¢The following components are to be used to assess the relationship between the Sponsor â€™s product and the AE ; the greater the correlation with the components and their respective elements (in number and/or intensity ), the more likel y the Sponsor â€™s product caused the AE: 0574PH"
102,page_102,"PRODUCT: MK-7264 102 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 -Exposure: Is there evidence that the participant was actuall y exposed to the Sponsor â€™s product such as: reliable history, acceptable compliance assessment (pill count, diary , etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen? -Time Course: Did the AE fo llow in a reasonable temporal sequence from administration of the Sponsor â€™s product? I s the time of onset of the AE compatible with a drug -induced effect (applies to studies with investigational medicinal product)? -Likely Cause: Is the AE not reasonabl y explained by another etiology such as underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors. -Dechallenge: Was the Sponsor â€™s product discontinued or dose/exposure/frequency reduced? -If yes, did the AE resolve or improve? -If yes,this is a positive dechallenge. -If no, this is a negative dechallenge. -(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability ; (2) the AE resolved/improved despite continuation of the Sponsor â€™s product; (3) the s tudy is a single -dose drug stud y; or (4) Sponsor â€™s product(s) is/are only used 1 time.) -Rechallenge: Was the participant re -exposed to the Sponsor â€™s product in this study ? -If yes, did the AE recur or worsen? -If yes, this is a positive rechallenge. -If no, this is a negative rechallenge. (Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability , or (2) the study is a single -dose drug study ); or (3) Sponsor â€™s product(s) is/are used only 1 time.) NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND MAY HAVE BEEN CAUSED BY THE SPONSOR â€™S PRODUCT, OR I F RE -EXPOSURE TO THE SPONSOR â€™S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N ADVANCE BY THE SPONSOR CLINI CAL DIRECTOR, AND IF REQUI RED, THE IRB/IEC . â€¢Consistency with study intervention profile: Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor â€™s product or drug class pharmacology or toxi cology ? 0574PH"
103,page_103,"PRODUCT: MK-7264 103 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 â€¢The assessment of relationship will be reported on the case report forms/worksheets b y an investigator who is a qualified physician according to his/her best clinical judgment, including consideration of the above elements. â€¢Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor â€™s product relationship). -Yes, there is a reasonable possibility of Sponso râ€™s product relationship: -There is evidence of exposure to the Sponsor â€™s product. The temporal sequence of the AE onset relative to the administration of the Sponsor â€™s product is reasonable. The AE is more likely explained by the Sponsor â€™s product than by another cause. -No, there is not a re asonable possibility of Sponsorâ€™ s product relationship: -Participant did not receive the Sponsor â€™s product OR temporal sequence of the AE onset relative to administration of the Sponsor â€™s product is not reasonable OR the AE is more likely explained by another cause than the Sponsorâ€™s product. (Also entered for a pa rticipant with overdose without an associated AE.) â€¢For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causalit y. â€¢There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the Sponsor. However, it is very important that the investigator always make an assessment of causalit y for every event before the initial transmission of the SAE data to the Sponsor. â€¢The investigator may change his/her opinion of causality in light of follow -up information and send an SAE follow -up report with the updated causality assessment. â€¢The causality assessment is 1 of the criteria used when determining regulatory repor ting requirements. Follow -up of AE and SAE â€¢The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested b y Sponsor to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. â€¢New or updated information will be recorded in the CRF. â€¢The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information. 0574PH"
104,page_104,"PRODUCT: MK-7264 104 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.3.5 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electro nic data collection t ool â€¢The primary mechanism for reporting to the Sponsor will be the electronic data collection (EDC) tool. â€¢Electronic reporting procedures can be found in the EDC data entry guidelines (or equivalent). â€¢If the electronic s ystem is unavai lable for more than 24 hours, then the site will use the paper AE Reporting form. â€¢Reference Section 8.4.1 for reporting time requirements. â€¢The site will enter the SAE data into the electronic sy stem as soon as it becomes available. â€¢ After the stud y is compl eted at a given site, the EDC tool will be taken off -line to prevent the entry of new data or changes to existing data. â€¢If a site receives a report of a new SAE from a study participant or receives updated data on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can report this information on a paper SAE form or by telephone (see next section). â€¢Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or equivalent). SAE reporting to the Sponsor via paper CRF â€¢If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE paper CRF is the preferred method to transmit this information to the Sponsor. â€¢In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a cop y of the SAE data collection tool sent by overnight mail or courier service. â€¢Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF pages within the designated rep orting time frames. â€¢Contacts and instructions for SAE reporting and paper reporting procedures can be found in the Investigator Study File Binder (or equivalent). 0574PH"
105,page_105,"PRODUCT: MK-7264 105 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, Follow -up, and Reporting Not applicable. 0574PH"
106,page_106,"PRODUCT: MK-7264 106 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing 10.5.1 Definitions Wome n of Childbearing Potential (WOCBP) A woman is considered fertile following menarche and until becoming postmenopausal unless permanentl y sterile. Women in the following categories are not considered WOCBP: â€¢ Premenarchal â€¢Premenopausal female with 1 of the following: - Documented h ysterectomy -Documented bilateral salpingectomy -Documented bilateral oophorectom y Note: Documentation can come from t he site personnelâ€™s review of the participantâ€™s medical records, medical examination, or medical history interview. â€¢Postmenopausal female -A postmenopausal state is defined as no menses for 12 months without an alternative medical cause . â€¢A high follicle sti mulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therap y (HRT). However, in the absence of 12 months of amenorrhea, confirmation with 2 F SH measurements in the postmenopausal range is required. -Females on HRT and whose menopausal status is in doubt will be required to use 1 of the nonhormonal highl y effective contraception methods if they wish to continue their HRT during the stud y. Otherwi se, they must discontinue HRT to allow confirmation of postmenopausal status before stud y enrollment. 10.5.2 Contraception Requirements Male Participants Male participants are not required to use a form of contraception. 0574PH"
107,page_107,"PRODUCT: MK-7264 107 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Female Participants Female participants of childbearing potential are eligible to participate if they agree to use oneof the contraception methods described in Table 9consistently and correctl y during the protocol -defined time frame in Section 5.1. Table 9 Contraceptive Methods Highly Effective Contraceptive Methods That Are User Dependenta Failure rate of <1% per year when used consistently and correctly. â—Com bined (estrogen -andprogestogen -containing) hormonal contraceptionb â—‹Oral â—‹Intravaginal â—‹Transdermal â—‹Injectable â—Progestogen only hormonal contraceptionb â—‹Oral â—‹Injectable Highly Effective Methods That Have Low User Dependency Failure rate of <1% per year when used consistently and correctly. â—Progestogen -only contraceptive implantb â—Intrauterine hormone -releasing system (IUS)b â—Intrauterine device (IUD) â—Bilateral tubal occlusion â—Vasectomized partner A vasectomized partner is a highly effective contrac eption method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. â—Sexual abstinence Sexual abstinence is consi dered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of t he study and the preferred and usual lifestyle of the participant. Notes: Use should be consistent with local regulations regarding the use of contraceptive methods for participants of clinical studies. aTypical use failure rates are higher than perfect -use failure rates (ie, when used consistently and correctly). bIf locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation. WOCBP = wome n of childbearing potential 10.5.3 Pregnancy Testing WOCBP should only be included after a negative highl y sensitive urine or serum pregnancy test. Pregnancy testing will be performed at Visit 1 (in WOCBP) and after Visit 1 whenever an expected menstrual cy cle is missed or when pregnancy is otherwise suspected. Testing can also be performed as necessary based on local requirements. 0574PH"
108,page_108,"PRODUCT: MK-7264 108 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical Research 1. Definitions a.Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.1 b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.2 c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of variations in DNA sequence on drug/vaccine response.2 d.DNA: Deox yribonucleic acid. e.RNA: R ibonucleic acid. 2. Scope of Future Biomedical Research The specimens consented and/or collected in this study as outlined in Section 8. 9will be used in various experiments to understand: â€¢The biology of how drugs/vaccines work â€¢Biomarkers responsible for how a drug/vaccine enters and is removed by the body â€¢Other pathway s drugs/vaccines may interact with â€¢The biology of disease The specimen(s) may be used for future assay development and/or drug/vaccine development. It is now well recognized that information obt ained from study ing and testing clinical specimens offers unique opportunities to enhance our understanding of how individuals respond to drugs/vaccines, enhance our understanding of human disease and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by the Sponsor or those working for or with the Sponsor. 0574PH"
109,page_109,"PRODUCT: MK-7264 109 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 3. Summary of Procedures for Future Biomedical Research . aParticipants for Enrollment All participants enrol led in the clinical study will be considered for enrollment in the future biomedical research substud y bInformed Consent Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during screening for protocol enrollment from all particip ants or legal guardians, at a study visit by the investigator or his or her d esignate. Informed consent for future biomedical r esearch should be presented to the participants on the visit designated in the SoA. If delay ed, present consent at next possible Participant Visit. Consent forms signed by the participant will be kept at the clinical study site under secure storage for regulatory reasons. A template of each stud y siteâ€™s approved informed consent will be stored in the Sponsorâ€™s clinical document repo sitory . ceCRF Documentation for Future Biomedical Research Specimens Documentat ion of participant consent for future biomedical r esearch will be captured in the eCRFs . Any specimens for which such an informed consent cannot be verified will be destroyed. dFuture Biomedical Research Specimen(s) Collection of specimens for future biomedical r esearch will be performed as outlined in the SoA. I n general, if additional blood specimens ar e being collected for future biomedical r esearch, these will usually be obtained at a time when the participant is having blood drawn for other stud y purposes. 4. Confidential Participant Information for Future Biomedical Research In order to optimize the resea rch that can be conducted with future biomedical research specimens, i t is critical to link participant' clinical information with future test results. I n fact little or no research can be conducted without connecting the clinical study data to the specimen. The clinical data allow specific anal yses to be conducted. Knowing participant characteristics like gender, age, medical history and treatment outcomes are critical to understanding clinical context of analytical results. To maintain privacy of information collect ed from specimens obtained for future biomedical r esearch, the Sponsor has developed secure policies and procedures. All specimens will be single -coded per ICH E15 guidelines as described below. 0574PH"
110,page_110,"PRODUCT: MK-7264 110 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 At the clinical study site, unique codes will be placed on the future biomedical research specimens. This code is a ra ndom number which does not contain any personall y identify ing information embedded within it. The link (or key ) between participant identifiers and this unique code will be held at the stud y site. No personal identifiers will appear on the specimen tube. 5. Biorepository Specimen Usage Specimens obtained for the Sponsor will be used for anal yses using good scientific practices. Anal yses utilizing the future biomedical r esearch specimens may be performed b y the Sponsor, or an additional third party (eg, a univ ersity investigator) designated by the Sponsor. The investigator conducting the anal ysis will follow the Sponsorâ€™s privacy and confidentiality requirements. Any contracted third party analyses will conform to the specific scope o f analy sis outlined in this substudy . Future biomedical r esearch specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor. 6. Withdrawal From Future Biomedical Research Participants may withdraw their consent for future biomedical re search and ask that their biospecimens not be used for future biomedical r esearch. Participants may withdraw consent at an y time by contacting the principal investigator for the main study . If medical records for the main study are still available, the inv estigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@merck.com). Subsequently, the participant's specimens will be flagged in the biorepository and restricted to main stud y use only. If specimens were collected from study participants specificall y for future biomedical research, these specimens will be removed from the biorepository and destroy ed. Documentation will be sent to the investigator confirming withdrawal and/or destruction, if applicable. I t is the respons ibility of the investigator to inform the participant of completion of the withdrawal and/or destruction, if applicable. Any analyses in progress at the time of request for withdrawal/destruction or alread y performed prior to the request being received b y the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received. In the event that the medical records for the main study are no longer available (eg, if the inve stigator is no longer required by regulatory authorities to retain the main study records) or the specimens have been completely anony mized, there will no longer be a link between the participantâ€™s personal information and their specimens. In this situation, the request for withdrawal of consent and/or destruction cannot be processed. 0574PH"
111,page_111,"PRODUCT: MK-7264 111 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 7. Retention of Specimens Future biomedical r esearch specimens will be stored in the biorepository for potential analysis for up to 20 y ears from the end of the main study . Spe cimens may be stored for longer if a regulatory or governmental authority has active questions that are being answered. In this special circumstance, specimens will be stored until these questions have been adequately addressed. Specimens from the study site will be shipped to a central laboratory and then shipped to the Sponsor -designated biorepository . If a central laboratory is not utilized in a particular stud y, the study site will ship directl y to the Sponsor -designated biorepository. The specimens wil l be stored under strict supervision in a limited access facilit y which operates to assure the integrity of the specimens. Specimens will be destro yed according to Sponsor policies and procedures and this destruction will be documented in the biorepository database. 8. Data Security Databases containing specimen information and test results are accessible only to the authorized Sponsor representatives and the designated study administrator research personnel and/or collaborators. Database user authentication i s highl y secure, and is accomplished using network securit y policies and practices based on international standards to protect against unauthorized access. 9. Reporting of Future Biomedical Research Data to Participants No information obtained from explorator y laboratory studies will be reported to the participant, famil y, or physicians. Principle reasons not to inform or return results to the participant include: Lack of relevance to participant health, limitations of predictive capability , and concerns regar ding misinterpretation. If important research findings are discovered, the Sponsor may publish results, present results in national meetings, and make results accessible on a public website in order to rapidl y report this information to doctors and partici pants. Participants will not be identified by name in any published reports about this study or in any other scientific publication or presentation. 10. Future Biomedical Research Study Population Every effort will be made to recruit all participants diagnosed and treated o n Sponsor clinical studies for f uture biomedical r esearch. 11. Risks Versus Benefits of Future Biomedical Research For future biomedical research, risks to the participant have been minimized and are described in the Future Biomedical Research in formed consent. 0574PH"
112,page_112,"PRODUCT: MK-7264 112 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 The Sponsor has developed strict securit y, policies, and procedures to address participant data privacy concerns. Data privacy risks are largel y limited to rare situations involving possible breach of confidentiality . In this highl y unlikely situation, there is risk that the information, like all medical information, may be misused. 12. Questions Any questions related to the future biomedical research should be e mailed directly to clinical.specimen.management@merck.com. 13. References 1. National Cancer Institute [I nternet]: Available from https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618 2. International Conference on Harmonization [Internet] : E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. Available from http://www.ich.org/products/guidelines/efficacy /efficacy - single/article/definitions -for-genomic -biomarkers- pharmacogenomics - pharmacogenetics -genomic -data-and-sample -cod.html 3. Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and I nvestigational Site Staff. Available at http://i- pwg.org/ 4. Industry Pharmacogenomics Work ing Group [Internet]: Pharmacogenomics Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 0574PH"
113,page_113,"PRODUCT: MK-7264 113 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 10.7 Appendix 7: Country -specific Requirements The information in this appendix is added to the main protocol to describe the Off -treatment Durability Study Periodthat will be conducted only at certain stud y sites in the United Kingdom, United States of America, Ukraine, and Poland . 1.1Synopsis Study Type : The Off-treatment Durabilit y Study Period is observational. Inter vention Model : At selected sites and countries, participants from an y treatment group (ie, MK -7264 45 mg BID , MK -7264 15 mg BID, or placebo )who provide written informed consent, may also participate in a 3-month , Off-treatment Durabilit y Study Period. Estimated Duration of Study : The Sponsor estimates that the Off-treatment Durability Study Period will require approximately 16 months from the time the first participant starts the Off -treatment Durability Study Period until thelast participantâ€™s last study -related telephone call of the Off -treatment Durability Study Period. Number of Participants : Approximately 150 total participants who complete the Main and Extension Study Periods (up to Week 52) of this study and another ongoing ,Phase 3 study being conducted b y the Sponsor (P030) will be enrolled in the Off-treatment Durability Period of the study in which they are participating . The number of participants enrolled from each stud y ma y var y. Duration of Participation : Participants in the Off-treatment Durabilit y Study Period will be in the study for approximately 3 more months after their Week 52 visit. 0574PH"
114,page_114,"PRODUCT: MK-7264 114 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 1.2 Schema *Note: Visits 8, 10, 12, 14 , 15, 16, and 17 will be conducted by telephone. Visit 14 is a safety follow -up after the last dose of study intervention. BID = twice daily 0574PH"
115,page_115,"PRODUCT: MK-7264 115 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 1.3 Schedule of Activities (SoA) Study Period Extension/ Off-treatment Durability Study PeriodOff-treatment Durability Study Period Notes Follow -up Disc Durability Periodâ€œOff -treatment Durability Study Periodâ€ is also referred to as â€œDurability Periodâ€ Visit Number Visit 13 (Last visit of Extension Study Period and start Durability Study Period)Visit 14 (TC)Visit 15 (TC) Month 1Visit 16 (TC) Month 2Visit 17 (TC) Month 3Sections noted below may be referenced in the main body of the protocol (for general information and information about the Main and Extension Study Periods) and in Appendix 7 (information specific to the Durability Period). Scheduled Day Day 365 Day 379 Day 393 Day 421 Day 449 Scheduling Window (Recommended)Â±4 days +7days Â±7 days Â±7 days Â±7 days Scheduled Week Week 52 Week 54 Week 56 Week 60 Week 64 Written I nformed Consent for Durability Study PeriodX Consent may be obtained at Visit 9 or later, but prior to performing any procedures related to the Durability Period. I f obtained prior to Visit 13, consent should be reviewed with the participant at Visit 13. Inclusion/Exclusion Criteria for Durability PeriodX Collect/Review Participant Comment CardX X X X X X During the Durability Period, review of comment card will be conducted during each TC. See Section 8.1.6 below. Issue/I nstruct in use of new Participant Comment Cards for Durability PeriodX Review Concomitant MedicationsX X Review Treatments U sed for Cough and any use of ACEIX X X X Study I ntervention AccountabilityX Contact I RT System X Efficacy Procedures Activate ePROs X X X X X See Section 8.2.2 below. CSD Daily Cough Severity VAS Daily LCQ X X X X X 0574PH"
116,page_116,PRODUCT: MK-7264 116 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FI NAL PROTOCOL 26-APR -2019 Study Period Extension/ Off-treatment Durability Study PeriodOff-treatment Durability Study Period Notes Follow -up Disc Durability Periodâ€œOff -treatment Durability Study Periodâ€ is also referred to as â€œDurability Periodâ€ Visit Number Visit 13 (Last visit of Extension Study Period and start Durability Study Period)Visit 14 (TC)Visit 15 (TC) Month 1Visit 16 (TC) Month 2Visit 17 (TC) Month 3Sections noted below may be referenced in the main body of the protocol (for general information and information about the Main and Extension Study Periods) and in Appendix 7 (information specific to the Durability Period). Scheduled Day Day 365 Day 379 Day 393 Day 421 Day 449 Scheduling Window (Recommended)Â±4 days +7days Â±7 days Â±7 days Â±7 days Scheduled Week Week 52 Week 54 Week 56 Week 60 Week 64 EQ5D -5L X X X X X PGIC X X Safety Procedures Physical Examination X Directed physical exam Vital Signs X Weight X Hematology & Chemistry X Urinalysis (w/Microscopy)X Dipstick performed for ALL participants. Samples are also collected and sent to central laboratory for ALL participants. See Table 8 (Section 10.2 â€“Appendix 2 ). Specialized Urine Collection for Crystal AssayX Only if central laboratory urinalysis is positive for crystals and/or unexplained hematuria. See Section 8.3.7. (main body of protocol). Adverse Event MonitoringX X Spontaneous reports of certain AEs will be collected after V14. See Section 8.4.1 below for AE reporting requirements after V14. Pharmacodynamics/Biomark ers Pharmacokinetic Sample (blood)X AE = adverse event; ACEI = angiotensin converting enzyme inhibitor; CSD = Cough Severity Diary; Disc = discontinuation; ePRO = electronic patient -reported outcome; EQ5D -5L = EuroQoL 5 Version 5L dimensions questionnaire; I RT = interactive response technology; LCQ = Leicester C ough Questionnaire; PGIC = Patient Glo bal Impression of Change; TC = telephone contact; V = visit; VAS = Visual Analog Sc ale 0574PH
117,page_117,"PRODUCT: MK-7264 117 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 2.1 Study Rationale The M K-7264 Phase 3 program is designed primarily to define the efficacy , safet y and tolerability of MK-7264, an orall y available P2X3 antagonist, for the treatment of refractory or unexplained chronic cough (RCC, UCC) . The Phase 3 studies are designed as randomized, parallel treatment for 1 year with either placebo or 1 of 2 MK-7264 dose levels (15 mg BID, 45 mg BID). However, it is currentl y unknown how participants will respond to cessation of treatment with MK -7264 after 1 y ear of th erapy. Though limited, short -term data from Protocol 012 (the phase 2b dose ranging stud y with MK -7264) suggests that participants treated with MK -7264 for 12 weeks and observed 14 day s after discontinuation of tre atment showed a mean cough frequency off-treatment that did not increase compared to baseline (Week 0 ), suggesting no evidence of immediate rebound cough . The addition of the Off -treatment Durabilit y Study Period via the proposed amendment is intended to explore the impact of withdrawing MK -7264 therap y in RCC/UCC patients who have been treated for 1 year. 3 Hypothesis, Objectives, and Endpoints Objectives Endpoints Exploratory ï‚·Objective: To evaluate the off -treatment durability after 1 year of treatment with MK-7264, over the course of 3 months off treatment ï‚·Cough Severit y VAS ï‚·LCQ ï‚·CSD ï‚·PGIC ï‚·EQ5D -5L ï‚·Objective: To evaluate the time toâ€œloss of responseâ€ in on- treatment responders over the course of 3 months off treatmentï‚·Time to loss of response based on VAS ï‚·Time to loss of response based on CSD ï‚·Time to first use of a medication for cough 4.1 Overall Design Approximately 150 total participants ,in either this study orP030 at selected sites and countries, will enter a n Off -treatment Durabilit y Study Period at their last visit of the Extension Study Period (V13). The duration of this period will be approximately 3 months. Individual participation in the entire stud y is expected to be approximately 66weeks from Screening (Visit 1) through the end of the Off-treatment Durability Study Period (Visit 17) . Specific procedures to be performed during the Off-treatment Durability Period of the study , as well as associated visit windows, are outlined in the SoA above . General information about each procedure is in Section 8 of the main body of the protocol. Information specific to 0574PH"
118,page_118,"PRODUCT: MK-7264 118 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 the Off -treatment Durability Study Period is in various sections of this appendix (eg , Section 6.5 Concomitant Therapy). The final database lock for this protocol will be conducted after participants have completed, or discontinued prior to the completion of the Extension Study Period . The final database lock will occur independent ofenrollment in the Off -treatment Durability Study . The data from the Off -treatment Durability Study Period will be summarized in a separate report from the Main and Extension Study Period data. 5.1 Inclusion Criteria Participants are eligible to be included in the Off-treatment Durability Study Period onl y if all of the following additional criteria appl y: 1.Participant completed the Main and Extension Study Period s, on study intervention, through the evening prior to Visit 13. 2.Participant completed the baseline , (Visit 2, Day 0)ePRO diaries (ie, LCQ and EQ5D -5L). 3.Participant completed the Visit 13 L CQ. 4.Participant was at least 80% compliant with completion of the Cough Severity VAS throughout all s tudy periods. 5.Participant was at least 80% compliant with taking the study intervention throughout the Main and Extension Study Periods . Informed Consent 6.Participant (or legall y acceptable representative if applicable) provides written informed consent for the Off-treatment Durability Study Period . 5.2 Exclusion Criteria Participants are excluded from participation in the Off-treatment Durability Study Period if the following criteria apply : 1.Participant isexpected to need to take an angiotensin converting enzyme inhibitor during the Off-treatment Durability Study Period. 2.Participant experienced a serious or clinicall y significant adverse experience which is still present at the time of providing informed consent for the Off-treatment Durability Study Period. 3.Participant has had clinically significant changes in his/her general medical condition since enrolling in P027. 0574PH"
119,page_119,"PRODUCT: MK-7264 119 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 6.5 Conco mitant Therapy Between Visit 13 and Visit 14: Participants must adhere to the guidance parameters (Section 6.5 of main protocol) and exclusion criteria (Section 5.2 of main protocol) regarding use of c oncomitant therap y until the Visit 14 telephone contact (ie, for approximately the first 2 weeks of the Off-treatment Durability Study Period ). After Visit 14: ï‚·Participants may take medications and use other treatment as neede d, with one exception: oParticipants should continue to refrain from use of angiotens in converting enzy me inhibitors through completion of the Off-treatment Durability Study Period. 8.1.5.2 Concomitant Medications During the Off -treatment Durability Study Period, only the following treatments will be recorded in the eCRF: ï‚·Treatments used for cough ,(prescription and over -the-counter) including natural/herbal remedies, lozenges, or drinks that may include an active anti - tussive or expectorant. ï‚·Angiotensin converting enzy me inhibitors 8.1.6 Participant Comment Card Participants will be p rovided new participant comment card s for use during the Off-treatment Durability Study Period to capture treatments used between scheduled telephone contacts. The participant comment card should be discussed at each telephone contact as outlined in the SoA. Participants will be encouraged to return comment cards to the study site. Instructions will be provided. Concomitant therap y described above (Section 8.1.5.2) will be entered into the eCRF . 8.1.8 Assignment of Treatment/Randomization Number Participants in the Off-treatment Durabilit y Study Period will continue with the same treatment/randomization number assigned at stud y start. 0574PH"
120,page_120,"PRODUCT: MK-7264 120 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 8.2.2 Electronic Patient -reported Outcomes Participants in the Off-treatment Durabilit y Study Period will continue to complete the following ePRO measures as specified in the Off-treatment Durability Study Period SoA above : CSD, Cough Severity VAS, LCQ, PGIC, and EQ5D -5L. Participants will be instructed to complete the daily ePRO measures (CSD and Cough Severity VAS) at approximately the same time each day , from the evening of Visit 13 (ie, the last visit of the Extension Period) until the evening before Visit 17 (ie, last visit of the Off- treatment Durability Study Period) or Discontinuation Visit. If a participant fails to complete the CSD and/or Cough Severit y VAS ePRO measure(s), the eDiary will allow the participant, based on recall, to complete the measures at an y time in the next 24 hours. Participants will also be asked to complete the visit ePRO measures ( LCQ, EQ5D 5L, and/or PGIC) on the day of the telephone visits as outlined in the SoA. I f a participant fails to complete an y of the visit ePRO measure(s), the eDiary will allow the participant, based on recall, to complete these measures at any time in the next 48 hours. I f these visit ePROs are not completed, site personnel may be asked to reactivate visit questionnaires for the participant and the participant may be asked to complete them at a later date . Electronic PRO measures must be ac tivated as outlined in the SoA. Visit 13,Visit 15, Visit 16, Visit 17 and the Discontinuation visit ePROs are â€œactivatedâ€ b y entering actual visit/event dates in the vendor portal ( Engage ). 8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information Between Visit 13 and Visit 14: For all study participants, including those entering the Off-treatment Durability Study Period, see Section 8.4.1 of the main protocol for information regarding collection of AEs, SAEs, and Other Reportable Safety Event Information through the 14-day safet y follow -up contact (Visit 14) . After Visit 14: For participants in the Off -treatment Durability Study Period, after Visit 14, the following must be reported to the Sponsor within 24 hours of learning of the event : ï‚·Any drug-related SAE s or SAEs considered to be study participation related and brought to the attention of the investigator ï‚·Any drug -related NSAEs brought to the attention of the investigator during the time the participant is active in the Off-treatment Durability Study Period 0574PH"
121,page_121,"PRODUCT: MK-7264 121 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 ï‚·Any pregnancy that is brought to the attention of the investigator during the time the participant is active in the Off-treatment Durability Study Period. The pregnancy must be followed to completion/termination. I f the pregnancy continues to term, the outcome (health of the infant) must also be reported. If the investigator elects to submit AEs for non -Merck products, they should be reported to the Market ing Authorization H older (MAH) for that product or to the health authority according to the institutionâ€™s policy or local laws and regulations . 8.10 Visit Requirements Off-treatment Durability Study Period ï‚·Participants must provide written informed consent to participate in the Off-treatment Durability Study Period. (See Sections 8.1.1 and 8.1.1.1 of the main body of the protocol .) oConsent may be obtained at Visit 9 or later, but prior to performing an y procedures related to the Off-treatment Durability Study Period. If obtained prior to Visit 13, the consent should be reviewed with the participant at Visit 13. ï‚·Participants will begin the 3- month Off-treatment Durability Study Period on the same day as their final clinic visit (V isit 13) of the Extension Study Period. ï‚·Participants will not take study intervention during the Off-treatment Durability Study Period. ï‚·Participants will continue to complete ePROs as outlined in the SoA. ï‚·No additional clinic visits will be required after the final visit of the Extension Study Period (Visit 13). oTelephone contacts will o ccur as specified onthe SoA ï‚·Participants will be provided with instructions to return their eDiary device to the study site at the end of t he Off-treatment Durability Study Period. 9 Statistical Analysis Plan 9.2 Responsibility for Analyses/In -house Blinding The Main Period of the phase 3 study will be completed while the Extension Study Period and Off -treatment Durability Study Period ar e ongoing. Selected members of the Sponsor study team may be unblinded to review the data from the Main Study Period and author a CSR for facilitating regulatory submission . 0574PH"
122,page_122,"PRODUCT: MK-7264 122 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 A final database lock will occur after all partic ipants have completed the Extension Study Period. This database lock will occur independent of enrollment into the Off -treatment Durability Study Period. The data from the Off-treatment Durability Study Period will be summarized in a separate report from th e Main and Extension Study Period data. The investigator site personnel and the participants will be blinded to intervention assignment until the entire study is completed. 9.3 Hypotheses/Estimation No hy pothesis will be tested for the Off -treatment Durab ility Study Period . Point estimates and 95% confidence intervals (as appropriate) will be provided for the efficacy and safety endpoints. 9.4 Analysis Endpoints The main anal yses will be performed in all subjects who enter the Off-treatment Durability StudyPeriod. It is acknowledged that this population will include participants with vary ing measures of cough impact and severit y as assessed by the ePROs both at the end of the 1- yeartreatm ent (ie , Week 52), as well as compared to prestudy baseline (i e,Week 0). The primary metric of treatment durability will compare the ePRO measurement after 12 weeks off -treatment, t o the measurement at Week 52 (ie , immediately prior to treatment discontinuation), and will specificall y seek to describe the proportion of participants who either fail to maintain their treatment response, or who maintain treatment response. One way to describe â€œfailure to maintain the responseâ€ for a given ePRO, as an example, is that either the 12 weeks off -treatment measurement is de creased by at least X% of the Week 52 response, or the participant needs treatment for cough. The actual threshold would be based on considerations about clinical lyimportant differences and real-world data experiences. The definition will be specific to e ach ePRO. In addition, the data will be explore dto examine the impact of on- treatment response to MK-7264 on the outcome measures described above. Specificall y, the on -treatment measurement (defined as the dif ference in the Week 52 measurement compared to Week 0) will be categorized using different threshold definitions of â€œresponseâ€, and the subsequent off-treatment ePRO measurement in the Off -treatment Durability Study Period will be explored as a function of the on -treatment response. One way to descr ibe the â€œon -treatment responseâ€ for VAS, as an example, is that a participant has a Week 52 measurement at least X -mm lower than the Week 0 measurement. The definition will be specific to each ePRO. The final details about the anal ysis endpoints, as well a s other aspects of the anal yses, will be documented in anOff-treatment Durability Study Period memo , separate from the treatment period supplemental SAP, to be finalized before the completion of the Off-treatment Durability Study Period. 0574PH"
123,page_123,"PRODUCT: MK-7264 123 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 9.5 Analysis Populations Analy ses will generally be based on All Subjects Enrolled. 9.6.1 Statistical Methods for Efficacy Analyses For each e PRO separately , the proportion of participants who maintain treatment response during the 12 -week off-treatment period will be estimated and the associated 95% CI will be calculated using the Clopper -Pearson method. Time -to-event endpoints will be summarized using Kaplan -Meier estimates. 9.6.2 Statistical Methods for Safety Analyses In the beginning of the Off -treatment Durabilit y Study Period, up to 14 day s after the last dose of study intervention , AE collection will follow the same process as i n the Main and Extension Study Periods and will be anal yzed with the AEs from the M ain and Extension Study Periods in the CSR . For the Off-treatment Durability Study Period ,post 14 day s after the last dose of study intervention , only drug -related SAEs, SAEs considered to be study participation related, drug-related NSAEs, and any pregnancy that is brought to the attention of the investig ator will be collected. While such events will not be considered treatment emergent, they will be summarized in a separate report . 9.6.3 Summaries of Baseline Characteristics, Demographics, and Other Analyses The number and percentage of participants who discontinue from the Off -treatment Durability Study Period and the primary reasons for discontinuation will be display ed. Demographic variables (including age, gender, race, weight and height), baseline characteristics, and primary and co -morbid conditions will be summarized at Week 0 either by descriptive statistics or categorical tables. 9.7 Interim Analyses No interim ana lysis is planned during the Off -treatment Durability Study Period. 9.8 Multiplicity Multiplicity is not applicable since this study has no inferential testing. 9.9 Sample Size and Power Calculations The intended sample size for the Off -treatment Durabilit y Study Period is a pproximately 150 total participants across both P027 and P030. 0574PH"
124,page_124,PRODUCT: MK-7264 124 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 9.10 Subgroup Analyses No subgroup anal ysis is planned. 9.11 Compliance (Medication Adherence) Not applicable since no study intervention will be taken by the participant s during the Off- treatment Durability Study Period. 9.12 Extent of Exposure Not applicable since no study intervention will be taken by the participants during the Off- treatment Durability Study Period. 0574PH
125,page_125,PRODUCT: MK-7264 125 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 10.8 Appendix 8: Abbreviations Abbreviation Expanded Term ACCP American College of Chest Physician AE Adverse event ALT (SGPT) Alanine aminotransferase (serum glutamic pyruvic transaminase) ANCOVA Analysis of covariance APaT All participants as treated AST (SGOT) Aspartate aminotransferase (serum glutamic oxaloacetic transaminase) ATP Adenosine triphosphate ATS American Thoracic Society BID Twice daily CF Com pact flash CFR Code of Federal Regulations CI Confidence interval CKD EPI Chronic Kidney Disease Epidemiology Collaboration CP Conditional power CRF Case report form CSD Cough Severity Diary CSR Clinical study report DMC Data Monitoring Committee DNA Deoxyribonucleic acid ECG Electrocardiogram ECI Event of clinical interest eCRF Electronic case report form eGFR Estimated glomerular filtration rate EMA European Medicines Agency EOC Executive Oversight Committee ePRO Electronic patient -reported outcome EQ5D -5L EuroQoL 5 Dimensions Questionnaire ERS European Respiratory Society FAS Full analysis set FDA Food and Drug Administration FDAAA Food and Drug Administration Amendments Act FEV 1 Forced expiratory volume in 1 second FVC Forced vital capacity GCP Good Clinical Practice GERD Gastroesophageal reflux disease HRQoL Health -related quality of life IB Investigatorâ€™s Brochure ICF Informed Consent Form ICH International Conference on Harmonization IEC Independent Ethics Committee IRB Institutional Review Board IRT Interactive response technology LCQ Leicester Cough Questionnaire NSAE Non-serious adverse event PGIC Patient Global Impression of Change PK Pharmacokinetic PP Per protocol PRO Patient -reported outcome RBC Red blood cell (count) RNA Ribonucleic acid 0574PH
126,page_126,PRODUCT: MK-7264 126 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 Abbreviation Expanded Term SAE Serious adverse event SD Standard deviation SF-12 12-item short form survey SoA Schedule of Activities SOP Standard operating procedure sSAP Supplemental Statistical Analysis Plan UACS Upper airw ay cough syndrome VAS Visual analog scale WPAI Work productivity and activity impairment WBC White blood cell (count) WOCBP Woman/Women of childbearing potential 0574PH
127,page_127,"PRODUCT: MK-7264 127 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 11 REFERENCES [Barclay , J., et al 2002] Barclay J, Patel S, Dorn G, Wotherspoon G, Moffatt S, Eunson L , et al. Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci. 2002 Sep 15;22(18):8139 - 47.04JQYJ [Chamberlain, S. A., et al 2015]Chamberlain SA, Garrod R, Douiri A, Masefield S, Powell P, Bucher C, et al. The impact of chronic cough: a cross -sectional European survey . Lung. 2015 Jun;193(3):401- 8. Erratum in: L ung. 2015 Aug;193(4):615.04MMTF [Chung, K. F. 2014] Chung KF. Approach to chronic cough: the neuropathic basis for cough h ypersensitivity syndrome. J Thorac Dis. 2014 Oct;6(Suppl 7):S699- 707.04R3SD [Chu ng, K. F., et al 2006] Chung KF, McGarvey L, Widdicombe J. American College of Chest Phy sicians' cough guidelines. Lancet. 2006 Mar 25;367(9515):981 -2.04KQMY [Cockay ne, D. A., et al 2000] Cockay ne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, e t al. Urinary bladder h yporeflexia and reduced pain-related behaviour in P2X3 -deficient mice. Nature. 2000 Oct 26;407(6807):1011 - 5.04K6L W [Dworkin, R. H., et al 2009] Dworkin RH, Turk DC, McDermott MP, Peirce -Sandner S, Burke LB, Cowan P, et al. Interpre ting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009 Dec;146(3):238- 44.03Z3YR [Gibson, P., et al 2016] Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. Chest. 2016 Jan;149(1):27- 44.04MMZ9 0574PH"
128,page_128,"PRODUCT: MK-7264 128 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 [Hay bittle, J. L . 1971] Haybittle JL . Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793- 7.03P23D [Irwin, R. S., et al 2006] Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, et al. Diagnosis and management of cough executive summary : ACCP evidence -based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):1S -23S.04KW7B [Kardos, P ., et al 2010] Kardos P, Berck H, Fuchs KH, Gillissen A, Klimek L , Morr H, et al. Guidelines of the German Respiratory Society for diagnosis and treatment of adults suffering from acute or chronic cough. Pneumologie. 2010 Nov;64(11):701 -11.04KQP6 [Khakh, B. S. 2006] Khakh BS, North RA. P2X receptors as cell - surface ATP sensors in health and disease. Nature. 2006 Aug 3;442(7102):527 -32.04JRKF [Miettinen, O. and Nurminen, M. 1985]Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213- 26.03R2SH [Morice, A. H., et al 2004] Morice AH, Fontana GA, Sovijarvi AR, Pistolesi M, Chung KF, Widdicombe J, et al. The diagnosis and management of chronic cough. Eur Respir J. 2004 Sep;24(3):481 -92.04KQPD [Morice, A. H., et al 2006] Mori ce AH, McGarvey L, Pavord I, on behalf of the British Thoracic Societ y Cough Guideline Group. Recommendations for the management of cough in adults. Thorax 2006;61(Suppl 1):i1 -i24.03QMXM [North, R. A. 2004] North RA. P2X3 receptors and peripheral pain me chanisms. J Phy siol. 2004 Jan 15;554(Pt 2):301 -8.04JRR8 [Peto, R., et al 1976] Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Canc er 1976;34:585- 612.03PBF0 0574PH"
129,page_129,"PRODUCT: MK-7264 129 PROTOCOL/AMENDMENT N O.:027-03 MK-7264 -027-03 FINAL PROTOCOL 26-APR -2019 [Souslova, V., et al 2000] Souslova V, Cesare P, Ding Y, Akopian AN, Stanfa L, Suzuki R, et al. Warm -coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature. 2000 Oct 26;407(6807):1015 -7.04K76C [The committee for The Japanese Respiratory Society guidelines 2006]The committee for The Japanese Respiratory Society guidelines for management of cough. Concept and use of guidelines. Respirology . 2006:11(Suppl 4);S135 -S13604KW9M 0574PH"
